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Abstract 
Gamma-aminobutyric acid is the main inhibitory neurotransmitter in 
central nervous system. To assure a controlled GABAergic 
transmission GABA must be quickly removed from synapse, which 
occurs through specific transporters expressed both in pre-synaptic 
terminal (GAT-1) and surrounding astrocytes (GAT-1 and GAT-3). 
Adenosine, which is a well-known neuromodulator, promotes GABA 
release in the hippocampus (Cunha and Ribeiro, 2000). The main 
goal of this thesis was to identify a possible role of adenosine upon 
GABA uptake into pre-synaptic terminals and into astrocytes. 
In pre-synaptic terminals, the removal of endogenous adenosine by 
ADA inhibited GABA uptake, an effect that was mimicked by the 
blockade of A2A receptors. Thus, endogenous adenosine, through the 
activation of A2A receptors, promotes GABA uptake into pre-synaptic 
terminals.  Experiments with activators and inhibitors of 
transduction pathways revealed that AC/cAMP/PKA is the 
transduction pathway associated with this effect. In fact, the 
activation of PKA restrains an inhibitory tonic influence mediated by 
PKC, resulting in an increase of GABA uptake. The increase of 
transport rate occurs through the enhancement of the expression of 
GAT-1 at the surface membrane. 
In astrocytes, adenosine has a biphasic effect upon GABA uptake. 
This biphasic effect is mediated by the adenosine A1-A2A receptors 
heteromers, whose presence in astrocytes was identified in this 
work. The adenosine A1-A2A receptor heteromer is coupled to both 
xxviii 
Gi/0 and Gs protein, being AC/cAMP/PKA the intracellular pathway 
associated. At low concentration, adenosine activates the A1 
protomer, which through Gi/0 protein inhibit AC, decreasing PKA 
activity and consequently, GABA uptake mediated by both GAT-1 
and GAT-3. When adenosine levels rise, adenosine activates 
preferentially the A2A protomer, which through Gs activity enhances 
PKA activity, promoting GABA uptake into astrocytes. The adenosine 
A1-A2A receptors heteromer can be viewed as a unique entity since it 
reaches and leaves the membrane as an entire complex and all the 
components have to be available for the heteromer be functional. 
Moreover, this work clearly showed that the heteromer is associated 
with both Gs and Gi/0, being a tetramer of A1-A1-A2A-A2A, rather than 
an A1-A2A complex coupled to Gq as previously thought.   
Globally, at tripartite synapse level, adenosine controls the final 
destination of GABA after its release into the synapse. At low levels, 
adenosine will inhibit uptake into astrocytes but promote the uptake 
of GABA into presynaptic terminals, therefore facilitating the 
inhibitory phasic and tonic transmission. At higher levels of 
adenosine, GABA uptake into astrocytes will be favoured, which may 
decrease GABAergic tonic transmission, therefore facilitating 
excitability. In conclusion, this work highlighted a yet unknown 
mechanism through which adenosine may contribute to the switch 
between inhibition and excitation, through a concerted cross-talk 
between astrocytes and inhibitory neurons.  
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Resumo 
O ácido gama-aminobutírico (GABA) é o principal neurotransmissor 
inibitório do Sistema Nervoso Central (SNC). Uma vez na sinapse o 
GABA é rapidamente recaptado através de transportadores 
específicos expressos pelos neurónios mas também pelas células da 
glia, que envolvem a sinapse.  
A rápida recaptação de GABA pelos transportadores permite um 
controlo adequado dos níveis de GABA na sinapse, o que é 
fundamental para a limitação temporal e espacial da transmissão 
inibitória. Este controlo é assegurado por transportadores 
específicos expressos no terminal pré-sináptico e nos astrócitos que 
envolvem a sinapse. Actualmente são conhecidos quatro 
transportadores de GABA: três de alta afinidade (GAT-1, GAT-2, GAT-
3) e um de baixa afinidade (BGT-1). O GAT-1 é o principal 
transportador de GABA, sendo expresso pelos neurónios e também 
pelas células da glia. Por sua vez, O GAT-3 é o principal 
transportador das células gliais. Em conjunto, estes dois 
transportadores são os responsáveis pela recaptação de GABA nas 
sinapses do sistema nervoso central. 
A adenosina é um conhecido neuromodulador, que desempenha, ao 
nível do sistema nervoso central, um vasto leque de acções, que 
resulta numa inibição tónica do SNC. De entre as funções 
desempenhadas, a adenosina modula a concentração de 
neurotransmissores da sinapse, regulando quer a sua libertação 
vesicular quer a sua recaptação por transportadores. 
xxx 
A adenosina exerce as suas acções através de receptores acoplados 
a proteínas G. Até ao momento foram identificados quatro subtipos 
diferentes de receptores: dois de alta afinidade (A1 e A2A) e dois de 
baixa afinidade (A2B e A3). Os receptores A1 e A3 são receptores 
inibitórios, estando classicamente acoplados a proteínas Gi/0. Por seu 
lado, os receptores do subtipo A2 são receptores excitatórios, 
estando geralmente acoplados a proteínas Gs. 
Tendo como ponto de partida o efeito modulador da adenosina 
através da activação dos receptores A2A, sobre libertação de GABA 
no hipocampo (Cunha e Ribeiro, 2000), este trabalho teve como 
principal objectivo a identificação de um possível efeito modulador 
da adenosina sobre a recaptação de GABA para os terminais pré-
sinápticos e também para os astrócitos, através dos transportadores 
GAT-1 e GAT-3. 
Os resultados obtidos neste trabalham indicam claramente que a 
adenosina através da activação dos receptores A2A promove a 
recaptação de [3H]GABA para os terminais pré-sinápticos mediada 
pelo transportador GAT-1. Com o objectivo de determinar o efeito 
da adenosina endógena, os terminais pré-sinápticos (sinaptossomas) 
foram incubados com adenosina desaminase (ADA, 1U/ml), tendo 
sido observada uma diminuição da recaptação de [3H]GABA.  A ADA 
degrada a adenosina em inosina, um metabolito inactivo para os 
receptores de adenosina, permitindo assim inferir o efeito da 
adenosina endógena. O efeito inibitório causado pela remoção da 
adenosina endógena foi mimetizado pelo bloqueio dos receptores 
A2A com o antagonista selectivo SCH 58261 (50 nM). O envolvimento 
xxxi 
dos receptores A2A foi ainda confirmado através do uso do agonista 
selectivo destes receptores (CGS 21680, 30 nM): a activação dos 
receptores A2A pelo CGS 21680 promoveu a recaptação de 
[3H]GABA, mediada pelo transportador GAT-1. 
 O envolvimento de outros subtipos de receptores de adenosina, 
especificamente os subtipos A1 e A2B, foi avaliado através do uso de 
agonistas e antagonistas selectivos. Tanto a activação como o 
bloqueio dos receptores A1 ou A2B não causaram qualquer efeito 
sobre a recaptação de [3H]GABA mediada por GAT-1 em 
sinaptossomas.   
Ensaios de biotinilação, realizados após incubação dos 
sinaptossomas com o agonista selectivo dos receptores A2A, 
mostraram que o efeito excitatório da adenosina sobre a recaptação 
de [3H]GABA ocorre através do aumento do número de 
transportadores GAT-1 na membrana celular. Este efeito foi 
confirmado por curvas de saturação do transportador GAT-1, que 
mostraram um aumento da velocidade máxima do transportador 
após incubação com o agonista selectivo dos receptores A2A, o que é 
indicativo de um aumento do número de transportadores GAT-1 na 
membrana celular. 
A via de transdução de sinal associada ao efeito dos receptores A2A 
foi identificada através de ensaios de recaptação realizados na 
presença de bloqueadores e activadores de cinases intracelulares. O 
bloqueio da proteína cinase do tipo A (PKA) pelo H-89 (1µM) 
preveniu totalmente o efeito do CGS 21680, enquanto a activação 
da adenilato ciclase (AC) pela forskolin (10µM) imitou a acção do 
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agonista selectivo dos receptores A2A. Assim, os resultados indicam 
que a adenosina, por activação dos receptores A2A promove a 
recaptação de [3H]GABA mediada por GAT-1, através da activação da 
via da PKA.  
Foi ainda testado o envolvimento da via de sinalização mediada pela 
proteína cinase do tipo C (PKC). O bloqueio da PKC pelo GF109203X 
(1µM) promoveu a recaptação de [3H]GABA mediada por GAT-1. Em 
concordância, a activação da PKC por ésteres de forbol (12,13- 
didecanoato de forbol – PDD 250nM) inibiu a recaptação de 
[3H]GABA mediada por GAT-1, indicando que a PKC está 
endogenamente a inibir o transporte de [3H]GABA para os terminais 
pré-sinápticos. 
Estes resultados sugerem assim, o envolvimento das duas vias de 
sinalização na recaptação de [3H]GABA mediada por GAT-1. Estudos 
de recaptação realizados com diferentes combinações de 
activadores e bloqueadores de ambas as proteínas cinases indicam 
que a activação dos receptores A2A da adenosina, com consequente 
activação da PKA, restringe o efeito tónico inibitório da PKC sobre o 
transporte de [3H]GABA, o que resulta numa potenciação da 
recaptação de GABA através do transportador GAT- 1 para o 
terminal pré-sináptico, por aumento do número de transportadores 
presentes na membrana celular.  
O estudo de recaptação de [3H]GABA em astrócitos sugere a 
existência de um efeito bifásico mediado pela adenosina sobre os 
transportadores GAT-1 e GAT-3. A incubação de culturas primárias 
de astrócitos com cloroadenosina (CADO), um análogo não-
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metabolizável da adenosina teve um efeito bifásico sobre o 
transporte: a baixas concentrações (0,3µM), a CADO inibiu o 
transporte enquanto que concentrações mais elevadas (3 e 10 µM) 
de CADO promoveram a recaptação de [3H]GABA. 
 Por outro lado, a remoção de adenosina endógena pela acção da 
adenosina desaminase (ADA, 1U/ml) diminuiu a recaptação de 
[3H]GABA mediada por GAT-1 e por GAT-3, sugerindo que as 
concentrações de adenosina endógena presentes na cultura de 
astrócitos promovem o transporte de [3H]GABA. 
A realização de ensaios de recaptação com fármacos selectivos para 
os receptores de adenosina permitiu a identificação dos receptores 
envolvidos. Assim, o agonista selectivo dos receptores A2A (CGS 
21680, 30nM) promoveu a recaptação de [3H]GABA mediada por 
GAT-1 e GAT-3. Surpreendentemente, este efeito para além de ter 
sido bloqueado pelo antagonista selectivo dos receptores A2A (SCH 
58261, 50nM) foi também prevenido pelo bloqueio dos receptores 
A1 com o antagonista selectivo DPCPX (50nM). Por seu lado, a 
activação dos receptores A1 com o agonista selectivo CPA (30nM) 
levou à diminuição da recaptação de [3H]GABA mediada por GAT-1 e 
por GAT-3. Este efeito foi bloqueado quer pelo antagonista dos 
receptores A1 quer pelo antagonista dos receptores A2A. Estes 
resultados sugerem a existência de uma interacção entre os 
receptores A1 e A2A da adenosina nos astrócitos. De facto, a 
existência de uma interacção entre os receptores A1 e A2A da 
adenosina é conhecida desde há bastante tempo, tendo sido 
descrita inicialmente no hipocampo (Cunha et al., 1994; Lopes et al., 
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1999) e na junção neuromuscular (Correia-de-Sá e Ribeiro, 1994). A 
natureza desta interacção era desconhecida até 2006, quando se 
identificou a ocorrência de heterómeros de receptores da adenosina 
A1-A2A em células imortalizadas transfectadas (Ciruela et al., 2006), 
através de ensaios de bioluminesce ressonance energy transfer 
(BRET). Recorrendo a esta tecnologia, bem como a ensaios de 
ligação, identificou-se neste estudo, pela primeira vez, a presença de 
heterómeros de receptores de adenosina A1-A2A nos astrócitos. O 
estudo reportado nesta dissertação foi pois o primeiro a identificar 
inequivocamente a presença de heterómeros A1-A2A em células não 
imortalizadas. 
A identificação do subtipo de proteínas G acopladas ao heterómero 
de receptores de adenosina A1-A2A foi realizada através de ensaios 
de ligação de [35S]GTPγS acoplados a imunoprecipitação e de ensaios 
de recaptação realizados na presença de toxinas que bloqueiam 
selectivamente a actividade das proteínas Gs e Gi/0. Os ensaios 
realizados indicam claramente que os heterómeros de receptores da 
adenosina A1-A2A estão acoplados a ambas as proteínas Gs e Gi/0, e 
não a uma única proteína Gq, como inicialmente se supunha, com 
base no que ocorre na heteromerização dos receptors da dopamina. 
O trabalho descrito nesta dissertação demonstrou ainda que o 
heterómero de receptores de adenosina A1-A2A é na verdade um 
tetrâmero formado por dois receptores A1 e dois receptores A2A (A1-
A1-A2A-A2A), o que permite o acoplamento de duas proteínas G 
diferentes.   
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Ensaios de recaptação de [3H]GABA realizados na presença do 
activador da AC, forskolin, e do inibidor competitivo da PKA, Rp-
cAMPs, sugerem que o heterómero de receptores de adenosina A1-
A2A sinaliza através da via AC/cAMP/PKA. O presente estudo 
permitiu ainda concluir que os heterómeros de receptores da 
adenosina A1-A2A funcionam como uma única entidade, que para ser 
funcional, necessita que todos os componentes estejam disponíveis 
para activação. Assim se entende que o bloqueio do receptor A1 ou 
da proteína Gi/0 previna o efeito mediado pela activação dos 
receptores A2A, bem como o bloqueio dos receptores A2A ou da 
proteína Gs previna o efeito inibitório mediado pelos receptores A1. 
Assim, nos astrócitos, o efeito bifásico da adenosina sobre a 
recaptação de [3H]GABA é mediado pela activação dos heterómeros 
de receptores da adenosina A1-A2A. A baixa concentração, a 
adenosina activa preferencialmente os receptores A1, levando à 
activação de proteínas Gi/0, que, por inibição da actividade da AC, 
provocam a redução dos níveis de cAMP, inibindo a PKA e 
reduzindo, consequentemente, a recaptação de GABA mediada por 
GAT-1 e GAT-3. Por outro lado, em concentrações superiores, a 
adenosina através da activação dos receptores A2A, e consequente 
activação de proteínas Gs, por activação da AC, eleva os níveis de 
cAMP, o que promove a actividade da PKA, e aumenta o transporte 
de GABA mediada por GAT-1 e GAT-3 em astrócitos. 
Considerando a sinapse tripartida, os resultados sugerem que em 
baixas concentrações a adenosina conduz preferencialmente o 
GABA para o terminal pré-sináptico, favorecendo portanto a 
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transmissão fásica inibitória e impedindo o esgotamento das 
reservas pré-sinápticas. Em concentrações mais elevadas, a 
adenosina aumenta a recaptação de GABA pelos astrócitos, o que 
deverá diminuir a inibição tónica e permitir o aumento da 
excitabilidade. Assim, através da modulação dos transportadores de 
GABA, a adenosina pode ser considerada como um agente 
amplificador do tónus GABAérgico. Quando o tónus inibitório é 
prevalente, a adenosina direcciona a recaptação de GABA para os 
terminais pré-sinápticos, facilitando a transmissão fásica inibitória. 
Pelo contrário, a facilitação da recaptação de GABA pelos astrócitos 
reduz a inibição tónica, favorecendo a transmissão excitatória.  
Em suma, este trabalho revela um mecanismo até agora 
desconhecido, através do qual a adenosina pode contribuir para a 
transição entre uma situação inibitória e outra excitatória, 
fenómeno que envolve a interacção entre astrócitos e neurónios 
inibitórios.  
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1 Introduction 
1.1 GABA 
Gamma-aminobutyric acid (GABA) is the main inhibitory 
neurotransmitter in the central nervous system. Its presence in the 
central nervous system was described for the first time in 1950 
(Awapara et al., 1950; Roberts and Frankel, 1950; Udenfriend, 1950). 
During the following years, several works identified the inhibitory 
role of GABA, particularly at the crustacean neuromuscular junction 
(Otsuka et al., 1966; Potter, 1968). Later on, in 1970, GABA was 
localized to mammalian nerve terminals (Bloom and Iversen, 1970) 
and further studies revealed the association between GABA release 
and inhibition of cortical firing, clarifying the role of GABA as a 
neurotransmitter (Iversen et al., 1971). At that time, several studies 
had reinforced this role of GABA in nervous system, namely the 
study on distribution of GABA and its related metabolic enzymes 
(Roberts and Eilderberg, 1960), the description of sodium-
dependent GABA uptake mechanism (Elliott and van Gelder, 1960; 
Iversen and Neal, 1968) and the identification of GABA effects on 
post synaptic membranes (Krnjevic and Schwartz, 1967), which 
unequivocally supported the role of GABA as a neurotransmitter. 
This role was reinforced by the work of Curtis and colleagues, which 
showed that bicuculline, prevented the action of GABA and also the 
postsynaptic inhibition in the cerebral cortex (Curtis et al., 1970), 
allowing the identification of receptor-mediated effects of GABA. 
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Figure 1.1 – Schematic representation of the evidence of GABA as a 
neurotransmitter in mammalian cerebral cortex (Iversen et al., 1971) 
1.1.1 GABA Receptors 
GABA is estimated to be present in 60-75% of the synapses in the 
CNS (Durkin et al., 1995). When it is released into the synapse, GABA 
binds to different receptors: GABAA, GABAC and GABAB.  The first 
two are ionotropic receptors, mainly located in postsynaptic neurons 
while the later is a metabotropic receptor, localized both pre and 
postsynaptically. 
1.1.1.1 GABAA receptors 
GABAA is the main GABA receptor and its structure was identified in 
1990 (Olsen and Tobin, 1990). GABAA receptors belong to the ligand-
gated ion channel superfamily that includes nicotinic receptors for 
acetylcholine, glycine receptors and also serotonin receptors. GABAA 
is a pentameric receptor composed by distinct polypeptides.  At the 
moment, several distinct peptides have been identified, namely six 
α-subunits, three β-subunits, three γ-subunits, one δ-subunit, one ε-
subunit, one π-subunit and one θ-subunit (Schofield, 1987; 
MacDonald and Olsen, 1994; Mehta and Ticku, 1999).  
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Figure 1.2 – Schematic representation of a GABAA receptor (adapted from 
Owens and Kriegstein, 2002).  
Although a functional GABAA receptor always includes one α, one β 
and one γ subunit (Pritchett et al., 1989), the GABAA subunits can be 
assembled in several possible combinations, with some of them 
being preferred. For example, GABAA receptors containing α1 
subunits combined with β2 and γ2 subunits are the most abundant 
form in the brain (McKernan and Whiting, 1996). Furthermore, 
different subunits compositions of the receptors seem to be related 
with different cellular localizations, where they can mediate synaptic 
or extrasynaptic signaling (Mody, 2001). 
The majority of GABAA receptors have affinity for benzodiazepines, 
which, allosterically, exacerbate the effect of GABA. This property is 
the basis for therapeutic effect of benzodiazepines as anxiolytic 
agents (for review, Bowery and Smart, 2006). The GABAA receptors 
contain other modulatory binding sites, sensitive to barbiturates, 
neurosteroids and ethanol (Macdonald and Olsen, 1994).   
GABA binding to the receptor leads to a conformational change, 
which allows a net inward or outward flow through the channel, 
depending on the electrochemical gradient. GABAA receptors carry 
mainly chloride (Cl-) ions but they can also carry other ions like 
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bicarbonate (HCO3
-), although with lower efficiency (Bormann et al., 
1987; Kaila, 1994). 
1.1.1.2  GABAC receptors 
A related ionotropic GABA receptor was named GABAC by Drew and 
colleagues, in 1984 (Drew et al., 1984). This receptor is a chloride-
selective channel but is insensitive to the GABAA antagonist, 
bicuculline. GABAC are homo or hetero-pentomeric receptors 
composed by ρ subunits (Cutting et al., 1991, 1992).  
 
Figure 1.3 – Schematic representation of GABAC receptor (adapted from 
Owens and Kriegstein, 2002).  
As the ρ subunits share extensive sequence homology with some 
GABAA subunits, GABAC receptors can be considered as 
pharmacological variants of GABAA receptors. However different 
studies involving GABAC receptors have strongly suggested that they 
have distinct pharmacology, structure, function, genetics and 
cellular localization, and consequently should be considered as an 
independent class of GABA receptors (Bormann, 2000). Although 
GABAC receptors were first identified in the retina (Feigenspan et al., 
1993; Qian and Dowling, 1993), posterior data suggests that GABAC 
receptor has a widespread distribution in the CNS (López-Chávez et 
al., 2005).  
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1.1.1.3 GABAB receptors 
In 1980, it was described the existence of a different GABA receptor 
(GABAB), that was insensitive to bicuculline, chloride independent 
and responsible for the baclofen inhibitory effect upon 
neurotransmitter release in CNS (Bowery et al., 1980).   The GABAB 
receptor was insensitive for bicuculline and chloride independent 
and was termed GABAB receptor (Bowery et al., 1980).  GABAB is a 
metabotropic receptor which signals through Gi/0 proteins, 
decreasing adenylate cyclase activity and modifying calcium and 
potassium conductances. GABAB receptors are expressed either at 
pre-synaptic and pos-synaptic levels. Presynaptic activation of 
GABAB receptor results in inhibition of calcium channels, which leads 
to a reduction in neurotransmitter release. At the pos-synaptic level, 
the effect of GABAB is mediated by enhancement of potassium 
conductance, which leads to neuron hyperpolarization (Bormann, 
1988). 
Cloning of GABAB receptor showed a seven-transmembrane 
receptor that exists as a heterodimer composed of GABAB1 and 
GABAB2 subunits (White et al., 1998). Interestingly, the GABAB 
receptors were the first G-protein coupled receptors to be described 
as heteromeric receptors (Kaupmann et al., 1998).  However GABAB 
subunits cannot work separately: the GABAB1 subunit binds to all 
known GABAB ligands (Kaupmann et al., 1997), while GABAB2 
involved in different roles, namely: (1) to mask the retention signal 
of the GABAB1 subunit, allowing that GABAB heteromer to reach the 
cell surface (Margeta-Mitrovic et al., 2000; Calver et al., 2001; 
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Pagano et al., 2001), (2) to contain the molecular determinants 
required for G-protein coupling (Galvez et al., 2001); (3) to play a 
critical role in G-protein activation within the heteromer (Margeta-
Mitrovic et al., 2001; Robbins et al., 2001; Duthey et al., 2002; 
Havlickova et al., 2002); and (4) to increase agonist affinity on 
GABAB1 (Kaupmann et al., 1998; White et al., 1998; Galvez et al., 
2001). Thus GABAB can be considered as a natural complementation 
of two non-functional receptors: one subunit recognizing the ligand 
and the other activating the G protein (Pin et al., 2003).  
 
 
 
Figure 1.4 – Schematic representation of GABAB receptor (adapted from 
http://www.pharma.uzh.ch/research/neuropharmacology/researchareas/
signaltransduction/introduction.html).   
1.1.2 GABA metabolism 
Neurons lack pyruvate carboxylase, so they are unable to de novo 
synthesis of glutamate and GABA (Patel, 1974; Shank et al., 1985), 
which suggests the occurrence of a metabolic crosstalk between 
neurons and glial cells. In fact, the discovery of glutamine and 
glutamate pools in neurons and astrocytes was indicative of a 
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glutamate/glutamine cycle, working between neurons and glial cells 
(van den Berg and Garfinkel, 1971; Benjamin and Quastel, 1972).  
Considering a GABAergic synapse, the majority of GABA is taken up 
into presynaptic terminals (see Schousboe, 2000), where without 
any metabolic changes, GABA can quickly be package into vesicles by 
a vesicular GABA transporter (vGAT), being available for dependent 
calcium exocytic release.  
However, GABA can also be taken up into astrocytes (it has been 
estimated that 20% of released GABA is taken up into surrounding 
astrocytes, see Schousboe, 2000). By this path, GABA is firstly 
metabolized into glutamate and glutamine. Then, glutamine is 
redirected to the presynaptic terminal, where, GABA is 
resynthetized. This metabolic pathway is known as the 
aforementioned glutamate/GABA-glutamine cycle. Briefly, after 
being taken up into astrocytes, GABA is catabolised to succinate (a 
tricarboxylic acid (TCA) cycle intermediate via the concerned action 
of GABA transaminase and semialdehyde dehydrogenase. Succinate, 
through TCA cycle, will originate α-ketoglutarate, which is 
transaminated to glutamate by glutamate transaminase. Glutamate 
is then converted to glutamine by the glutamine synthetase (GS). 
Glutamine is then released to the extracellular space, from where is 
taken up into presynaptic neurons. After being taken up, glutamine 
is converted to glutamate by phosphate-activated glutaminase 
(PAG). Glutamate is finally converted into GABA, by glutamate 
decarboxylase (GAD) (see figure 1.5 and Bak et al., 2006).  
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Figure 1.5 – Schematic representation of glutamate/GABA-glutamine cycle 
in a GABAergic synapse (adapted from Bak et al., 2006). 
1.1.3 GABA transporters 
Ambient levels of neurotransmitter in the synapse result from the 
balance between neurotransmitter release, diffusion within the 
synaptic cleft and the uptake through transporters. The main role 
attributed to neurotransmitter transporters is the shutdown of 
synaptic transmission. In the case of ionotropic receptors, both 
receptor desensitization and neurotransmitter uptake mediated by 
transporters contribute to the end of transmission, being unclear 
which is the principal phenomenon. Within these, extrasynaptic 
receptors desensitize slower than synaptic ones, so the relative 
contribution of transporters for shutting down GABA action at 
ionotropic receptors varies according to their location. In contrast, 
for metabotropic receptors, which desensitize slower than 
ionotropic receptors, neurotransmitter uptake is the predominant 
mechanism through which the synaptic transmission is finished 
(Borden, 1996). 
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Besides the temporal delimitation of synaptic transmission, 
transporters also contribute for synaptic spatial control by 
preventing the neurotransmitter spill over, assuring the precise 
location of transmission (see Krogsgaard-Larsen et al., 1987). It was 
indeed demonstrated that the maintenance of appropriate levels of 
transmitter in the synaptic cleft by transporters is crucial for normal 
brain function (Giros et al., 1996; Tanaka et al., 1997). 
From a metabolic perspective, neurotransmitter uptake by 
transporters prevents the depletion of intracellular pools, preserving 
metabolic energy balance.  The maintenance of these pools is critical 
for homeostasis, especially during periods of high activity. As 
mentioned above, neurotransmitter recycling can, however, be 
direct or indirect: the direct recycling occurs when the 
neurotransmitter is taken up directly to the pre-synaptic terminal, 
allowing the prompt replenishment of synaptic vesicles. The indirect 
recycling involves the surrounding astrocytes and the uptake by 
these cells implies metabolic conversion before the transmitter is 
available to be packaged into exocytic vesicles, as it was shown 
above. 
GABA levels at the synapse are therefore mainly regulated by the 
specific transporters (GATs) expressed in neurons and astrocytes, 
which were identified in 1968 (Iversen and Neal, 1968). However, 
even before the recognition of GATs, Elliot and van Gelber (1958) 
had already demonstrated that GABA added to the incubation 
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medium can accumulate in slices of cerebral cortices (Elliot and van 
Gelber, 1958).  
 
Figure 1.6 – Schematic representation of a GABAergic synapse. As 
illustrated, GATs are expressed in both presynaptic terminals and 
astrocytes (adapted from Owens and Kriegstein, 2002). 
1.1.3.1 GABA transporters family 
GABA transporters belong to the family of Na+/Cl- coupled receptors. 
In each transporter cycle, one uncharged GABA molecule is co-
transported with two Na+ ions and one Cl- ion (see figure 1.7 and 
Kanner and Schuldiner, 1987). Thus GABA is carried up its 
concentration gradient using energy from the inward Na+ gradient 
and the flow of one positive charge downs the electrical gradient 
(Richerson and Wu, 2003).  
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Figure 1.7 – Schematic representation of GABA transport. Each molecule of 
GABA is co-transported with two sodium ions and one chloride ion 
(adapted from Richerson and Wu, 2003) 
Shortly, GABA binds the transporter in its resting state, facing 
extracellular space. After the binding of GABA, Na+ and Cl- ions, the 
transporter undergoes a conformational change enabling GABA and 
ions to face intracellular space, where they are released. Then, the 
unfilled transporter reverts to the resting state, waiting for a new 
cycle of transport (Borden, 1996).  
Furthermore, it was shown that the magnitude of GAT-1 mediated 
currents is altered in response to changes in Na+, Cl- and GABA 
gradients (Lu and Hilgemann, 1999). Although these experiments 
were performed using nonphysiological concentrations, they 
provided initial evidence that transport can be modified (and 
possibly reverted) in response to ionic concentration changes.  
So far, four distinct GABA transporters have been identified: GAT-1, 
GAT-2, GAT-3 and BGT-1. The first three are high affinity-
transporters and the last is a low-affinity transporter. 
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1.1.3.2 GAT-1 
GAT-1 was the first neurotransmitter transporter to be cloned 
(Guastella et al., 1990). GAT-1 mRNA was found in all brain regions, 
being the highest levels of hybridization signal observed in 
brainstem nuclei, ventral tegmental area, pontine nuclei, 
cerebellum, thalamus, basal forebrain, hippocampus, olfactory bulb 
and neocortex. Concerning cellular localization, GAT-1 is expressed 
by both neurons and astrocytes. Although GAT-1 is mainly expressed 
at GABAergic neurons (which express concomitantly GAT-1 and 
GAD67), it can also be found in a small number of glutamatergic 
cells, suggesting that GABA uptake system mediated by GAT-1 is 
strongly expressed in the brain, being more widespread than the 
GABA synthesizing system (Minelli et al., 1995). GAT-1 is a 67 kDa 
protein with twelve transmembrane regions, with both N- and C- 
termini in the intracellular space. GAT-1 has four putative 
glycosylation sites, being three of them located on the large 
extracellular loop that connects membrane segments 3 and 4. GAT-1 
has also eight putative phosphorylation sites: three putative protein 
kinase C phosphorylation sites are intracellular, two at the N-
terminal and one at C-terminal. The other three sites for PKC and the 
single site for PKA are located externally or within membrane 
segments (Guastella et al., 1990), being therefore of questionable 
functional relevance.  
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Figure 1.8 – Schematic representation of the GABA transporter GAT-1. 
The rectangles represent the twelve transmembrane domains, connected 
by extramembrane loops. The large extracellular loop, between membrane 
segments 3 and 4, contains three potential glycosylation sites, illustrated 
by the branched lines (adapted from Kanner, 1994). 
1.1.3.3 GAT-2  
GAT-2 mRNA was initially identified only at cells of the 
leptomeninges (pia and arachnoid - Durkin et al., 1995). Later, a 
weak GAT-2 immunoreactivity was observed in the cortical 
parenchyma, where GAT-2 is expressed by neuronal and non-
neuronal cells (Conti et al., 1999). However, the predominant 
localization of GAT-2 to leptomeninges and blood vessels suggests 
that GAT-2 function is mainly related to the regulation of GABA 
levels in the cerebrospinal fluid (Minelli et al., 2003). 
1.1.3.4 GAT-3  
In the early 90’s, several studies indicated that GAT-3 was absent or 
very weakly expressed at the cerebral cortex (Clark et al., 1992; 
Durkin et al., 1995; Ikegaki et al., 1994). Then, in 1996, Minelli and 
colleagues showed that GAT-3 is expressed in cerebral cortex, 
exclusively at astrocytes, being GAT-3 the main GABA transporter 
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expressed in glial cells (Minelli et al., 1996). In addition, Durkin and 
colleagues showed that GAT-3 mRNA is present in many brain areas, 
though it is less abundant the GAT-1 mRNA (Durkin et al., 1995).  
1.1.3.5 BGT-1 
BGT-1, the fourth GABA transporter, was known as a result from 
renal physiology studies, where a betaine transporter was initially 
identified. This transporter had the ability to concentrate urine 
through the uptake of the betaine (glycine betaine), that was co-
transported with Na+ and Cl- (see Borden, 1996). Then, Yamauchi 
and colleagues isolated a clone encoding a Na+/Cl- dependent 
transporter, which was able to utilize both GABA and betaine as 
substrates. Hence, the clone was named BGT-1 (Betaine/GABA 
transporter). Surprisingly, BGT-1 has higher affinity for GABA (KM =93 
µM) than for betaine (KM =398 µM) (Yamauchi et al., 1992). 
The expression of BGT-1 as well as its role in CNS is still not clear 
although the presence of BGT-1 mRNA in human and mouse brain 
may suggest its involvement in GABAergic transmission. However, 
the distribution of BGT-1 mRNA does not correlate with GABAergic 
pathways, which corroborates the hypothesis that BGT-1 might not 
play a role in finishing GABA effects at synapses. Alternatively, 
betaine may be the primary substrate for BGT-1 in the brain (as it is 
in the kidney), which suggests an involvement of BGT-1 in 
osmoregulation, thus BGT-1 could contribute to the volume control 
in the CNS. Osmoregulation is particularly important for brain 
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function (see Borden, 1996), as the skull is a rigid and non-
expandable container.  
1.1.3.6 GABA transporters modulation 
Considering that the control of GABA concentration at synapse is 
strongly regulated by GABA transporters, their modulation is a key 
factor to assure adequate GABA levels for brain function. GAT 
modulation occurs mainly by changes in their expression at the 
membrane level. In fact, this expression is not static and 
transporters can cycle to and from membrane on the time scale of 
seconds to minutes, being this cycling regulated by different factors, 
including extracellular signals (Zahniser and Sorkin, 2004; Sattler and 
Rothsein, 2006), protein phosphorylation (Foster et al., 2006) and 
interactions with accessory proteins (Quick, 2006).  
The average number of GAT-1 molecules in a cultured cortical 
inhibitory bouton is approximately 3000-4000 (Chiu et al., 2002) and 
the size of the recycling pool is about 30% of total GAT-1 (Wang and 
Quick, 2005). Then, about 1000 GAT-1 molecules traffic to and from 
the membrane, with GAT-1 being inserted into the membrane in a 
calcium-dependent manner and internalized via a clathrin-
dependent process (Deken et al., 2003). The regulation of 
membrane expression levels can occur through changes in recycling 
pool size or modification of exocytosis and endocytosis rate. 
Changes at transporters surface membrane expression occur in a 
scale of minutes (Mennerick et al., 1999; Blakely and Bauman, 2000; 
Deken et al., 2000; Robinson, 2002). 
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Firstly, GAT-1 is modulated by its own substrate, GABA, being this a 
concentration dependent effect, involving changes in 
phosphorylation state, which consequently modify the transporter 
surface expression (Hu and Quick, 2008). 
In fact, phosphorylation seems to be a critical cellular mechanism 
responsible for changes in the membrane expression of 
transporters. As aforementioned, GAT-1 has eight putative 
phosphorylation sites (Guastella et al., 1990) and it was described 
that PKC activation decreases membrane GAT-1 levels (Corey et al., 
1994), in a way that is independent of protein synthesis. This action 
of PKC activators is mimicked by phosphatase inhibitors, suggesting 
that changes in membrane levels are dependent on protein 
phosphorylation. However, it was shown that the effect of PKC upon 
GAT-1 surface expression still occurs when consensus residues for 
PKC phosphorylation are removed (Corey et al., 1994). Thus, it 
seems that there are other cellular mechanisms through which PKC 
can influence GAT-1 levels. In fact, a subsequent study showed that 
PKC effect upon GAT-1 function occurs through the regulation of 
syntaxin A1 availability to interact with the transporter. Further, a 
mutant transporter that fails to interact with syntaxin A1 is not 
regulated by the PKC (Beckman et al., 1998).  
Like PKC, Ca2+ depletion also decreases surface expression of GAT-1, 
while hypertonic sucrose treatment increases its surface expression 
(Beckman et al., 1999; Deken et al., 2003). Interestingly, these 
effects are not mediated by the same cellular mechanism: PKC and 
sucrose application modifies the endocytosis rate but does not 
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change the recycling pool size, which is dramatically diminished by 
extracellular calcium depletion (Wang and Quick, 2005).  
1.1.3.7 Reversal of GABA transporters  
It is known for a long time that neurotransmitters transporters can 
revert (Schwartz, 1987; Pin and Bockaert, 1989; O’Malley et al., 
1992; Attwell et al., 1993; Levi and Reiteri, 1993; Cammack et al., 
1994; Lu and Hilgemann, 1999). For instance, after extracellular 
calcium removal, GABA is still released from cortical slices in 
response to: (1) an increase in K+ to 50mM; (2) an exposure to 
veratridine (50 µM); (3) a high-frequency electrical stimulation 
(Szerb, 1979). GABA is also released from cultured striatal neurons, 
in the absence of calcium (Pin and Bockaert, 1989) and from cortical 
neurons in response to 55-56 mM of K+ or 100 µM of glutamate 
(Belhage et al., 1993). Neurotransmitter release in the absence of 
extracellular calcium occurs by the reversal of transporters since it is 
prevented by the blockade of transporters (Pin and Bockaert, 1989; 
Belhage et al., 1993). As these studies were performed using non-
physiological stimuli, the transporters reversal was initially 
associated with pathological conditions such as ischemia (Nicholls 
and Attwell, 1990; Levi and Raiteri, 1993). However, transporter-
mediated GABA release can also occur in response to presynaptic 
stimulation (Schwartz, 1987; Bernath and Zigmond, 1988) or in 
response to an elevation in extracellular K+ concentration from 3 to 
12 mM (Gaspary et al., 1998), a level of K+ that is reached in vivo 
during neuronal firing (Krnjevic et al., 1980; Somjen and Giacchino, 
1985) and during seizures (Fisher et al., 1976). In 2001, a study by 
Introduction 
18 
Wu and colleagues corroborate the hypothesis that GABA 
transporters reverse more easily than previously recognized: GABA 
reversal was induced by a small depolarization of membrane 
potential caused by 6mM K+ in hippocampal cultures (Wu et al., 
2001. This potassium increase is physiologically relevant as 
extracellular potassium concentration increases during neuronal 
firing in vivo. For example, an increase in [K+] to > 12mM occurs in 
the rat hippocampus in vivo in response to electrical stimulation of 
the angular bundle (Somjen and Giacchino, 1985). Then, instead of 
being associated with some pathological state, the reversal of GABA 
transporters seems to be related with modifications in the ratio 
between intra and extracellular concentrations of GABA. In fact, the 
rate of GABA uptake is governed by a driving force, which decreases 
as extracellular GABA concentration reduces. Then, the GABA uptake 
by transporters occurs until the equilibrium between intra and 
extracellular concentrations is achieved. Thus, GABA transporters 
are unable to uptake all the GABA, and extracellular GABA 
concentration fall around 0.1-0.8 µM (Hagberg et al., 1985; Lerma et 
al., 1986; Tossman et al., 1986; Phillis et al., 1994; Cavelier et al., 
2005).  
1.1.3.8 GABA transport impair and neurological disorders 
As GATs are the main responsible for GABA clearance from synapse, 
a transporter dysfunction will consequently originate an unbalance 
in GABA concentrations, which has been associated with several 
pathologies, especially in epilepsy (e.g. Richerson and Wu, 2004), in 
which some therapeutic options are related with GABA transporter. 
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A possible therapeutic option in epilepsy is to increase the inhibitory 
tone in order to prevent seizures. This can be achieved through the 
blockade of GABA uptake or by the reversal of GABA transporters. 
Interestingly, in animal models, specific blockers of GAT-1 and 
blanket GABA transporter inhibitors have been shown to be 
selectively effective against different types of seizures. This can be 
due to a differential distribution of GABA transporters among brain 
regions. GAT-1 is predominantly expressed in the forebrain and 
limbic areas while GAT-3 is mainly presented in the brainstem. The 
kindled focal and generalised secondary seizures, and clonic 
convulsions, induced by chemoconvulsants and originated in limbic 
system or forebrain, are abolished by GAT-1 blockers. On the other 
hand, convulsions induced by electro shocks (originated in the basal 
ganglia and brainstem) are inhibited by non-selective GATs inhibitors 
(Nielsen et al., 1991; Swinyard et al., 1991; Dalby et al., 1997). 
Actually, the discovery of a potential use of GABA transporter 
inhibitors in epilepsy occurred thirty years ago (Krogsgaards-Larsen 
et al., 1981) and since then, several non-selective inhibitors have 
been experimentally demonstrated to possess anticonvulsant 
activity (Dalby et al., 1997; Dalby, 2003; White et al., 2005). 
Nowadays, tiagabine, a specific GAT-1 inhibitor (Borden et al., 1994), 
is used as an adjuvant therapy for patients with focal seizures, 
namely with complex partial temporal lobe epilepsy and secondary 
generalised tonic-clonic seizures (Uthman et al., 1998).  
Other therapeutic approach involving the GATs reversal is the use of 
vigabatrine, which blocks GABA transaminase, the enzyme 
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responsible for GABA catabolism. The inhibition of GABA 
transaminase will increase GABA intracellular levels, favouring the 
reversal of GABA transporters (Wu et al., 2001, 2003).  
The reversal of GABA transporters was also observed during 
ischemic conditions, where the increase of extracellular K+, by the 
inactivation of Na+/K+ ATPase, is enough to reverse GATs. In fact, 
GAT-1 inhibition reduced the amount of GABA released (and 
subsequently, cell swelling) during energy deprivation (Zeevalk and 
Nicklas, 1996). So, although it has been considered that the 
potentiation of GABAergic transmission contributes to reduce 
ischemia-induced damage (Green et al., 2000), the neuroprotective 
effect mediated by GATs inhibition can be related with a decrease in 
the GABA released by the reversal of transporters (and consequently 
to a decrease in extracellular GABA levels) instead of being 
associated with a enhancement in extracellular GABA, caused by the 
blockade of GABA uptake, as some authors had suggested (Phillis, 
1995; Green et al., 2000). The reversal of GATs associated with an 
increase in intracellular GABA concentrations, which is also observed 
during ischemia (Erecinska et al., 1984), contributes to an 
overactivation of GABAA receptors, which leads to an increased 
influx of Cl- ions, and subsequently, to cell swelling and eventually 
cell death.   
The enhancement in intracellular GABA levels is the result of three 
different aspects: first, the reduced ATP levels found under ischemia, 
stimulate GABA synthesis by GABA decarboxylase (Madl and Royer, 
2000); second, the reduction of pH, that occurs under ischemia, 
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inhibits GABA transaminase, leading to an accumulation of 
intracellular GABA (Madl and Royer, 2000);  third, the disruption of 
vesicular H+-dependent GABA storage during ischemia rises 
cytoplasmic GABA, promoting GABA transporters reversal under 
ischemic conditions (see Allen et al., 2004). Recently, Clarkson and 
colleagues identified an excessive tonic inhibition after stroke which 
was associated to the observed decrease in GAT-3 expression in 
peri-infarct cortex (Clarkson et al., 2010).  Thus, besides the reversal 
of the transporters, changes in transporters expression are also 
associated with ischemic conditions, which make GATs potential 
targets in treatment of stroke. 
1.1.3.9 Influence of GATs upon tonic and phasic GABAergic 
transmission. 
GABA acts through GABAAR and mediates both phasic and tonic 
inhibition. Phasic inhibition is a transient and point-to-point 
phenomena, as a consequence of the release of GABA following 
nerve terminal depolarization, leading to inhibitory postsynaptic 
currents (IPSCs). Tonic inhibition is associated with the spillover of 
GABA outside the synaptic areas leading to lower but sustained 
extracellular GABA levels. The main feature of phasic GABAAR-
mediated inhibition is the rapid synchronous opening of a relatively 
small number of channels that are clustered at the synaptic junction, 
whereas tonic inhibition results from random, temporally dispersed 
activation of receptors that are distributed over the neuronal 
surface. This distinction involves a deep difference in the control of 
Introduction 
22 
neuronal network activity by phasic and tonic forms of inhibition 
(see Farrant and Nusser, 2005). 
At the central nervous system, the extracellular GABA concentration 
ranges from 0.2 to 2.5µM (Lerma et al., 1986; Tossman et al., 1986; 
Ding et al., 1998; Kuntz et al., 2004). At ambient GABA 
concentrations, the extra- and peri-synaptic GABAAR are 
preferentially activated as they have higher affinity for GABA, as 
compared to synaptic GABAAR.  These extra-synaptic receptors are 
then responsible for tonic inhibition (Brickley et al., 1996; Farrant 
and Nusser, 2005), which is highly related with sustained changes in 
extracellular GABA concentration, therefore to changes in the 
activity of GABA transporters. In fact, GABA transporters are 
responsible for the maintenance of homeostatic GABA levels. This 
control can be achieved by changes in uptake rates- which are 
related with protein surface expression – but also by the reversal of 
GABA transporters (Gaspary et al., 1998; Richerson and Wu, 2004). 
Some electrophysiological studies have reported the influence of 
GATs in GABAergic transmission. For instance, in rat neocortex and 
in the hippocampus, GAT-1 blockers increase the decay time of 
evoked inhibitory post-synaptic currents (eIPSCs) without modifying 
the spontaneous IPSCs (sIPSCs) (Thompson and Gahwiler, 1992; 
Engel et al., 1998; Overstreet and Westbrook, 2003; Keros and 
Hablitz, 2005), as well as enhance the amplitude of tonic GABAAR 
mediated currents (Nusser and Mody, 2002; Semyanov et al., 2003; 
Keros and Hablitz, 2005; Marchionni et al., 2007;), thus indicating 
that GAT-1 affects both tonic and phasic GABAergic transmission. 
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This influence of GAT-1 upon phasic and tonic transmission was 
further confirmed by Bragina and colleagues, using GAT-1 KO mice 
(first characterized by Jensen in 2003), who showed that a chronic 
impairment in GAT-1-mediated GABA uptake in the neocortex 
modifies both phasic and tonic GABAAR-mediated inhibition. GAT-1 
KO mice showed an increase in glutamate decarboxylase 
(GAD65/67) expression but no changes in GAT-3 expression or 
distribution (Bragina et al., 2008). 
The influence of GABA transporters upon tonic transmission is 
probably related with transporters features, since GATs just take up 
GABA until reach equilibrium, being not able to remove all the 
extracellular GABA. This implies that a small (few micromolar) 
amount of GABA remains extracellularly, being enough to activate 
extra-synaptic GABAA receptors, which are the responsible for tonic 
inhibition. 
The majority of studies about the influence of GABA transporters 
upon GABAergic transmission have been focused in the neuronal 
transporter, GAT-1. But, recently, a study had highlighted the role of 
glial transporter GAT-3 upon GABAergic transmission. It was 
observed that the GAT-3 blockade (just when GAT-1 was previously 
blocked) reduces the frequency of sIPSC (Kirmse et al., 2009), 
attributing to GAT-3, a role in modulation of phasic GABAergic 
transmission, at least when GAT-1 is blocked, which means that the 
contribution of GAT-3 under basal conditions is still unclear. 
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1.2 The tripartite synapse and glial cells 
For many years, glial cells were considered as supportive cells and 
unable to communicate with neurons or other glial cells. But, in the 
90’s years, several studies revealed the existence of bidirectional 
communication between neurons and astrocytes. These different 
studies led Araque and colleagues to propose that synapses are 
tripartite, consisting of synaptically associated glia as well as the 
presynaptic and the postsynaptic terminals (Araque et al., 1999). 
 It was probably the discovery that astrocytes can be excited non-
electrically that expanded the brain communication to non-synaptic 
elements and changed the paradigm of brain function based on 
neuronal activity to a function dependent on neuron-glia network.  
There are four different types of glial cells: astrocytes, 
oligodendrocytes, microglia and Schwann cells. The first three are 
present in the central nervous system while the last one can be only 
found in the peripheral nervous system. Oligodendrocytes and 
Schwann cells are responsible for myelin production while microglia 
is related with immune defense of nervous system.  
1.2.1 Astrocytes  
The central nervous system is mainly composed of glia, in a 
proportion (in humans) of 1 neuron to 10 glial cells. These cells were 
identified by Rudolf Virchow in 1858. In his lecture, he described 
astrocytes as connective tissue, a kind of as “nervenkitt” or nerve-
cement. Virchow named these cells as neuroglia (Virchow, 1858, 
quoted by Kettenmann and Verkhratsky, 2008).  Although for him 
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neuroglia was a connective tissue, he admitted that it also contained 
a certain number of cellular elements. But Virschow was not the first 
to identify glial elements, Robert Remak had previously described, in 
1838, a sheath around single nerve cells (R. Remak, PhD Thesis, 
University of Berlin, 1838, quoted by Kettenmann and Verkhratsky, 
2008) and Heinrich Müller had previously discovered the radial 
fibers in the retina in 1851 (these cells were latter called as Müller 
glial cells).  
During the following years, many different forms of glial cells were 
described and images were published (Deiters, 1865; Henle and 
Merkel, 1869; Golgi, 1903, quoted by Kettenmann and Verkhratsky, 
2008). Later, in 1893, Michael von Lenhossek proposed the name 
astrocyte (von Lenhossek, 1893, quoted by Kettenmann and 
Verkhratsky, 2008). Astrocytes were then classified as fibrous or 
protoplasmic astrocytes by Kölliker (Kölliker, 1889, quoted by 
Kettenmann and Verkhratsky, 2008) and Andriezen (Andriezen, 
1893, quoted by Kettenmann and Verkhratsky, 2008).  Thus, 
although they are known since the 19th century, astrocytes were 
neglected for a long time, probably because they are not able to 
generate action potentials. They used to be considered as silent and 
supportive cells with relevant roles in metabolic pathways and also 
neurotransmitters uptake from synapse. In fact, it was early 
suggested that glial cells may remove and inactivate the products of 
neuronal activity (Lugaro, 1907, quoted by Henn and Hamberger, 
1971). Later, it was shown that glial cells have the ability to 
accumulate amino acids (aspartic acid, threonine, serine, proline;  
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Hamberger, 1971) as well as neurotransmitters (glutamate, glycine, 
norepinephrine, serotonin, dopamine and γ-aminobutyric acid; 
Hamberger, 1971; Henn and Hamberger, 1971). 
Then, in the early 90’s, the arousal of fluorescence imaging 
techniques to monitor intracellular calcium levels, allow to identify a 
form of excitability based on variations of intracellular calcium 
concentration in astrocytes (Charles et al., 1991; Cornell-Bell, 1990). 
 These studies suggested the involvement of non-neuronal elements 
to synaptic and non-synaptic transmission and came to revolutionize 
the field. Thus, nowadays astrocytes are considered as greatly 
polyvalent cells that are implicated in virtually all processes in the 
CNS. A single astrocyte can sense the activity and integrate the 
function of hundreds of neurons within its domain. Furthermore, 
each astrocyte extends processes to wrap blood vessels. Then, 
astrocytes work as local integration units and bridges between 
synaptic and non-synaptic communication (Volterra and Meldolesi, 
2005), also control brain homeostasis.  
1.2.1.1 Astrocytes excitation 
The excitation of astrocytes in the form of calcium waves can be 
divided in two main categories: one is dependent on chemical 
signals generated by neuronal circuits (neuron-dependent 
excitation) and the other is independent of neuronal input 
(spontaneous excitation) (see Volterra and Meldolesi, 2005).  
Neuron-dependent excitation of astrocytes is a widespread 
phenomenon that was firstly described in the hippocampus and 
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cerebellum (Bezzi and Volterra, 2001; Haydon, 2001). Different 
molecules are involved in this type of excitation: glutamate, GABA, 
acetylcholine, noradrenaline, dopamine, ATP, nitric oxide and brain 
derived neurotrophic factor (BDNF) (Khan et al., 2001; Matyash et 
al., 2001; Araque et al., 2002; Rose et al., 2003; Zhang et al., 2003; 
Zonta et al., 2003; Bowser and Khakh, 2004; Fellin et al., 2004). 
Astrocytes can discriminate neuronal inputs of different origins, and 
can integrate concomitant inputs. In fact, it was shown that 
astrocytes discriminate between the activity of cholinergic and 
glutamatergic synapses and also distinguish glutamatergic activity 
belonging to different axon pathways, for example, astrocytes have 
the ability to discriminate between the glutamate released by 
Schaffer collaterals or by alveus terminals (Perea and Araque, 2005).  
Astrocytic spontaneous excitation was initially described in acute 
brain slices (Parri et al., 2001; Aguado et al., 2002; Nett et al., 2002) 
and later during in vivo recordings (Hirase et al., 2004; Nimmerjahn 
et al., 2004). Spontaneous excitation occurs especially during 
development and decreases considerably during the first two 
postnatal weeks, when synaptic circuit formation occurs (Parri et al., 
2001). This form of astrocyte excitation decreases but does not 
disappear with adulthood (Nett et al., 2002; Aguado et al., 2002) and 
it is generated by calcium release from internal stores when IP3 
receptors are activated, supplemented by influx of extracellular 
calcium, possibly through voltage-gated channels (Parri et al., 2001; 
Nett et al., 2002; Aguado et al., 2002). Importantly, spontaneous 
excitation of astrocytes can result in the excitation of neighbouring 
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neurons (Parri et al., 2001). So, both neurons and astrocytes are 
sources of excitation, and operate in coordinated networks (Aguado 
et al., 2002; Hirase et al., 2004; Nimmerjahn et al., 2004). In fact, 
astrocytes are active players in synaptic transmission, and they 
express a range of neurotransmitter receptors (Kettenmann et al., 
1984; Verkhratsky and Steinhauser, 2000), which allow them to 
sense synaptic activity. On the other hand, astrocytes can modulate 
transmitter levels in the synapse through the release of 
gliotransmitters by exocytosis, transporters or membrane channels 
(Volterra and Meldolesi, 2005; Pankratov et al., 2006), or by 
neurotransmitter uptake (Tzingounis and Wadiche, 2007).   
1.2.1.2 Gliotransmission 
According to Volterra and Meldolesi, a gliotransmitter is a substance 
that respects four criteria: (1) it is synthesized and/or stored in glial 
cells; (2) it shows a release regulated by physiological stimuli; (3) it 
promotes fast (milliseconds to seconds) responses in neighbouring 
cells; and (4) it has a role in physiological processes (Volterra and 
Meldolesi, 2005). Later, a fifth criterion was proposed: the release of 
gliotransmitter can be regulated by pathological stimuli (Martín et 
al., 2007).  
Gliotransmitter release can occur by both exocytosis and non-
exocytosis mechanisms, but for a long time, it was not clear that 
astrocytes expressed the necessary machinery to exocytose 
gliotransmitters. In 2004, a clear synaptic-like microvesicle (SLMV) 
compartment, which is competent for glutamate exocytosis was 
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identified in adult hippocampal astrocytes as well as a calcium 
dependent exocytic mechanism in cultured astrocytes (Bezzi et al., 
2004). The SLMV resembles glutamatergic synaptic vesicles, 
although less packed (Volterra and Meldolosi, 2005). This SLMV 
expresses exocytic proteins as R-SNAP, R-SNARE, VAMP3 and also 
vesicular glutamate transporters, vGLUTs (Bezzi et al., 2004). 
Furthermore, astrocytic exocytosis is quite different from neuronal 
exocytosis, since it is significantly slower than in neurons and the 
release machinery shows a higher affinity for calcium (Bezzi et al., 
2004; Kreft et al., 2004).  
On the other hand, gliotransmitter exocytosis is obviously not 
triggered by the entry of extracellular calcium in response to action 
potentials but by the activation of GPCR, which lead to an IP3-
induced Ca2+ release from endoplasmic reticulum.  
Further differences related with exocytic proteins expression have 
been described (see Volterra and Meldolosi, 2005). 
Considering calcium changes, the increment of calcium is probably 
not the only mechanism involved in gliotransmitters release. In fact, 
other stimuli can evoke release of transmitters (Muyderman et al., 
2001; Joseph et al., 2003). For example, it was described that GPCR-
induced glutamate release was abolished by inhibiting the synthesis 
of prostaglandins, TNF-α or both (Bezzi et al., 1998, 2001; Pasti et 
al., 2001).  
Non-exocytic gliotransmitters release occurs through specialized 
proteins as channels or transporters present in the membrane of 
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astrocytes. Different plasma membrane channels have been 
associated with non-exocytic transport such as: (1) volume-
regulated anion channels (VRACs); (2) GAP-junction hemichannels; 
(3) purinergic P2X receptors; and (4) cystine-glutamate antiporter. 
Under hypo-osmotic conditions such ischemia, astrocytes swell and 
became permeable to anionic aminoacids as glutamate, aspartate 
and taurine, which are released through VRAC (Kimbelberg et al., 
1990). 
GAP junctions form a pore between two adjacent cells, connecting 
their cytoplasm, and allowing molecules up to 1kDa to diffuse 
between adjacent cells (Malarkey and Parpura, 2008). GAP junctions 
are constituted by two connexins, usually named as hemichannels. 
These hemichannels can open directly to the extracellular space, 
allowing the release of different compounds. In fact, the opening 
probability of gap hemichannels is very low at physiological 
conditions but increases as the calcium concentration goes down, 
allowing the release of glutamate (Ye et al., 2003) and ATP (Arcuino 
et al., 2002; Stout et al., 2002). 
Purinergic P2X7 ion channel could mediate the release of glutamate. 
Application of ATP to cultured astrocytes expressing P2X7 receptors 
induced an inward current that was increased by low divalent cation 
external solution. The induced current was insensitive to voltage 
changes, which differentiates it from channels such as gap junctions. 
Release of glutamate was induced by ATP application. This release 
seems to be calcium independent since glutamate release was not 
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reduced after cell incubation with a membrane permeable calcium 
chelator (Duan et al., 2003). 
Glutamate release has been also associated with Na+-independent 
cystine/glutamate exchanger. Astrocytes are known as the main 
source of glutathione in central nervous system and its synthesis is 
dependent on the cystine uptake that occurs through both plasma 
membrane Na+-independent cystine/glutamate exchanger and Na+-
dependent glutamate transporters (see McBean, 2002). Although 
under physiological condition, cystine/glutamate exchanger has no 
effect on glutamate release (Cavalier and Atwell, 2005); it can 
assume more relevance when cystine levels are modified. 
Finally, gliotransmitter can also be released by the reversal of glial 
transporters. Regarding glutamate, once in the synapse, it is mainly 
taken up by glial cells through the specific transporters, GLAST and 
GLT-1 (Gadea and López-Colomé, 2001). In physiological conditions, 
and due to the fast conversion of glutamate into glutamine, the 
transporters do not usually revert. But, under pathophysiological 
conditions, such as ischemia, the ionic unbalance (increased K+ 
levels) can favour the transporter reversal, allowing glutamate 
release. In fact, it was reported for the first time in 1990, that the 
reversal of glutamate transporters is triggered by an elevation of 
extracellular potassium levels (Szatkowski et al., 1990). Although the 
range of potassium levels used in that work never occur under 
physiological conditions, several studies using transporter blockers 
have shown that reversal of glutamate transporters can occur during 
periods of ischemia or metabolic blockade (Longuemare and 
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Swanson, 1995; Zeevalk et al., 1998; Seki et al., 1999; Li et al., 1999; 
Rossi et al., 2000). Importantly, it was shown that the reversal of 
glutamate transporters can be a major event leading to astrocytic 
cell death (Re et al., 2006). However, the extracellular increase of 
glutamate levels is not the cause of astrocytic death, being the result 
of depletion of cytoplasmic glutathione (Malarkey and Parpura, 
2008). In fact, glutathione synthesis is dependent on the cystine 
uptake, which occurs through the above mentioned 
cystine/glutamate exchanger. The reversal of glutamate transporters 
depletes intracellular glutamate and abolishes the uptake of cystine, 
causing oxidative stress, which ultimately can result in cell death.  
Comparing to glutamate, few studies about astrocytic GABA release 
have been done. But it was shown that activation of glutamate 
transporters results in GABA release through reversal of glial GABA 
transporters (Héja et al., 2009). More recently, it was shown that 
besides potassium elevation and glutamate, glycine and d-serine are 
also able to induce astrocytic release of GABA (Lee et al., 2011a). 
Further, GABA release was reduced when IP3 receptors were 
previously blocked, suggesting that GABA release can be associated 
not only with calcium influx from outside but also from intracellular 
calcium stores, in response to metabotropic receptor activation (Lee 
et al., 2011a). Furthermore, additional GABA was found to be 
released in the presence of BAPTA, a calcium chelator, corroborating 
previous results showing that GABA can be released from astrocytes 
in a calcium independent way, through transporter reversal.  
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So, astrocytes modulate synaptic transmission both by release of 
gliotransmitters and by uptake of neurotransmitters. The uptake is 
particularly relevant in the case of glutamate, as it is mainly taken up 
into astrocytes. On the other hand, GABA is mainly taken up by pre-
synaptic terminals. However the role of glial GABA transporters in 
the clearance of synaptic GABA is not negligible (see Schousboe et 
al., 2004). 
Astrocytes are also involved in shaping synaptic connectivity in the 
brain by controlling the genesis and maintenance of synapses and 
also by affecting synaptic strength and plasticity (see Kettenmann 
and Verkhratsky, 2008). Furthermore, it seems that astrocytes can 
behave as a stem cell since they have the ability to re-enter in the 
cell cycle and produce all types of neural cells, from neurons to 
microglial cells (see Kettenmann and Verkhratsky, 2008). 
Astrocytes are also involved in the control of brain homeostasis 
through several distinct mechanisms: regulation of volume and 
composition of extracellular space, namely K+ and neurotransmitters 
levels and water movement (see Kettenmann and Verkhratsky, 
2008); control of blood-brain barrier (see Kettenmann and 
Verkhratsky, 2008); release of reducing equivalents as glutathione 
(see Giaume et al., 2007); chemoattraction of cells to their territory, 
for example, astrocytes coordinate the spatial positioning of 
oligodendrocytes (Tsai et al., 2002), attract microglia and 
lymphocytes during inflammatory reactions and after injuries 
(Babcock et al., 2003; Marella and Chabry, 2004) and may drive 
reparative neural stem cells to lesion sites (Imitola et al., 2004). 
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Astrocytes, through the release of GABA, can also regulate microglia 
function. It was recently shown that GABA can suppress the reactive 
response of both astrocytes and microglia to the inflammatory 
stimulants lipopolysaccharide (LPS) and interferon-γ by inhibiting 
induction of inflammatory pathways mediated by NFκB and p38 
MAP kinase (Lee et al., 2011b). These findings shed a new light upon 
the role of astrocytes on immunological responses in CNS but also a 
new role for GABA, which by becoming a player in inflammatory 
reactions, clearly exceeds its role as the classical main inhibitory 
neurotransmitter.  
In fact, astrocytes respond to traumatic and chemical brain injury, 
gliosis and astrocytic swelling (see Aschner, 1998). Astrogliosis 
implies phenotypic alterations, astrocyte proliferation and growing, 
up-regulation of enzymes and cytoskeletal proteins, as glial fibrillary 
acidic protein (GFAP) and vimentin. An increase in the levels of 
transforming growth factor β (TGFβ), nerve growth factor (NGF), 
basic-fibroblast growth factor (bFGF) and growth factors receptors, 
as truncated forms of TrkB also occurs. These processes are usually 
regarded as neuroprotective, since they involve the production of 
neurotrophins and isolate damaged tissue (see Daré et al., 2007). 
Astrogliosis is also associated with an increase in extracellular 
adenosine. Moreover, the elevated levels of adenosine that follow 
brain injury could modulate astrogliosis, as suggested by the 
increase number of GFAP-positive cells after microinjection of an 
adenosine analogue into rat cortex (Hindley et al., 1994). 
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1.3 Adenosine 
Adenosine, which is a well-known neuromodulator, was first 
described in the heart, where it causes bradycardia and dilates the 
coronary arteries, causing a reduction in arterial pressure (Drury and 
Szeent-Györgi, 1929).  
 
Figure 1.9 – Chemical structure of adenosine. Adenosine is a nucleoside, 
constituted by the purine adenine and a ribose ring. 
The possibility of purinergic neurotransmission was first raised in 
1954 when Holton and Holton suggested that ATP could be the 
transmitter released at central and peripheral terminals of sensory 
nerve fibers (Holton and Holton, 1954). Twenty years would pass 
before a specific role for adenosine in neurotransmission was 
hypothesized, after the discovery that iontophoretic applications of 
adenosine or its nucleotides caused a potent depressant effect on 
the responses of neurons (Phillips et al., 1974, 1975, 1979a, b; 
Kostupoulos et al., 1975; Kostupoulos and Phillis, 1977). 
In addition to the description of its electrophysiological effects, in 
1970, adenosine was classified as a potent activator of adenylate 
cyclase, capable of promoting cAMP production in the brain (Sattin 
and Rall, 1970). In 1976, it was suggested that adenosine effects 
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might be mediated by an adenylate cyclase-linked extracellular 
receptor (Mah, 1976).  
The role of adenosine as a neurotransmitter or as a neuromodulator 
at the central nervous system was reinforced by different studies 
showing its release, in a calcium-dependent manner, from several in 
vivo and in vitro preparations (Pull and Mcllwain, 1972; Sulakhe and 
Phillis, 1975; Kuroda and Mcllwain, 1974; Schubert et al., 1976; 
Daval et al., 1980; Jhamandas and Dumbrille, 1980). 
Although adenosine is not a classical neurotransmitter, there is 
some evidence that it may act as a retrograde messenger: when 
released by a postsynaptic neuron (that was loaded with adenosine 
by a patch pipette), adenosine was able to inhibit by 80% the 
excitatory postsynaptic potentials in that cell, suggesting that 
neurons, through the release of adenosine, can regulate their own 
excitatory afferents (Brundege and Dunwiddie, 1996). 
Thus, without being a neurotransmitter, adenosine influences 
synaptic transmission, at the pre-synaptic level by inhibiting or 
promoting neurotransmitter release; pos-synaptically by 
hyperpolarizing or depolarizing neurons; and also non-synaptically 
by modulating glial cell activity. 
In fact, one of the most prominent pre-synaptic effects of adenosine, 
through A1 receptors activation, is the ability to inhibit the release of 
virtually every classical neurotransmitter. Still, adenosine most 
prominent effects occur upon excitatory glutamatergic synapses 
(e.g. Dunwiddie and Hoffer 1980; Kocsis et al., 1984), where it can 
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often completely abolish synaptic transmission. Indeed, a major role 
of adenosine is to reduce excitability in the brain.  
Adenosine can also promote neurotransmitter release (by A2A 
receptors activation), although this type of modulation is much less 
frequent (Cunha et al., 1994, Cunha and Ribeiro, 2000).  
Adenosine is also regarded as an important neuroprotector, being 
these effects mainly mediated by the activation of A1 receptors. 
Furthermore, adenosine efficiently connects synaptic activity, 
energy expenditure and nucleic acid metabolism, by acting as a 
sensor of the bioenergetic state of the cell (Newby et al., 1985). 
Moreover, adenosine directly regulates transmethylation reactions, 
including DNA methylation (Boison et al., 2002), which can lead to 
long-lasting epigenetic modifications.   
Other than at the cellular level, the influence of adenosine upon 
cerebral blood flow enables it to further act as an energy balancing 
metabolite: when metabolism is increased, elevated ATP catabolism 
will produce higher amounts of adenosine, which (through the 
activation of A2A receptors, Phillis, 1989) will induce vasodilation, 
allowing an improvement of oxygen and nutrient delivery via the 
cerebral vasculature.  
1.3.1 Adenosine synthesis 
In the central nervous system, the main source of adenosine is the 
dephosphorylation of 5’-AMP by 5’-nucleotidases (5’-NTs), (Meghji, 
1993). These enzymes dephosphorylate non-cyclic nucleoside 
monophosphate to nucleosides and inorganic phosphate. So far, 
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seven distinct nucleoside monophosphate phosphohydrolases or 5’-
nucleotidases (EC 3.1.3.5 and EC 3.1.3.6) have been cloned. 
Nucleotidases are responsible for both intracellular and extracellular 
synthesis of adenosine from the dephosphorylation of AMP. An 
alternative source of adenosine concerns the hydrolysis of S-
adenylhomocysteine (SAH), which is catalyzed by SAH hydrolase 
(SAHH) (Palmer and Abeles, 1979). 
1.3.1.1 Extracellular synthesis of adenosine 
Adenosine found at the extracellular space can be released via 
equilibrative nucleotide transporters or be synthesized locally via 
ATP catabolism, which involves several enzymes, namely: ecto-
nucleotidases, ecto-phosphodiesterases, and apyrases. These 
enzymes dephosphorylate all the adenine nucleotide into 5’-AMP, 
which is then dephosphorylated by ecto-5’-nucleotidase into 
adenosine. The entire catalytic pathway is complete in a few 
hundred milliseconds, and the rate-limitative step is the 
dephosphorylation of AMP into adenosine by ecto-5’-nucleotidase 
(Dunwiddie et al., 1997). 
1.3.1.2 Ecto-nucleotidase 
After the vesicular release of ATP (which is co-secreted with 
neurotransmitters), ATP is metabolized by ecto-ATPase, ecto-
ADPase and finally ecto-5’-nucleotidase, originating adenosine 
(Richardson et al,. 1987; Zimmermann et al., 1986). Additionally, 
cAMP can also be released into the extracellular space, by 
probenecid-sensitive transporter (Rosenberg and Li, 1995), 
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contributing to increase extracellular adenosine concentrations 
(Dunwiddie et al., 1992; Brundege et al., 1997). 
Ecto-nucleotidases are able to convert most nucleotides (except 
cAMP) into adenosine in less than a second (Dunwiddie et al., 1997). 
Ecto-nucleotidases are highly expressed in the brain, where they are 
mainly associated with glial cell membranes (Naidoo, 1962; 
Kreutzberg et al., 1978; Schoen and Kreutzberg, 1995). Functionally, 
there is some evidence that ectonucleotidases are in close physical 
proximity with pre-synaptic inhibitory A1 receptors (see Dunwiddie 
and Masino, 2001).  
1.3.1.3  Intracellular synthesis of adenosine 
For the net extracellular adenosine levels, the intracellular synthesis 
of adenosine is at least as significant as adenosine formation from 
breakdown of extracellular ATP (Lloyd et al., 1993; Lloyd and 
Fredholm, 1995). Intracellular synthesis of adenosine occurs mainly 
by AMP dephosphorylation, which is catalyzed by cytoplasmic 
nucleotidases. The presence of cytosolic 5’-nucleotidase in the brain 
was firstly demonstrated in 1982 (Montero and Fes, 1982).  
Another source of adenosine is the transmethylation pathway, 
where adenosine results from the hydrolysis of S-
adenosylhomocysteine (SAH) catalyzed by SAH hydrolase (SAHH, 
E.C.3.3.1.1), which also originates L- homocysteine (Palmer and 
Abeles, 1979; Schrader et al., 1981). This enzyme was firstly 
described in 1959, in rat liver. SAHH catalyses a reversible reaction, 
that preferentially evolves towards S-adenosylhomocysteine 
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synthesis (de la Haba and Cantoni, 1959). SAHH is expressed by most 
brain areas, being the higher expression levels present at cortex and 
cerebellum. Inside the cell, SAHH displays a nuclear expression 
where it is involved in transmethylation mechanisms. In detail, 
different methyl-transferases convert S-adenosylmethionine (SAM) 
into S-adenosylhomocysteine (SAH), which is then metabolized into 
adenosine and homocysteine by S-adenosylhomocysteine hydrolase 
(SAHH). So, adenosine is an obligatory end product of SAM-
dependent transmethylation reactions and because of that is able to 
inhibit methylation reactions. To avoid this inhibition, adenosine is 
phosphorylated into AMP by a long isoform of adenosine kinase 
(ADK), which was described as a nuclear ADK (Cui et al., 2009). 
Under normal conditions SAHH has low impact upon neuronal 
excitability (Pak et al., 1994), suggestive of a minor role in the 
control of cytoplasmic levels of adenosine in neurons.  
1.3.2 Nucleoside transporters 
Intracellular adenosine is not stored in vesicles nor released by 
exocytosis as a classical neurotransmitter. Instead, adenosine is 
released to the extracellular space through nucleoside transporters. 
Besides releasing adenosine, adenosine transporters also take it into 
the cell. The relevance of adenosine uptake by nucleoside 
transporters in terminating adenosine effects was first supported by 
different studies showing that nucleoside transporter blockade 
produce vasodilation, potentiate the ability of adenosine or 
decrease locomotor activity (Crawly et al., 1983), depresses 
neuronal activity (Motley and Collins, 1983), increases nociceptive 
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thresholds (Yarbrough and McGuffin-Clineschmidt, 1981), and exerts 
anti-convulsive effects (Dragunow and Goddard, 1984). Therefore, 
nucleoside transporter inhibitors exacerbate the effects mediated by 
adenosine.  
Nucleoside transporters can be divided in two main classes: the 
equilibrative (Na+-independent) nucleoside transporters (ENTs) and 
the concentrative (Na+-dependent) nucleoside transporters (CNTs) 
(Baldwin et al., 1999). Six isoforms of CNTs (CNT1 - CNT6) and four 
isoforms of ENTs (ENT1 - ENT4) have been cloned, to date. 
Equilibrative transporters mediate nucleoside transport in both 
directions, depending on the nucleoside concentration gradient 
across the membrane. The four transporters are widely distributed 
and all of them are able to transport adenosine but they have 
different abilities to transport other nucleosides (Balwin et al., 
2004). The transport mediated by concentrative transporters is 
independent of nucleoside gradient, being coupled to sodium.  
Adenosine uptake in the brain occurs primarily by facilitated 
diffusion via equilibrative transporters, although some of it (10-20%) 
can be mediated by concentrative transporters (Geiger and Fyda, 
1991; Parkinson et al., 1994). 
Nucleoside transporters are essential to facilitate the diffusion of 
adenosine produced in the cytoplasm to the extracellular space. 
They are also crucial to regulate the levels of extracellular adenosine 
as transporters are the main molecules responsible for removing 
adenosine from the extracellular space (Geiger and Fyda, 1991). 
They are thus responsible for restraining, both spatial and 
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temporally, purinergic modulation. As adenosine can be transported 
into and out the cells by equilibrative transporters, regulation of 
intracellular adenosine levels is critical to the regulation of 
extracellular adenosine concentration. Then, if the intracellular 
adenosine rises, ENTs will release adenosine for the extracellular 
space and when extracellular adenosine increases, ENTs will uptake 
the nucleoside into the cells. So, changes in the activity of enzymes 
involved in adenosine metabolism will modify the transporters 
activity.  Transporter inhibitors can either increase (Sanderson and 
Scholfield, 1986; Phillis et al., 1989; Dunwiddie and Diao, 1994) or 
decrease (Gu et al., 1995) extracellular adenosine levels, depending 
on the transmembrane adenosine gradient and consequently 
depending on transport direction, into or out the cell. However, 
since the extracellular synthesis of adenosine from catabolism of 
nucleotides constitutes an alternative source of adenosine, the 
direction of transport is usually in the inward direction. Therefore, 
transporter inhibition usually leads to an increase in the extracellular 
levels of adenosine. Recent data suggests that, even under ischemic 
conditions, neuronal ENTs work in the inward direction, since 
adenosine uptake into neurons outweighs adenosine release (Zhang 
et al., 2011). Thus, this result suggests that nucleoside transport 
activity restrains the neuroprotective effect of adenosine under 
ischemic conditions.  
The source of adenosine may influence the activation of the 
different adenosine receptors subtypes. Thus, adenosine released by 
nucleoside transporters will activate preferentially A1 receptors, 
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while adenosine derived from the extracellular catabolism of 
nucleotides will mainly act on A2A receptors (Cunha et al., 1996). 
1.3.3 Adenosine degradation  
Unlike its nucleotides, adenosine is usually not degraded outside the 
cell. So, adenosine must be first taken up through nucleoside 
transporters and then be inactivated either by deamination through 
adenosine deaminase (ADA) or by phosphorylation through 
adenosine kinase (ADK). 
It is accepted that the catabolic reaction responsible for adenosine 
degradation is dependent on its intracellular concentration. As such, 
at low concentrations, adenosine is mainly inactivated by 
phosphorylation while at higher concentrations, ADK activity is 
saturated and adenosine is predominantly deaminated by adenosine 
deaminase (Meghji and Newby, 1990). 
1.3.3.1  Adenosine Kinase 
Adenosine Kinase (ADK, EC 2.7.1.20) is the major adenosine-
metabolizing enzyme, being expressed mainly in astrocytes. ADK 
phosphorylates adenosine into AMP. In fact, its low KM for 
adenosine suggests that ADK is the main enzyme responsible for 
adenosine catabolism, at least, for low adenosine concentration 
conditions. This premise is supported by several pieces of evidence: 
the fact that inhibition of ADK suppresses seizure activity in various 
models for epilepsy (Kowaluk and Jarvis, 2000); the release of higher 
amounts of adenosine by ADK-deficient fibroblasts in cultures, when 
compared to that released by ADA-deficient fibroblasts (Huber et al., 
Introduction 
44 
2001); the ability of ADK inhibition to increase endogenous 
adenosine and depress neuronal activity in hippocampal slices, 
which is not affected by ADA inhibition (Pak et al., 1994). In addition, 
the relevance of ADK for adenosine metabolism is also suggested by 
the existence of a substrate cycle between adenosine and AMP, 
which involves 5’-nucleotidase and ADK, functioning as an 
amplification system enabling small changes in ADK activity to result 
in significant changes in adenosine concentration. ADK and 
adenosine can be considered as key regulators of metabolism and 
cellular energetic balance. Both adenosine and ADK are involved in 
several physiological processes in most, if not all, invertebrate and 
lower species.  
The regulation of ambient adenosine levels by ADK seems to have a 
key role in the susceptibility of brain tissue to ischemic injury. The 
increase in adenosine levels that is induced by ischemia has been 
previously attributed to a downregulation of ADK expression (Lynch 
et al., 1998). Furthermore, transgenic mice overexpressing ADK, with 
decreased levels of adenosine, show a higher than expected cell 
death after a short period of ischemia (Pignataro et al., 2007). 
Indeed, pharmacological inhibition of ADK in animal models is an 
effective strategy to suppress epileptic seizures as well as to protect 
strategy from stroke induced injuries (Kowaluk et al., 1998).  
Moreover, ADK inhibitor has a better side-effect profile than the use 
of A1 receptors agonists (Kowaluk et al., 1998; Kowaluk and Jarvis, 
2000; Jarvis et al., 2002; Gouder et al., 2004). As a result, a novel 
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generation of ADK inhibitors has been developed, but its therapeutic 
use in clinical practice has not been established yet.  
1.3.3.2  Adenosine Deaminase 
Adenosine deaminase (ADA, E.C.3.5.4.4) catalyzes the hydrolytic 
deamination of adenosine to inosine. The importance of ADA for 
inactivation of adenosine was demonstrated several years ago. In 
1980, Dunwiddie and Hoffer described that ADA increases the size of 
evoked field responses in rat hippocampal slices (Dunwiddie and 
Hoffer, 1980). On the other hand, inhibition of ADA (by 
deoxycoformycin) causes adenosine-like sedative and hypnotic 
effects (Major et al., 1981; Radulovacki et al., 1983). Also, it was 
demonstrated that ADA inhibition prevents histological changes in 
the hippocampus by decreasing the infarct area and neuronal 
degeneration in animal models of global forebrain ischemia or focal 
ischemia (Lin and Phillis, 1992; Phillis and O'Regan, 1989). 
Although the enzyme localization is mainly cytosolic, there are 
several evidences supporting the existence of an ecto-enzyme, 
bound to the extracellular side of membrane (Franco et al., 1998). 
This ecto-ADA activity has been shown to have extra-enzymatic and 
co-stimulatory functional roles. It was, initially, described that ADA 
modulates ligand binding and signaling through A1 receptors in 
DDT1MF-2 cells (a smooth muscle cell line). In fact, it was shown 
that binding of ADA to adenosine A1 receptors increases their affinity 
for the ligand, suggesting that ADA was required for an effective 
coupling of G protein to A1 receptor. Ecto-ADA seems therefore to 
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play a crucial role in adenosine signaling by facilitating signal 
transduction via A1 receptors, an effect that was preserved even 
when ADA was enzymatically inactive (Ciruela et al., 1996).   
ADA and A1 receptors have a high degree of colocalization both at 
cellular membrane level and at intracellular vesicles, which suggest 
that ADA and A1 receptors can mutually regulate cell surface 
expression and also share a common endocytic pathway. Thus, in 
addition to its role upon A1 receptor signaling, ADA is also involved 
in A1 receptor desensitization (Ciruela et al., 1996; Saura et al., 
1998). Furthermore, the co-internalization of ADA and A1 receptor in 
the consequence of agonist stimulation is probably the molecular 
mechanism responsible for the enhancement of plasma adenosine 
levels found after caffeine and sulfophenyltheophylline consumption 
(Conlay et al., 1997).  
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Figure 1.10 – Schematic representation of adenosine metabolism. 
Adenosine can be synthesized intra- and extra-cellulary. Inside the cell 
adenosine is formed from AMP metabolism through endo-5’-nucleotidase 
(5’NT) or by the transmethylation reaction catalyzed by s-
adenosylhomocysteine hydrolase (SAHH), which converts s-
adenosylhomocysteine (SAA) into adenosine and homocysteine. At the 
extracellular space, adenosine derives from the metabolism of 
ATP/ADP/AMP, being the last reaction catalyzed by the ecto-nucleotidase 
(Ecto 5’NT). The release of adenosine through the equilibrative nucleoside 
transporters is an alternative source of adenosine. Regarding clearance of 
extracellular adenosine, in some cases it can be converted into inosine by 
ecto-adenosine deaminase (ecto-ADA) in the extracellular space, but in 
most cases adenosine is taken up by the equilibrative nucleoside 
transporter into cells where adenosine can be phosphorylated to AMP by 
adenosine kinase (ADK) or deaminated to inosine by adenosine deaminase 
(ADA). 
1.3.4 Adenosine levels regulation at brain 
In the brain, adenosine concentrations are normally kept in the 
range of 25-250nM (Dunwiddie and Masino, 2001) by a steady-state 
expression of ADK, which is mainly expressed by astrocytes (Gouder 
et al., 2004). Thus, physiological concentrations of adenosine are 
sufficient to tonically activate a substantial fraction of the high 
affinity A1 and A2A receptors (Dunwiddie and Masino, 2001).  
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The extracellular levels of adenosine are mainly regulated by an 
astrocyte-based adenosine cycle (Boison et al., 2010). Astrocytes 
expressed both equilibrative nucleoside transporters – ENT1 and 
ENT2 (which were described above) - and the adenosine uptake into 
astrocytes is driven by intracellular phosphorylation of adenosine 
into 5´-adenosine monophosphate by adenosine kinase (Boison et 
al., 2010).  
In fact, under normal conditions, ADK phosphorylates intracellular 
adenosine and keeps the intracellular concentrations low, which 
sustains the concentration gradient that allows adenosine uptake 
into the cells by equilibrative nucleosides transporters. However, 
conditions prompting an increase in intracellular adenosine will 
reverse transport direction, leading to release of adenosine into the 
extracellular space (Gu et al., 1995).  
The levels of extracellular adenosine seems to be regulated by both 
adenosine A1 and A2 receptors since A1 receptors blockade increases 
extracellular levels of adenosine in cardiac fibroblasts (Andresen et 
al., 1999), and activation of A2A receptors promotes adenosine 
transport in the hippocampus (Pinto-Duarte et al., 2005) and at 
chromaffin cells (Delicado et al., 1990). 
1.3.5 Adenine nucleotides, adenosine and signaling 
As mentioned before, at the extracellular space, adenine nucleotides 
are converted into adenosine. In the past, it was hypothesized that 
nucleotides, namely ATP, could directly activate adenosine 
receptors. Though the initial proposal of purinergic receptors 
Setting GABA levels: GABA transporters modulation by adenosine receptors 
49 
nomenclature made by Burnstock (1976) clearly postulated the 
existence of ATP and adenosine receptors separately, it is now 
plainly established that at the hippocampus, both ATP and ATP 
analogues have to be extracelullarly converted into adenosine to 
exert their inhibitory effects on synaptic transmission through the 
activation of adenosine A1 receptors (Cunha et al., 1998). 
Although ATP is not able to activate adenosine receptors, it acts 
through the activation of two different classes of membrane 
receptors, the ionotropic P2X and the metabotropic P2Y (for review, 
Ralevic and Burnstock, 1998). Also cAMP evolved as relevant second 
messenger, which regulates several intracellular phenomena.  
Finally, adenosine regulates many physiological processes, especially 
in excitable tissues as heart or brain, through the activation of four 
distinct G protein coupled receptors. 
In the brain, adenosine is involved in several physiological and 
pathological processes, namely, regulation of sleep, arousal, 
neuroprotection, epilepsy. The involvement of adenosine in a huge 
number of brain phenomena is related with a high expression of its 
receptors, although some adenosine effects are receptor-
independent. Interestingly, although adenosine is involved in 
relevant physiological roles, including neuroprotection, the blockade 
of its receptors generally improves mental function and 
performance (Dunwiddie and Masino, 2001). 
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1.3.6 Adenosine receptors and signaling pathways 
Adenosine acts on cell surface G-protein coupled receptors, which 
activate different intracellular pathways. G protein coupled 
receptors are formed by a single peptide channel, with seven alpha-
helices transmembrane domains, a C- intracellular terminal and an 
N- terminal localized at the extracellular space. The N-terminal 
usually contains one or more glycosylation sites. The C- terminal 
contains phosphorylation and palmitoylation sites, which are 
involved in regulation of receptor desensitization and internalization 
(Perez and Karnik, 2005).  
So far, four different adenosine receptors have been cloned: A1, A2A, 
A2B and A3.  Adenosine receptors are widely distributed throughout 
the body, including the brain, being responsible for several distinct 
functions on the central nervous system as well as at the periphery.  
The expression of adenosine receptors is not homogenous in 
different central nervous system areas. Adenosine A1 receptors are 
particularly prevalent in the central nervous system, expressed in 
both neurons and glial cells. A1 receptors can be expressed either 
pre- or post-synaptically. Higher expression levels were found in the 
cortex, hippocampus, cerebellum, thalamus, brain stem and spinal 
cord (see Ribeiro et al., 2002). mRNA encoding A1 receptor was also 
found in basal ganglia, where, A1 receptors are present on both 
dopaminergic nigrostriatal and glutamatergic corticostriatal 
terminals (Wardas, 2002). Adenosine A2A receptors are mostly 
expressed in the basal ganglia and olfactory bulb. However it is 
possible to find mRNA encoding A2A receptor in other brain regions 
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where they are poorly expressed, namely in the hippocampus and 
the cortex (see Sebastião and Ribeiro, 1996). The A2B receptors are 
mainly expressed in peripheral organs, being weakly expressed in 
the brain (Dixon et al., 1996). Finally, A3 receptors present an 
intermediate expression level in the human cerebellum and, as A2B 
receptors, display a low expression in the entire brain (see Fredholm 
et al., 2001). 
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Figure 1.11 – Distribution of adenosine A1 and A2A receptors in the brain. 
Higher alphabets correspond to higher levels of expression (adapted from 
Ribeiro et al., 2002).  
A1 and A2A are high affinity receptors, with Kd values of 70 and 
150nM, respectively, which allow its tonic activation by basal 
adenosine; A2B and A3 are considered low affinity receptors, with 
affinity constant values around 5100 and 6500 nm, respectively (see 
Dunwiddie and Masino, 2001). Interestingly, human A3 receptors 
show higher affinity for adenosine (see e.g. Fredholm et al., 2001).  
Classically, A1 and A3 receptors inhibit adenylate cyclase (AC) 
through the coupling to Gi or G0. A2A and A2B receptors are coupled 
to Gs or Golf, promoting adenylate cyclase activity. A2B receptors are 
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also coupled to Gq/11, through which they can activate phospholipase 
C (PLC) (Ryzhov et al., 2006). The A3 receptor can also couple to 
Gq/11, also activating phospholipase C (Fredholm et al., 2001). For the 
receptors coupled to AC, the increase of cAMP mediated by 
adenylate cyclase leads to the activation of cAMP dependent protein 
kinase (PKA), which in turn phosphorylates different targets such as 
ionotropic receptors or transmitter transporters. On the other hand, 
the activation of phospholipase C converts phosphatidylinositol 4, 5-
bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 1, 4, 5-
trisphosphate (IP3). Then DAG activates protein kinase C (PKC), 
which phosphorylates different substrates, while IP3 stimulates 
calcium release from intracellular stores. Then, elevation of cytosolic 
Ca2+ can stimulate a variety of signaling pathways, including a family 
of phosphatidyl serine-dependent serine/threonine-directed kinases 
collectively called protein kinase C (PKC), phospholipase A2 (PLA2), 
Ca2+-dependent K+ channels, and nitric oxide synthase (NOS). IP3 can 
also promote calcium influx from extracellular sources, if previous 
IP3 stimulation depleted CA
2+ intracellular store (see Ralevic and 
Burnstock, 1998). 
The activation of G proteins can modify the activity of several 
enzymes and ion channels in a way that is independent of second 
messenger production. For example, A1 receptors, via Gi activation, 
lead to activation of several types of K+-channels and to blockade of 
N-, P- and Q-type Ca2+ channels (see Fredholm et al., 2001). A3 
receptors are also able to modulate Ca2+ levels, through the 
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inhibition of adenylate cyclase. Both A2A and A2B receptors can 
modify the levels of intracellular calcium (see Fredholm et al., 2001). 
Aside from the involvement of AC/cAMP/PKA and PLC/IP3-DAG/PKC, 
other transduction pathways are associated with adenosine receptor 
activation, namely the mitogen-activated protein kinase (MAPKs) 
(Schulte and Fredholm, 2003). The MAPK family is constituted by 
three main groups:  extracellular regulated kinases (ERK) such as 
ERK1 and ERK2, stress-activated protein kinases (SAPK) such as p38 
and jun-N-terminal kinase (JNK). These kinases are usually activated 
by tyrosine-kinases receptors (Seger and Krebs, 1995), but G protein 
coupled receptors can also signal through them (Gutkind, 1998; 
Liebmann, 2001; Marinissen and Gutkind, 2001). In fact, all 
adenosine receptors can be associated with MAPK pathway. First 
evidence for this came from a study with COS-7 cells transiently 
transfected with adenosine A1 receptors, which could activate 
ERK1/2 via Gi/0 (Faure et al., 1994).  
Activation of A2A receptors also increases MAPK activity (Sexl et al., 
1997). Interestingly, the signal pathway used by A2A receptors to 
activate MAPK can vary, depending on the cellular machinery 
availability. Thus, in CHO cells, A2A receptors-mediated ERK1/ERK2 is 
mediated by Gs-AC-cAMP-PKA-MEK1, while in HEK 293 cells, MAPK 
activation by A2A receptors involves PKC but not PKA, even though 
cAMP levels are found to be enhanced by Gs activity (Seidel et al., 
1999). Adding to the activation of MAPK, A2A receptors can also 
inhibit ERK phosphorylation (Hirano et al., 1996).  
Introduction 
54 
The activation of A2B receptors can activate the three main branches 
of MAPK family (ERK1/2, p38 and JNK) (see Fredholm et al. 2001).  
Finally, the A3 receptors activate ERK1/2 in human fetal astrocytes 
(Neary et al., 1998). Also, the phosphorylation of ERK1/2 was clearly 
demonstrated in CHO cells, transfected with A3 receptors (see 
Schutle and Fredholm, 2000).  
To conclude, MAPK activation by adenosine receptors is quite similar 
to that prompted by other G protein coupled receptors (Gutkind, 
1998; Sugden and Clerk, 1998; Luttrell et al., 1999). Interestingly, 
ERK1/2 phosphorylation is promoted either by receptors coupled to 
Gs (A2A/A2B) or to Gi/0 (A1/A3) proteins. The MAPK-mediated effects 
of adenosine receptors are mainly related to DNA synthesis, cellular 
differentiation, proliferation and apoptosis (see Schulte and 
Fredholm, 2003). 
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Figure 1.12 – Associated pathways to adenosine receptors.  Adenosine A1 
and A3 receptors are usually coupled to Gi/0 proteins, decreasing the 
activity of adenylate cyclase (AC). Adenosine A2A and A2B receptors are 
usually coupled to Gs, activating AC. Additionally, A3 and A2B receptors may 
couple to Gq/11 proteins, activating PLC pathway. Further, all adenosine 
receptors can activate the MAPK pathway.  
Adenosine receptors activity is regulated by its expression at the 
membrane level which results from a balance between endocytosis 
and exocytosis rates. In turn, the endocytosis rate is related with the 
desensitization mechanism. It reduces receptor expression at 
membranes, consequently decreasing receptor activity and 
restraining the duration and intensity of signal. Desensitization can 
be classified as homologous or heterologous, with the first being 
dependent and specific for agonist binding and the second induced 
by receptor phosphorylation by PKA or PKC, in the presence or 
absence of ligand. Adenosine receptor subtypes desensitize 
differently: A1 receptors are slowly phosphorylated and internalized 
(several hours are need to complete the process). A2A and A2B 
receptors desensitize faster, with down-regulation kinetics faster 
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than 1h. The A3 receptors have the fastest desensitization profile, 
which often occurs within minutes (Klaasse et al., 2008).  
1.3.7 A1-A2A adenosine receptors interaction  
Since the 90s that a close cross-talk between adenosine A1 and A2A 
receptors has been identified either at the central nervous system 
(Cunha et al., 1994; Lopes et al., 1999) or at the neuromuscular 
junction (Correia-de-Sá and Ribeiro, 1994). In fact, at the 
hippocampus, A2A receptors are co-expressed and colocalized with 
A1 receptors (Cunha et al., 1994). Since then, the results strongly 
indicated that both receptors interact with each other. For example, 
the activation of A2A receptors attenuates the ability of A1 receptors 
to inhibit population spike at the hippocampus (Cunha et al., 1994, 
O’Kane and Stone, 1998) as well as at the neuromuscular junction 
(Correia-de-Sá et al., 1994).  However these studies did not clarify 
the type of interaction between A1 and A2A receptors. Thus, in 1999, 
it was shown that  the activation of A2A receptors decrease 
presynaptic A1 receptors binding as well as A1 receptors functional 
responses in young adult rat hippocampus (Lopes et al., 1999).  
More recently and taking advantage of BRET assays, Ciruela and 
colleagues have shown that adenosine A1 and A2A receptors can 
heteromerize in transfected HEK cells. Moreover, the A2A receptors 
activation reduces the affinity of A1 receptors agonists (Ciruela et al., 
2006). It has been suggested that under basal conditions, the 
relatively low extracellular levels of adenosine preferentially 
stimulate A1 receptors, which has a higher affinity to adenosine 
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(Fredholm et al., 2001). Then, when adenosine concentration is 
increased, it will mainly activate A2A receptors in the heteromer. This 
activation will inhibit the A1 receptor mediated effects (Ciruela et al., 
2006). According to Ciruela et al., (2006), the existence of adenosine 
A1-A2A receptors heteromers allows that adenosine can facilitate or 
inhibit glutamatergic transmission depending on concentration of 
adenosine. 
1.4 Heteromers of G protein coupled receptors  
For a long time, GPCR were considered to exist as monomers within 
the plasma membrane (Lefkowitz, 2004; Hill, 2006). However, in the 
last decade, studies have highlighted the existence of GPCR 
heteromers (Ciruela et al., 2001; Ferré et al., 2002; Ginés et al., 
2000; Hillion et al., 2002; Canals et al., 2003; Milligan, 2004). 
The GABAB1-GABAB2 heteromer is frequently considered as the first 
identified GPCR heteromer (White et al., 1998). But, considering that 
the GABAB1 and GABAB2 molecules are not active when they are 
alone, this complex should be considered as a heteromeric receptor 
instead of a receptor heteromer. Thus, the δOR-κOR opioid receptor 
heteromer should be considered as the first reported 
neurotransmitter receptor heteromer (Jordan and Devi, 1999). Since 
then, an increasing list of GPCR heteromers have been identified 
(George et al., 2002; Agnati et al., 2003; Prinster et al., 2005). This 
list includes both heteromers between GPCR activated by the same 
ligand (e.g. D1-D2, A1-A2A) and activated by different ligands (e.g. A1-
D1, A2A-D2). The heteromerization can occur also between distant 
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related receptors, such as GPCR and ionotropic receptors 
heteromers (e.g. D1-NMDA, D5-GABAA) (Ferré et al., 2007). 
A receptor heteromer can be defined as a complex molecule made 
up of different receptor molecules for the same or different ligand 
while a receptor homomer is composed by two identical receptor 
molecules. The terms receptor heteromer or homomer imply a 
direct physical interaction between the receptor molecules and it 
does not contemplate receptors indirectly linked by intermediate 
proteins (Ferré et al., 2007). It is also important to clarify the 
difference between a receptor heteromer and a heteromeric 
receptor, being the last an oligomeric receptor for which the 
minimal functional unit is composed of different protein subunits, 
such as GABAA, NMDA or AMPA receptors, for example. On the 
other hand, the protomer molecules of a heteromer are active by 
themselves.  
The occurrence of neurotransmitter receptor heteromers was firstly 
suggested by radioligand binding assays, which demonstrated the 
existence of biochemical interaction between different GPCR 
(Gomes et al., 2000). They were initially named as “intramembrane 
receptor-receptor interactions” (see Agnati et al., 2003). These 
interactions are characterized by the fact that the stimulation of one 
receptor changes the binding characteristics of another receptor of 
endogenous or exogenous ligands in crude membrane preparations 
(Agnati et al., 2003). The use of crude membranes instead of intact 
cells allows the exclusion of intracellular signaling participation and 
advocates the existence of a kind of allosteric interaction between 
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adjacent receptors.  In fact, it was already hypothesized in 1993 that 
these intramembrane interactions could imply an intermolecular 
crosstalk, which implies the occurrence of GPCR heteromerization 
(Zoli et al., 1993).  
Thus, GPCR heteromerization is quite related with allosterism as 
each protomer can exhibit several biochemical properties, which are 
modifiable by the presence of the other protomer ligand. In fact, the 
term allosterism is defined as a type of regulation mediated by an 
effector at one specific site (usually named as allosteric site) on a 
protein that has the ability to influence the ligand binding or protein 
active at a topographically different site.   Interestingly, GPCR can 
display different properties when they are heteromerized. In fact, 
ligand binding alterations are a common property of 
neurotransmitter receptor heteromers, and are a useful tool to 
identify the presence of endogenous heteromers. For example, 
when dopamine D1 and D2 receptors are heteromerized, the specific 
ligands for D1 receptor lose the selectivity and can also activate the 
D2 receptor in the heteromer (Rashid et al., 2007). Also, δ and κ 
opioid receptors display different affinities for several exogenous 
and endogenous ligands when they are heteromerized (George et 
al., 2000). Changes on binding properties are probably related to 
some conformational alterations sensed by one protomer when a 
ligand binds to the other protomer (Ferré et al., 2007). The 
activation of one protomer can both increase and decrease the 
affinity of the other protomer for its specific ligands. On the other 
hand, this interaction can be unidirectional, meaning that only one 
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protomer can change the other receptor affinity, or bidirectional, 
when both protomers have the ability to change the other receptor 
affinity.  For example, considering the bidirectional effect, in the 
dopamine D2- somatostatin SST5 receptors heteromer, stimulation of 
D2 receptors significantly enhances the affinity of SST5 receptors for 
agonists and vice-versa (Rocheville et al., 2000). In the view of 
unidirectional modifications, and looking for adenosine A1-A2A 
receptors and A2A-D2 receptors heteromers, in both cases, only the 
A2A receptors activation has the ability to decrease ligand affinity for 
A1 receptor or D2 receptor (Ferré et al., 1991; Hillion et al., 2002; 
Canals et al., 2003; Ciruela et al., 2006).  
Several biochemical mechanisms have been proposed to allow the 
heteromerization of GPCR, namely the covalent disulfide bonds of 
extracellular, coiled-coil interactions and epitope-epitope 
electrostatic interactions of intracellular domains and interactions of 
transmembrane domains (by contact or domain swapping) (Bouvier, 
2001; Marshall, 2001; George et al., 2002; Woods and Ferré, 2005). 
On the other hand, the lipid bilayer, namely some particular 
domains as the lipid rafts and the scaffold proteins involved in the 
stability of membrane network, should also be important for 
receptor heteromerization (Agnati et al., 2003; Bockaert et al., 2004; 
Woods and Ferré, 2005; Allen et al., 2007). 
It is recognized that GPCR heteromers can traffic, signal and 
internalize as a unique entity, existing as dimers through their life 
cycle (Gurevich and Gurevich, 2008; Milligan, 2008) but some 
studies have shown that, at least, some heteromers have an intrinsic 
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ability to self-associate at the membrane level (Rocheville et al., 
2000; Harding et al., 2009). In fact, the D2-SST5receptors heteromer 
is formed at the plasma membrane level, after the stimulation of 
either protomer (Rocheville et al., 2000). It was also shown by single 
molecule total internal reflectance that the average lifetime of 
association of M1 muscarinic receptor homomer was around 0.5s 
and that no more than 30% of M1 receptors existed as M1-M1 
homomers at a given time (Hern et al., 2010). Thus, the stability of 
dimers at membrane level should be influenced by different factors, 
namely the presence of ligands and the level of receptor expression 
at membrane (Smith and Milligan, 2010).  
Moreover, the stability could even change between closely related 
GPCR, for example, it was demonstrated that β2-adrenoreceptor can 
form stable oligomers, whereas the β1-adrenoreceptor shows only   
transient physical interactions (Dorsch et al., 2009). 
An important issue about GPCR heteromerization concerns its 
advantage for the cells. If GPCRs are capable of signaling by 
themselves, why do they form heteromers? The first answer can be 
related with an increase in signaling possibilities, allowing a fine 
tuning of responses. But, there are probably other reasons: (1) the 
heteromerization can modify cell surface delivery and retention of 
certain GPCRs (Pin et al., 2003; Lopez-Gimenez et al., 2007; Canals et 
al., 2009); (2) can promote cross-activation (Carrillo et al., 2003) or 
cross-inhibition (Lavoie et al., 2002; Mercier et al., 2002; Barki-
Harrington et al., 2003; Lavoie and Hébert, 2003; Breit et al., 2004;) 
of signaling; (3) can modify desensitization profiles (Pfeiffer et al., 
Introduction 
62 
2001); (4) can increase (Jordan et al., 2001; McVey et al., 2001; 
Pfeiffer et al., 2002, 2003; Ramsay et al., 2002; Perron et al., 2003; 
Stanasila et al., 2003; Xu et al., 2003) or reduce (Breit et al., 2004; 
Lavoie et al., 2002; Lavoie and Hébert, 2003; Mercier et al., 2002) 
internalization rate. Moreover, heteromerization can also modify 
the lateral diffusion of receptors in the plasma membrane. It was 
shown that dopamine D1 receptors, which usually diffuse laterally in 
the plasma membrane, can be trapped in dendritic spines, after the 
activation of NMDA, promoting D1-NMDA receptors 
heteromerization (Scott et al., 2006).  
Another feature of heteromerization is the modification of G 
protein-coupling (Banères and Parello, 2003; Jastrzebska et al., 2006; 
Carriba et al., 2007; Rashid et al., 2007). For example, dopamine D1-
D2 receptors heteromer is coupled to Gq/11 protein. When the 
receptors are alone, dopamine D1 receptor is coupled to Gs while D2 
receptor is coupled to Gi/0 protein. Thus, the dopamine D1-D2 
receptors heteromerization allows dopamine to signal through a 
different pathway, involving PLC activation (Rashid et al., 2007). 
Furthermore, the existence of heteromers as A2A-D2 provides a tight 
crosstalk between two different neurotransmitter systems. More 
specifically, the activation of A2A receptors inhibits the effect 
mediated by D2 receptors activation (Fuxe et al., 2005). On the other 
hand, the heteromerization between receptors for the same ligand, 
such as A1-A2A, enables the heteromer to work as a function of the 
ligand concentration.  
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Taking advantage of some of their unique properties, GPCR 
heteromers arise as new possible therapeutic targets, and the 
development of drugs specifically designed to target them can, in 
the future, offer some clinical advantage. For example, A2A-D2 
receptors heteromer may play a crucial role in Parkinson Disease 
treatment since results from Phase II clinical trials demonstrated 
that the administration of istradefylline (a novel adenosine A2A 
receptor antagonist) attenuates diskinesias in Parkinson Disease 
patients treated with L-DOPA (Jenner, 2005).  
 
As above mentioned, adenosine is a ubiquitous neuromodulator, 
whose tonic effect is to depress nervous system activity. Adenosine 
influences synaptic transmission through different mechanisms: by 
modulating neurotransmitter levels at synapse; by hyperpolarizing 
or depolarizing neurons; by influencing directly neurotransmitter 
receptors, by modulating astrocyte functions. Neurotransmitter 
availability at the synapse can be modulated by controlling the 
neurotransmitter release or by controlling the neurotransmitter 
uptake through specific transporters expressed by neurons and glia. 
Among the different neurotransmitters whose levels can be 
modulated by adenosine, GABA assumes particular relevance, since 
its main function is, as adenosine, to regulate the excitatory tonus in 
the nervous system. It is known that adenosine can modulate GABA 
release from the presynaptic terminal. So, it is particular interesting 
to understand if adenosine can also modulate the removal of GABA 
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from the synapse, namely its uptake into presynaptic terminals and 
surrounding astrocytes. 
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2 Aims 
 
 
The main goal of this work was to identify the influence of adenosine 
receptors upon GABA transporters (GAT-1 and GAT-3) expressed 
both in pre-synaptic terminals and in surrounding astrocytes. 
 
As a modulatory role for adenosine on GABA transport was 
identified in the course of the study, a second goal was the 
identification of the transduction system operated by the receptors 
to modulate GABA transporters. 
 
As it was found a pharmacological interaction between adenosine A1 
and A2A receptors, a third goal was the characterization of adenosine 
A1 and A2A receptors heteromerization. 
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3 Techniques 
3.1 Isolated presynaptic terminals 
Isolated nerve terminals were firstly isolated by Hebb and Whittaker 
in 1958 (Hebb and Whittaker, 1958) and by Whittaker in 1959 
(Whittaker, 1959). The presynaptic terminals were isolated as a 
distinct fraction by differential and density gradient centrifugation 
and they present the most of the bound acetylcholine of the tissue 
(Gray and Whittaker, 1962). Later on, Whittaker and co-workers 
proposed the name synaptosomes for the isolated nerve terminals 
in order to emphasize their relatively homogeneity and their 
resemblance in physical properties to other subcellular organelles 
(Whittaker et al., 1964). Synaptosomes are able to uptake and 
release neurotransmitters or related molecules. In 1968, 
Marchbanks showed that the uptake of choline by synaptosomes 
was qualitatively and quantitatively very similar to the transport 
observed in more organized tissue (Marchbanks, 1968). 
Synaptosomes have also able to synthesized proteins (Gordon and 
Deanin, 1968) and they contain at least one mitochondrion, which 
allow a complete glucose based metabolism (Marchbanks and 
Whittaker, 1967). Thus, synaptosomes have been considered a good 
model to perform different studies, namely the ones related to 
release and uptake of neurotransmitters, functioning as an in vitro 
model of the presynaptic component of a synapse. 
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Figure 3.1 – Electronic microscopic visualization of a synaptosome. It is 
visible two mitochondria, marked with an M, which allow a complete 
glucose based mechanism; from Gredilla et al., 2012.  
3.2 Primary cultures of astrocytes 
Studies using primary cultures of astrocytes had significantly 
contributed to reveal astrocyte main functions.  
Although brain function results from the interaction between 
different types of cells, the use of isolated cultured cells allows the 
characterization of the function of each cell type in an independent 
way. 
The first monotypic culture of astrocytes was described almost forty 
years ago (Booher and Sensenbrenner, 1972) and most laboratories 
used protocols with few modifications derived from this pioneer 
work or from the later modification by McCarthy and Vellis (1980). 
Primary cultures of astrocytes are easy to prepare and in theory can 
be prepared from organism in any age, including embryonic, fetal, 
neonatal, young, adult and old organisms. But concerning yield and 
purity, the optimal age is during astrogenesis peak, which is after the 
peak of neurogenesis and before the peak of oligodendrogenesis 
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(Saura, 2007). In rat or mice the astrogenesis peaks is around birth, 
being the ideal period  from 2 days prenatal to 2 days postnatal for 
cortex and most CNS regions (Lim and Bosch, 1990), except 
cerebellum where time spans between post-natal  days 4 and 7 
(Hertz et al., 1985). 
Astrocytes in cultures can be different from those in vivo (see Hertz 
et al., 1998), but still that, primary cultures are considered a good 
model to study astrocytes properties, since they allow to work in 
very defined and stable conditions for a prolonged period of time. 
Notwithstanding, the use of primary cultures should be 
complemented with subsequent studies in more integrative models, 
like slices or in vivo experiments, which can testify the obtained 
results. A problem with these more integrated approaches is to 
distinguish between functions of astrocytes or other cellular 
component, namely neurons, a problem easily overcomed with the 
cultures.  
3.3 Biotinylation assays 
A good way to study surface expression of proteins is taking 
advantage of the extraordinarily stable, non-covalent interaction 
between avidin and streptavidin with biotin. In fact, by surface 
biotinylation it is possible to isolate the proteins expressed at 
surface level from the intracellular fraction. The affinity of avidin for 
biotin is known for a long time (György et al., 1941), and the same 
occurs in relation to the affinity of avidin for the bacterial protein 
streptavidin (Wilchek and Bayer, 1990). Since then several protocols 
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in biochemical fields has been used for different studies aiming to 
isolate surface membrane proteins. 
All the chemical reagents available for biotinylation of surface 
proteins are formed by three building blocks: (i) the biotin moiety, 
for the subsequent interaction of biotinylated proteins to avidin 
beads, (ii) a spacer arm of sufficient length to allow protein capture 
by the beads, (iii) a reactive moiety to establish the covalent bond 
between biotin and the amine groups of surface proteins. For steric 
hindrance reasons, interaction between avidin and biotinylated 
proteins could be dramatically improved by increasing the spacer 
arm. It influences also the solubility of the reagent and can also be 
cleavable by chemical or physical agents to facilitate protein release 
after capture. In what concerns the covalent bound, the most 
common reactive groups employed include reactive esters, like the 
N-hydroxysuccinimide (NHS) group, which undergoes a nucleophilic 
substitution reaction in the presence of primary amines (Elia, 2008). 
Then, by the use of avidin beads, it is possible to separate surface 
biotinylated proteins from the intracellular fraction.  
3.4 BRET – bioluminescence resonance energy transfer 
Bioluminescence resonance energy transfer (BRET) has been used to 
study a wide range of protein-protein interaction in bacterial (Xu et 
al., 1999), plant (Subramanian et al., 2004) and mammalian cells 
(Angers et al., 2000; Kroeger et al., 2001). The use of BRET to study a 
protein dimerization was first described in 1999 (Xu et al,. 1999). 
Since then, hundreds of protein-protein interactions have been 
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studied by BRET assays. Although a significant part of these studies 
has been done with G-protein coupled receptors (GPCR), BRET has 
also been used to study other types of protein-protein interaction, 
as those involving other membrane receptors (Scaffidi et al., 2004; 
Brown et al., 2005), cytosolic receptors (Garside et al., 2004; 
Michelini et al., 2004), integrins (de Virgilio et al., 2004; Scaffidi et 
al., 2004), enzymes (de Virgilio et al., 2004; Yung et al., 2004), 
endophilins (Trevaskis et al., 2005) and nuclear factors (Germain-
Desprez et al., 2003). The study of protein interaction by BRET 
implies heterologous coexpression of fusion proteins, which links 
proteins of interest to a bioluminescent donor enzyme or to an 
acceptor fluorophore. The non-radioactive transfer of energy from a 
donor enzyme to an acceptor fluorophore occurs after substrate 
oxidation, and its efficiency is inversely proportional to the sixth 
power of the distance between donor and acceptor. In fact, the 
energy released from the donor only excites the acceptor 
fluorophore if the distance between them is smaller than 10nm, 
resulting in light emission at a longer wavelength that can be 
detected and expressed relative to the donor light emission. Thus, a 
positive BRET signal is suggestive of a close physical interaction 
between the proteins under study.  
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Figure 3.2 – BRET- bioluminence resonance energy transfer.  BRET assays 
imply the expression of fusion protein, which results from the attachment 
of proteins of interest to a bioluminescence donor and to acceptor 
fluorophore. When the distance between the two fusion proteins are less 
than 10nm, the energy (that results from the added substrate oxidation by 
RLuc) will be transferred and accepted by the acceptor fluorophore. Image 
source: http://www.bio.utk.edu 
BRET assays are also suitable to study ligand-modulated protein 
interactions. A modification of BRET signal may represent an 
increase or decrease in the number or rate of interactions between 
the proteins of interest, although it can also mean conformational 
changes that influence the relative positioning of the donor and 
acceptor molecules (Pfleger et al., 2006). 
An advantage of BRET technique is the possibility of studying 
proteins interaction in live cells, where they are expressed in a near-
physiological environment in the correct cellular compartment. But, 
on the other hand, it is not possible to study endogenous proteins 
because of the need of fusion proteins (Pfleger et al., 2006). 
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3.5 GTP-γ-[
35
S]-assay  
The evaluation of each G protein activity can be achieved through 
the quantification of specific activity of labeled GTP. The [35S]GTP-γ-
assay was first performed with purified receptor and G protein 
systems in phospholipid vesicles using adrenergic receptors (Asano 
et al., 1984) and muscarinic receptors (Kurose et al., 1986). 
Nowadays, the assay is commonly performed using cell membranes 
that express the receptor of interest, as was firstly described by Hilf 
and co-workers (Hilf et al., 1989).  More recently, it is also been used 
to identify the G protein family coupled to GPCR heteromers (Rashid 
et al., 2007). 
G proteins are heteromeric structures constituted by three different 
subunits: α, β and γ. At the resting state, GDP is bound to α subunit 
of the heteromeric G protein. The activation of a GPCR by the 
agonist leads to the dissociation of GDP from α subunit, allowing 
GTP binding to α subunit. This leads to the dissociation of Gα-GTP 
and Gβγ subunits that are able to interact with the downstream 
effectors.  
The G protein heterotrimer is reformed by GTPase activity of the Gα 
subunit, forming Gα-GDP and so allowing Gα and Gβγ to recombine. 
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Figure 3.3 – G protein activation. At the resting state, GDP is bound to the 
α subunit of the heteromeric G protein. The binding of the agonist to the 
receptor leads to the dissociation of GDP from the α subunit, allowing the 
binding of GTP. After exchange of GDP with GTP on the α subunit, both the 
α subunit and the βγ complex may interact with other molecules to 
promote signaling cascades (from Nature Education 
www.nature.com/scitable). 
  
The [35S]GTP-γ-assay, using labeled GTP, can quantify G protein 
activity in response to the binding of ligands to GPCR. [35S]GTP 
replaces the endogenous GTP and binds to the Gα subunit in 
response to receptor activation. As the thiophosphate bond 
established between Gα and [
35S]GTP is resistant to hydrolysis by the 
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GTPase, G proteins are not recycled and the [35S]GTP-bound Gα 
subunits accumulate, which allows its quantification by measuring 
the amount of [35S]GTP incorporated, which is easily performed 
through liquid scintillation spectroscopy.  The GTP-γ-[35S] assay has 
been used for studying a wide range of GPCR (see Harrison and 
Traynor, 2003). Although this assay is easier to perform for Gi/0 
coupled receptors (this G protein family are more abundant and 
have higher rates of nucleotide exchange, and so a higher rate of 
labeled GTP incorporation), it is also been performed with receptors 
coupled to Gs and Gq/11 families. Further, by coupling [
35S]GTP-γ-
assay to immunoprecipitation, it  is possible to identify the family of 
G protein coupled to the receptor of interest. 
The main feature of this assay is related with the possibility of 
measuring an earliest functional consequence of receptor 
occupancy. Thus, it is possible to evaluate traditional 
pharmacological parameters like efficacy or affinity. On the other 
hand, by measuring an earlier event, it avoids some amplification or 
modulation that may occur when analyzing parameters further 
downstream of the receptor (Harrison and Traynor, 2003). 
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4 Methods  
4.1 Reagents 
GABA (γ-aminobutyric acid) was obtained from Sigma and the [3H] 
GABA (4-amino-n-[2, 3-3H]butyric acid) specific activity 87.00 
Ci/mmol and [35S] GTPγS specific activity 1250Ci/mmol, were 
obtained from Perkin Elmer Life Sciences (Boston, MA, USA). 
 ADA (adenosine deaminase, E.C. 3.5.4.4, 200U/mg in 50% glycerol 
(v/v), 10mM potassium phosphate) was acquired from Roche 
(Germany).  
CGS 21680 (4-[2-[[6-amino-9-(N-ethyl-β-D-ribofuranuronamidosyl)-
9H-purin-yl]amino]ethyl]benzenepropanoic acid hydrochloride), SCH 
58261  (2-(2-furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-
e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine), CPA (N6-
cyclopentyladenosine), DPCPX (8-cyclopentyl-1,3-dipropylxanthine),  
NECA  (5'-N-ethylcarboxamidoadenosine), MRS 1706 (N-(4-
acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-
purinyl)phenoxy]acetamide),  SKF 89976A hydrochloride (1-(4,4-
diphenyl-3-butenyl)-3-piperidinecarboxylic acid hydrochloride), (S)-
SNAP 5114 (1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]-(S)-3-
piperidinecarboxylic acid), U73122 (1-[6-[[(17β)-3-methoxyestra-
1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione),  
GF109203X (2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl) 
maleimide) were obtained from Tocris (Bristol UK).  
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CADO (2-chloro-adenosine), R-PIA (R-phenylisopropyladenosine), H-
89  (N-[2-(p-Bromocinnamylamino)ethyl]- 5- 
isoquinolinesulfonamide dihydrochoride), Rp-cAMPs (Rp-Adenosine 
3′,5′-cyclic monophosphorothioate triethylammonium salt hydrate),  
inosine, GDP (guanosine 5’-diphosphate), GTPγS (guanosine 5’-O-
[gamma-thio]triphosphate), PDD (4-β-phorbol 12, 13-didecanoate), 
forskolin, ChTx (Cholera Toxin from Vibrio cholerae), PTx (pertussis 
toxin from Bordetella pertussis) and Streptavidin were obtained 
from Sigma (MO, USA).  
Sulfo-NHS-LC-biotin and Avidin beads were obtained from Pierce 
(Rockford, IL, USA). 
Rat polyclonal anti-GAT-1 (ab426), rabbit polyclonal anti-beta actin 
(ab8227), rabbit polyclonal anti-alpha tubulin (ab4074)   were 
obtained from abcam (Cambridge, UK). Rabbit polyclonal anti-A1 
adenosine receptor (PA3-041) was obtained from Thermo Scientific 
(MA, USA). Rabbit polyclonal anti-Gαq/11 (sc-392), Goat polyclonal 
anti-Gαs (sc-26766), rabbit polyclonal anti-Gαi-3 (sc-262) and goat 
anti-Rabbit IgG-HRP (sc-2004) were obtained from Santa Cruz (CA, 
USA). Peroxidase anti-rabbit IgG, FITC-conjugated anti-rabbit IgG 
(FI-1000) and TRITC-conjugated anti-mouse IgG (T-2762) were 
obtained from Vector (CA, USA). Mouse anti-GFAP was obtained 
from Sigma (MO, USA). 
DMEM (Dulbecco’s modified Eagle’s medium), Glutamine, FBS 
(foetal bovine serum) were obtained from Invitrogen (NY, USA). 
Antibiotic antimycotic was obtained from Sigma (St. Louis, MO) 
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All other reagents were purchased from Sigma (St. Louis, MO).  
4.2 Experimental protocols 
4.2.1 Synaptosomes isolation  
Hippocampal synaptosomes were isolated as routinely performed in 
our laboratory (e.g. Vaz et al., 2008) from halothane anaesthetized 
male Wistar rats with 3-4 weeks of age, except otherwise stated; in 
some experiments, and for comparison, adult (6-8 weeks) rats were 
used; animal handling was according to the European guidelines 
(86/609/EEC) and Portuguese Law. Briefly, the hippocampi were 
homogenized in 15ml ice-cold sucrose solution (sucrose 0.32M, 
EDTA 1mM, HEPES 10mM, BSA 1mg/ml, pH 7.4) and centrifuged at 
3000g for 10min at 4ºC; the supernatant was then centrifuged at 
14000g for 12min at 4ºC and the pellet resuspended in 3ml of a 
Percoll 45 %( v/v) in KHR solution (NaCl 140mM, EDTA 1mM, HEPES 
10mM, KCl 5mM, glucose 5mM, pH 7.4). After centrifugation at 
14000g for 2min at 4ºC, the top layer (which corresponds to the 
synaptosomal fraction) was washed with KHR solution. The 
synaptosomal fraction was resuspended in Krebs-HEPES buffer (mM: 
NaCl 125, KCl 3, glucose 10, MgSO4 1.2, NaH2PO4 1, CaCl2 1.5, AOAA 
0.1, HEPES 10, pH 7.4). The amount of protein was quantified by 
Bradford´s Method (Bradford, 1976) and the protein concentration 
adjusted to 1.5 mg protein/ml. 
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4.2.2 Cell lines and primary astrocytic cultures  
The astrocytes were prepared from the cortex of newborn (P1-P2) 
Wistar rats of either sex, according to the European guidelines 
(86/609/EEC). Briefly, rat brains were dissected out of pups and 
cortex were isolated and the meninges and white matter were 
removed. Cortex was dissociated gently by grinding in DMEM 
(Dulbecco’s modified Eagle’s medium) (Invitrogen), filtered through 
a cell strainer and centrifuged at 200g, 10min. The pellet was 
resuspendend in DMEM and filtered. The cells were then seeded 
and kept for 4 weeks in DMEM supplemented with 10% (v/v) of heat 
inactivated FBS (foetal bovine serum), glutamine 2mM and antibiotic 
(Sigma) in a humidified atmosphere (5% CO2) at 37°C.  
CHO cells clones expressing A1 receptors, A2A receptors or both were 
obtained and cultured as previously indicated (Orru et al., 2011). 
HEK-293T cells were grown in DMEM supplemented with 2mM L-
glutamine, 100 U/ml penicillin/streptomycin, and 5% (v/v) of FBS. 
Cells were maintained at 37ºC in an atmosphere of 5% CO2, and 
were passaged when they were 80-90% confluent, i.e. 
approximately twice a week. 
4.2.3 [
3
H]GABA uptake assays 
In synaptosomes - [3H]GABA uptake assays were performed as 
previously indicated (Vaz et al., 2008) with minor modifications. 
Briefly, synaptosomes (0.5 mg protein/ml) were added to Krebs-
HEPES buffer at 37ºC and, except where otherwise specified, 
incubated with adenosine deaminase (ADA 1U/ml), to remove 
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endogenous extracellular adenosine) for 15min before the addition 
of the test drugs; test drugs were then added and incubation 
continued for further 20 min. Control samples were incubated for 
the same amount of time but in the absence of test drugs. 
Whenever the influence of a drug over another drug was assayed, 
the first (modifier) drug was allowed to equilibrate with the 
synaptosomes for 10 minutes before the addition of the test drug; in 
the corresponding control assays, the synaptosomes were incubated 
for the same amount of time in the absence of the modifier drug. 
GABA uptake was initiated by the addition of 5μM [3H]GABA (except 
otherwise specified) at a specific activity of 2x10-4Ci. This working 
[3H]GABA solution was obtained by addition of cold GABA to the 
purchased [3H]GABA into Krebs-HEPES buffer. The transport was 
stopped after 40seconds with 10ml of ice-cold Krebs-HEPES buffer, 
followed by rapid filtration. The amount of [3H]GABA taken up by 
synaptosomes was quantified by liquid scintillation counting. All 
assays were performed in three replicates. 
The non-specific, non-GAT-1 mediated GABA uptake was assayed in 
all experiments, in the presence of SKF89976a (20μM), a specific 
blocker of GAT-1, which was added 20 min before [3H]GABA. For 40s 
incubation with [3H]GABA (5μM), the radioactivity taken up by the 
synaptosomes in the presence of SKF89976a corresponded to 9.8 ± 
3.2% (n=9) of total radioactivity taken up by the synaptosomes in the 
absence of the GAT-1 inhibitor. In each experiment, the non-specific 
uptake was subtracted from total uptake to calculate the GAT-1 
mediated GAT-1 uptake. 
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In astrocytes - Assays were performed in a non supplemented low-
glucose DMEM. The astrocytes were incubated with ADA (1U/ml) for 
15 min before the addition of the test drugs; test drugs were added 
and incubation continued for further 20 min. GABA uptake was 
initiated by the addition of 30μM [3H]GABA (except otherwise 
specified) at a specific activity of 2x10-7Ci. The transport was 
stopped after 40s with 2 ml of ice-cold PBS. The amount of [3H]GABA 
taken up by astrocytes was quantified by liquid scintillation 
counting. The GAT-1- and GAT-3-mediated transports were 
calculated through the subtraction of the amount of GABA taken up 
in the presence of the specific blocker of GAT-1, SKF 89976a (20μM) 
or the specific blocker of GAT-3, SNAP 5114 (40 μM), respectively to 
the total transport.  
4.2.4 Biotinylation assays 
In synaptosomes - The synaptosomes (3-4mg protein/ml) were 
incubated with drugs for 35min (initially with ADA (1U/ml) for 
15min, followed by addition of test drug in the remaining 20min); 
equal incubation times were used in the parallel control assays, but 
in the absence of drugs. Synaptosomes were then washed three 
times with PBS/Ca2+/Mg2+ (1.37M NaCl, 21mM KCl, 18mM KH2PO4, 
100mM Na2HPO4.2H2O, 1M CaCl2, 0.5mM MgCl2) and then 
incubated for 1h with 1mg/ml Sulfo-NHS-LC-biotin (Pierce) in TEA 
buffer (0.01M TEA (triethylamine), 1M CaCl2, 150mM NaCl) with 
gentle shaking. The biotin reaction was quenched with 100mM 
glycine dissolved in PBS/Ca2+/Mg2+ for 30min. The synaptosomes 
were then lysed with radioimmunoprecipitation assay (RIPA) buffer 
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(Tris base 50mM, EDTA 1mM, NaCl 150mM, SDS 0.1%,  NP40 1%) 
supplemented with protease inhibitor cocktail and centrifuged at 
14000g, 4ºC, 10min. The pellet was discharged.  Biotinylated surface 
proteins were immunoprecipitated with Streptavidin (2µl/10 µg 
protein) (Sigma) overnight at 4ºC and centrifuged at 14000g, 10min 
at 4ºC. The pellet (biotinylated fraction) was separated from the 
supernatant (intracellular fraction). The biotinylated fraction was 
washed 3 times in 500 µl RIPA (14000g, 10min). Then, 70 µl of 
Laemmli buffer [Tris-HCl 70mM pH 6.8; glycerol 6%; SDS 2%;  DTT 
(DL-Dithiothreitol) 120mM; bromophenol blue 24 ppm] was added 
to the pellet and heated to 95ºC for 5min. The supernatant was 
collected (surface membrane expression) for Western Blot analysis. 
In astrocytes - Astrocytes were initially incubated with ADA (1U/ml) 
and then incubated for 30 min without (control) or with the agonists 
or antagonist of adenosine A1 receptors or A2A receptors or both. 
When antagonist and agonist were tested together, the antagonist 
was added 15 min before. After, they were incubated for 1 h with 1 
mg/ml Sulfo-NHS-LC-biotin (Pierce) in PBS/Ca2+/Mg2+ buffer with 
gentle shaking. The biotin reaction was quenched with 100 mM 
glycine for 30 minutes. The astrocytes were mechanically lysed with 
sucrose-containing buffer (sucrose 0.32M, EDTA 1mM, HEPES 
10mM, BSA 1mg/ml, pH 7.4) supplemented with protease inhibitor 
cocktail and centrifuged at 14,000 g, 4ºC, 10 min. Biotinylated 
surface proteins were immunoprecipitated with avidin beads 
(Pierce) overnight at 4ºC and centrifuged at 14,000 g, 10 min at 4ºC. 
The avidin beads were pelleted by centrifugation at 3,000g, 4ºC, 
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10min. The pellet (biotinylated fraction) was separated from the 
supernatant (intracellular fraction). Then, 150µl of Laemmli buffer 
[Tris-HCl 70mM pH 6.8; glycerol 6%; SDS 2%;  DTT (DL-Dithiothreitol) 
120mM; bromophenol blue 24 ppm] was added to the pellet and 
heated to 37ºC for 30 min. The avidin beads were removed by 
filtration.  Equal volumes of each sample was loaded on gel and 
resolved by SDS-PAGE. 
4.2.5 Western Blot 
For GAT-1 detection in synaptosomes - After denaturation (by 
Laemmli buffer heated at 95ºC for 5min), the synaptosomes extracts 
were run on an 8% acrylamide gel. Protein was transfected to a 
nitrocellulose membrane by electroblotting. Western blotting was 
performed using the anti-GAT-1 (1:5000), ab426 (abcam) and 
visualized using ECL reagents (Amersham). The protein amount was 
normalized by the anti – β-actin (1:7500), ab8227 (abcam). 
For GAT-1 and GAT-3 detection in primary astrocytic cultures – The 
astrocytes were mechanically lysed with sucrose-containing buffer 
(sucrose 0.32M, EDTA 1mM, HEPES 10mM, bovine serum albumin 
1mg/ml, pH 7.4). To clarify, the homogenate was centrifuged 
(13,000g, 10 min, at 4ºC) and the supernatant was collected.  After 
denaturation (by Laemmli buffer heated at 95ºC for 5 min), the 
extracts were run on a 10% acrylamide gel. Protein was transferred 
to a nitrocellulose membrane by electroblotting. Western blotting 
was performed using the anti-GAT-1 (1:100) and anti-GAT-3(1:200), 
kindly provided by N. Brecha, UCLA. After exposure to secondary 
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antibody (peroxidase anti-rabbit (1:250) Vector; Burlingame, CA), 
bands were visualized by BioRad Chemidoc and Quantity One 
software. 
4.2.6 Immunocytochemistry 
Primary astrocytes were incubated with ADA (1U/ml) for 15min, 
fixed in 4% paraformaldehyde for 20 min and washed with PBS 
containing 20 mM glycine (buffer A) to quench the aldehyde groups. 
Then, after permeabilization with 10% normal goat serum (NGS) 
containing 0.3% Triton X-100 for 5 min, cells were treated with PBS 
containing 1% bovine serum albumin. After 1 h at room 
temperature, astrocytes were incubated with antibodies rabbit anti-
GAT-1 (1:100; kindly provided by N. Brecha, UCLA) and mouse anti-
GFAP (1:800; Sigma) or rabbit anti-GAT-3 (1:200; kindly provided by 
N. Brecha, UCLA) and mouse anti- GFAP (1:800; Sigma) antibodies 
for 3 h at RT. After washes, astrocytes were stained with the 
secondary antibodies for 1.5 h at room temperature (FITC-
conjugated anti-rabbit IgG (FI-1000) and TRITC-conjugated anti-
mouse IgG (T-2762; Vector Laboratories). Dishes were then 
mounted, air-dried, and coverslipped using Vectashield mounting 
medium (H-1000; Vector). 
4.2.7 BRET  
Primary astrocytes or HEK-293T cells were transiently co-transfected 
with a constant amount of the cDNA encoding for receptors fused to 
RLuc, and with increasingly amounts of the cDNA corresponding to 
receptors fused to YFP, To quantify receptor-YFP expression, cells 
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(20 µg protein) were distributed in 96-well microplates (black plates 
with a transparent bottom) and fluorescence was read in a Fluo Star 
Optima Fluorimeter (BMG Labtechnologies, Offenburg, Germany) 
equipped with a high-energy xenon flash lamp, using a 10nm 
bandwidth excitation filter at 400nm reading. Receptor-fluorescence 
expression was determined as fluorescence of the sample minus the 
fluorescence of cells expressing the BRET donor alone. For BRET, the 
equivalent of 20µg of cell suspension was distributed in 96-well 
microplates (Corning 3600, white plates; Sigma) and 5µM 
coelenterazine H (Molecular Probes) was added. One minute later, 
the readings were collected using a Mithras LB 940 that allows the 
integration of the signals detected in the short-wavelength filter at 
485nm (440-500nm) and the long-wavelength filter at 530nm (510-
590nm). To quantify receptor-RLuc expression luminescence 
readings were also performed after 10 minutes of adding 5µM 
coelenterazine H. The net BRET is defined as [(long-wavelength 
emission)/(short-wavelength emission)]-Cf where Cf corresponds to 
[(long-wavelength emission)/(short-wavelength emission)] for the 
donor construct expressed alone in the same experiment. BRET is 
expressed as miliBRET units, mBU (net BRET x 1000). 
4.2.8 [
35
S] GTP-γ- S assay 
For quantification of GTP activity, GDP (10μM) was added to the 
primary astrocytic membranes and incubated on ice for 10 minutes. 
Membranes were incubated at 37ºC for 10 minutes with ADA 
(1U/ml) before the addition of DPCPX or SCH 58261 antagonists and 
after 10min minutes, the [35S]GTP-γ-S (1nM) and the tested drugs 
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were added and incubate for 30 minutes at 37ºC. Membranes were 
collected and solubilised and the antibodies were added: 5µg of 
anti–Gα i-3 (sc-262), 10µg of anti–Gα S (sc-26766) or 10µg of anti–Gα 
q/11 (sc-392), for Gi, GS and Gq studies, respectively. After an 
overnight incubation at 4ºC, protein G-sepharose was added and 
incubated for 90 min at 4ºC. The sepharose was washed 5 times 
with the solubilisation buffer and the incorporation of [35S]GTP-γ-S 
was measured by liquid scintillation.  
4.3 Statistical analysis  
All data are present in mean ± SEM to test for statistical significance, 
the data were analysed by Students’t-test or by one way ANOVA 
followed by Bonferroni’s multiple comparison test. Values of p ≤ 
0.05 were considered to represent statistically significant 
differences. 
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5 Results 
5.1 Adenosine modulation of GAT-1-mediated GABA uptake 
by synaptosomes 
5.1.1 Rationale 
To assure a controlled GABA signaling, GABA is quickly removed 
from the synaptic cleft, and this occurs through Na+ and Cl-
dependent GABA transporters (GATs) present in pre-synaptic nerve 
endings and surrounding astrocytes (Borden, 1996). The 
predominant GAT in GABAergic nerve endings is GAT-1 (Iversen and 
Kelly 1975). These terminals also possess adenosine A1 and A2A 
receptors. A1 receptors do not directly modulate GABA release 
(Cunha and Ribeiro, 2000) but influence the action of other 
neuromodulators upon GABA release (Cunha-Reis et al., 2008). A2A 
receptors facilitate GABA release (Cunha and Ribeiro, 2000). In spite 
of this detailed information on how release of GABA is controlled by 
the two high affinity adenosine receptors, no study so far has 
evaluated how the uptake of GABA into nerve endings is modulated 
by adenosine. I therefore investigated the influence of adenosine A1, 
A2A and A2B receptors upon GAT-1-mediated GABA transport. 
5.1.2 Adenosine A2A receptors tonically enhance GAT-1 -mediated 
GABA transport 
Before evaluating the influence of any drug on GABA uptake by 
synaptosomes, experiments were designed to define the time of 
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incubation with [3H]GABA, as well as the GABA concentration to be 
used in subsequent GABA uptake assays. [3H]GABA (5 µM) uptake 
was linear (correlation coefficient = 0.95) for incubation times 
ranging from 0 to 80 s. For 40 s incubation, the KM of GAT-1-
mediated GABA transport, determined in one experiment where 
[3H]GABA concentrations ranged between 0 and 10 µM, was 5 µM. 
This value is similar to that previously reported by others (1.57 µM < 
KM < 13 µM (Wood and Sidhu, 1986). An incubation time of 40 s and 
a [3H]GABA concentration of 5 µM were therefore used in all the 
subsequent experiments. Under these conditions and in the absence 
of test drugs the amount of [3H]GABA taken up by the synaptosomes 
through GAT-1, i.e., after subtraction of the uptake in the presence 
of SKF 89976A (20 µM), was 2.86 ± 0.34 nmol/mg protein (n= 25). To 
know if extracellular adenosine endogenously released by the 
synaptosomes could influence [3H]GABA uptake, synaptosomes 
were incubated for 15 min with adenosine deaminase (1 U/ml), an 
enzyme that catabolises adenosine into inosine. [3H]GABA was then 
added, and its uptake was compared with the uptake by 
synaptosomes incubated for the same period of time in the absence 
of ADA. As shown in figure 5.1.A, ADA decreased [3H]GABA uptake 
by 17 ± 2.6% (n = 4, p<0.01). This inhibition cannot be attributed to 
the formation of extracellular inosine as this adenosine metabolite 
even at a concentration (10 µM) higher than that expected to occur 
because of deamination of extracellular endogenous adenosine, had 
no effect on [3H]GABA uptake (n = 3,p > 0.05) (Fig. 5.1.A). As also 
shown in Fig. 5.1.A, blockade of A2A receptors with their selective 
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antagonist, SCH 58261 (50 nM), mimicked the effect of ADA (% 
inhibition of GABA uptake in the presence of SCH 58261: 25 ± 2.2%, 
n= 4, p < 0.01). When applied to synaptosomes where endogenous 
adenosine had been removed by ADA, SCH 58261 (50 nM) was 
devoid of effect upon [3H]GABA uptake (Fig. 5.1.B). Taken together 
the above results strongly indicate that GAT-1-mediated GABA 
transport is tonically facilitated by adenosine A2A receptors 
activation with endogenous adenosine. To avoid A2A receptors 
occupancy by endogenous extracellular adenosine, which would 
mask the action of added agonists, ADA (1 U/ml) was added to the 
incubation medium in all subsequent experiments, except otherwise 
indicated. 
Adenosine A2A receptors activation with the selective agonist CGS 
21680 (30 nM) (Jarvis et al., 1989) enhanced [3H]GABA uptake by 26 
± 1.0% (n=4, p< 0.01), an effect fully prevented by the presence of 
SCH 58261 (50 nM) (Fig. 5.1.B), a selective A2A receptor antagonist 
(Zocchi et al., 1996). When the effects of different concentrations of 
the A2A receptor agonist were compared in the same experiments, it 
was apparent that a maximum increase was attained with 30 nM of 
CGS 21680; an higher concentration caused a lower effect (Fig. 
5.1.C), probably because of receptor desensitization (Mundell et al., 
1997).  
The activation of adenosine A2A receptors leads to the same effect in 
adult rats (6–8 weeks), where CGS 21680 (30 nM) increased 
[3H]GABA uptake by 20 ± 3.4% (n=4, p < 0.001) (Fig. 5.2). This effect 
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was completely banned by the pre-incubation of the A2A receptor 
antagonist, SCH 58261 (50 nM).  
As can be concluded from the saturation curve shown in Figure 
5.1.D, the Vmax of GAT-1 was enhanced from 3.91 ± 0.18 nmol/mg 
protein in the control condition to 5.34 ± 0.20 nmol/mg protein in 
the presence of 30 nM of the adenosine A2A receptors agonist (p < 
0.005, n = 3), while the KM value was not significantly modified (4.01 
± 0.65 µM in the presence of CGS 21680 and 4.15 ± 0.63 µM in its 
absence, p > 0.05, n= 3), suggesting an increase in the number of 
membrane GAT-1 transporters without a change in the transporter 
affinity for GABA. An increase in the expression of GAT-1 in surface 
membranes (16 ± 3.1%, p= 0.0024, n= 5) was found in biotinylation 
assays with synaptosomes treated with CGS 21680 (30 nM) for 20 
min (Fig. 5.1.E). This increase in GAT-1 density at surface membranes 
was accompanied by a decrease of 14 ± 2.7% (p= 0.0033, n= 4) in the 
amount of GAT-1 in the intracellular fraction (Fig. 5.1.F). 
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Figure 5.1 – Adenosine, through adenosine A2A receptors, enhances GABA 
transport into nerve endings by increasing the surface density of GAT-1 
and maximum transport rate. Panel (A) illustrates the inhibition of GABA 
uptake caused by removal of endogenous extracellular adenosine with 
adenosine deaminase (ADA, 1 U/ml), which deaminates adenosine into 
inosine, or by preventing the action of endogenous adenosine over A2A 
receptors with a selective antagonist SCH 58261 (50 nM); the absence of 
effect of inosine (10 µM), the metabolite formed by adenosine 
deamination by ADA is also shown. Panel (B) illustrates the facilitation of 
GAT-1 mediated GABA transport by activation of A2A receptors with a 
selective agonist, CGS 21680 (30 nM), and the ability of the A2A receptors 
antagonist, SCH 58261 to prevent this effect. By itself SCH 58261 did not 
influence GABA transport as endogenous adenosine has been removed 
with ADA. The concentration-response curve for the effect of CGS 21680 is 
illustrated in panel C. Panel (D) shows a saturation curve, depicting the 
amount of GABA taken up as a function of the concentration of GABA. 
Panels (E) and (F) show results from western blots with a GAT-1 antibody, 
performed in the membrane sediment after biotinylation (E), to assess 
GAT-1 surface density or in the supernatant (F), to assess the density in the 
intrasynaptosomal pool. Note that the surface GAT-1 density was 
enhanced by the A2A receptors agonist, CGS 21680 whereas 
intrasynaptosomal GAT-1 density was decreased. The density of GAT-1 
(ordinates) is expressed in immunofluorescence arbitrary units, after 
normalization against b-actin, which was used as a loading control; 100% 
corresponds to GAT-1 density in the absence of CGS 21680. Representative 
western blots are showed in each panel below the corresponding column. 
In all panels the results are expressed as mean ± SEM, with n = 3–5. The 
statistical significance was calculated through one way ANOVA followed by 
Bonferroni’s multiple comparison test, (*p < 0.01). All tested drugs were 
incubated for 20 min before addition of [3H]GABA; while testing CGS 21680 
in the presence of SCH 58261, the antagonist was added 10 min before the 
agonist. In all experiments, except in those illustrated in (A), endogenous 
adenosine was removed by incubation with ADA (1 U/ml).  
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Figure 5.2 – Adenosine A2A receptors activation promotes GAT-1 
mediated GABA uptake in adult rats. The activation of A2A receptors by its 
selective agonist (CGS 21680, 30 nM) promoted GABA uptake. This effect 
was fully prevented by the presence of the adenosine A2A receptors 
selective antagonist (SCH 58261, 50 nM). All assays were performed after 
the removal of endogenous adenosine with ADA (1 U/ml). Results are as 
mean ± SEM with n = 4. The statistical significance was calculated by one 
way ANOVA followed by Bonferroni’s multiple comparison test (*p < 
0.001, n = 4). 
5.1.3 Adenosine A1 and A2B receptors do not affect GAT-1 
mediated GABA transport 
To evaluate the tonic influence of adenosine A1 and A2B receptors 
upon GAT-1 mediated GABA transport, experiments were performed 
in synaptosomes in the absence of ADA. As illustrated in figure 5.3.A, 
neither the blockade of the A1 receptors with its selective antagonist 
DPCPX, at a concentration of 50 nM, one hundred times higher than 
its KD for A1 receptors (Bruns et al., 1987) nor A1 receptors activation 
with its selective agonist, CPA at a concentration (30 nM) more than 
ten times higher than its KD for A1 receptors (Williams et al., 1986) 
have any effect on GAT-1-mediated GABA uptake. To evaluate the 
role of A2B receptors upon GABA transport and due to the lack of 
selective agonists of A2B receptors, a blanket agonist (NECA) was 
used in the presence of A2A and A1 receptors  selective antagonists, 
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SCH 58261 (50 nM) and DPCPX (50 nM). NECA was used at a 
concentration (3 µM) previously shown to induce A2B receptors-
mediated responses in astrocytes (Peakman and Hill, 1994) but it 
was devoid of effect on [3H]GABA uptake (Fig. 5.3.B). The adenosine 
A2B receptor antagonist, MRS 1706 (50 nM) (Kim et al., 2000) was 
also devoid of effect upon [3H]GABA uptake (p > 0.05, n = 4)  (Fig. 
5.3.B) in synaptosomes that were not pre-incubated with ADA. 
Altogether, these results indicate that neither endogenous nor 
exogenous activation of adenosine A1 nor A2B receptors affect GAT-1 
mediated GABA transport into nerve terminals. 
 
Figure 5.3 – Adenosine A1 and A2B receptors do not affect GAT-1 
mediated GABA transport into nerve endings. In Panel (A) it is shown the 
absence of influence of A1 receptors. Both the activation of A1 receptors by 
the selective agonist (CPA, 30 nM) and the blockade by the selective 
antagonist (DPCPX, 50 nM) failed to modify GABA uptake.  Panel (B) 
illustrates the absence of influence by adenosine A2B receptors. The 
blanket adenosine receptors agonist NECA (3 µM) was used as an A2B 
receptors agonist, as the adenosine A1 and A2A receptors were previously 
blocked by DPCPX (50nM) and SCH 58261 (50nM), respectively. Note that 
neither NECA, nor A2B receptors blockade with the selective antagonist 
MRS 1706 (50 nM), influenced GABA uptake. Results are mean ± SEM from 
four experiments. Statistical differences were evaluated by one way 
ANOVA followed by Bonferroni’s multiple comparison test and no 
statistical differences emerged (p > 0.05). Adenosine deaminase was not 
added. The antagonists were added 10 min before the agonists, when 
tested together.  
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5.1.4 Activation of adenylate cyclase mimics adenosine A2A 
receptors activation and PKA blockade prevents the action 
of the A2A receptors agonist 
To investigate the involvement of the adenylate cyclase (AC)/PKA 
transduction pathway in the enhancement of GABA transport into 
the nerve endings, a selective activator of AC, forskolin (Awad et al., 
1983) and a selective PKA inhibitor (Chijiwa et al., 1990) were used. 
Blockade of PKA with H-89 (1µM), per se, had no effect on [3H]GABA 
uptake (n = 3, p > 0.05, Fig. 5.4.A), but prevented the facilitatory 
action of CGS 21680 (30 nM) upon GABA transport (Fig. 5.4.B). On 
the other hand, AC activation with forskolin (10 µM) increased 
[3H]GABA uptake by 29 ± 5.1% (n = 6, p< 0.001, Fig. 5.4.A), therefore 
mimicking the effect of A2A receptors activation by CGS 21680 (30 
nM). As expected, the effect of forskolin (10 µM) on [3H]GABA 
uptake was prevented by H-89 (1 µM) (n = 3, p < 0.001, fig. 5.4.A). 
The facilitatory actions of forskolin and CGS 21680 upon GABA 
uptake were not additive (Fig. 5.4.B), suggesting that they operate a 
common pathway. 
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Figure 5.4 – Influence of the AC/PKA transduction pathway. Panel (A) 
shows the modifications of GAT-1 mediated GABA transport caused by the 
adenylate cyclase (AC) activator, forskolin (10 µM), and by the PKA 
inhibitor H-89(1 µM). Note that forskolin enhanced GABA uptake (p < 
0.05), an action prevented by H-89, although H-89 per se did not affect 
GABA transport into the nerve endings. Panel (B) illustrates how the 
manipulation of the AC/PKA pathway influences the adenosine A2A 
receptors mediated enhancement of GABA transport. Note that AC 
activation mimicked the effect of the A2A receptors agonist, CGS 21680, 
and that both effects were not additive; the PKA inhibitor, H-89, fully 
prevented the effect of CGS 21680. All assays were performed after the 
removal of endogenous adenosine with ADA (1 U/ml). Results are as mean 
± SEM with n = 3–6. The statistical significance was calculated by one way 
ANOVA followed by Bonferroni’s multiple comparison test, *p < 0.05. The 
incubation period with test drugs was 20 min; whenever forskolin or H-89 
were used together with CGS 21680, they were added 10 min before CGS 
21680; when testing the ability of H-89 to prevent the effect of forskolin, 
H-89 was added 10 min before forskolin. 
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5.1.5 PKC constitutively inhibits GABA transport, and prevents 
A2A receptors -mediated facilitation of GABA transport 
The influence of PKC upon GABA uptake was investigated by using 
its selective inhibitor, GF109203X (Toullec et al., 1991) and its 
activator, PDD (Castagna et al., 1982). Upon blockade of PKC with 
GF109203X (1 µM) [3H]GABA uptake was enhanced by 26 ± 5.8% (p < 
0.05, n = 5, Fig. 5.5.A), suggesting that PKC is tonically activated and 
inhibits GAT-1-mediated GABA transport. Further activation of PKC 
by PDD (250 nM) decreased [3H]GABA uptake by 17 ± 1.6% (p < 0.05, 
n = 4, Fig. 5.5.A), which indicates that tonic PKC activation is 
submaximal and reinforces the conclusion that PKC activation 
promotes the inhibition of GAT-1 mediated GABA transport into 
nerve endings. 
 To figure out the mechanism associated to the effect of PKC 
activation upon GABA transporter, saturation assays were 
performed. As it can be seen in Fig. 5.5.B the activation of PKC with 
PDD (250 nM) led to a decrease in the Vmax of GAT-1, from 1.81 ± 
0.08 nmol/mg protein in the control condition to 1.19 ± 0.06 
nmol/mg protein in the presence of PKC activator, PDD (p = 0.0013, 
n = 3). On the other hand, the value of KM was not significantly 
modified (4.38 ± 0.78 µM in the presence of PDD (250 nM) and 3.89 
± 0.80 µM in its absence, p > 0.05, n = 4), suggesting a decrease in 
the number of membrane GAT-1 transporters without a change in 
the transporter affinity for GABA. A decrease in the expression of 
GAT-1 in surface membranes (12 ± 2.1%, p = 0.0092, n = 3) was 
found in biotinylation assays with synaptosomes treated with PDD 
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(250 nM) for 20 min (Fig. 5.5.C). This reduction in GAT-1 density at 
surface membranes was accompanied by an augment of 12 ± 2.9% 
(p = 0.01, n = 3) in the amount of GAT-1 in the intracellular fraction 
(Fig. 5.5.C). Tonic inhibition of GABA transport by PKC might result 
from its constitutive activity, rather than from tonic activation of a 
membrane receptor coupled to phospholipase C (PLC), as blockade 
of PLC with U73122 (3 µM) had no effect on [3H]GABA uptake (p > 
0.05, n = 3, Fig. 5.5.E).  
When PKC was activated by PDD (250 nM), the A2A receptors 
agonist, CGS 21680 (30 nM), was no longer able to facilitate GABA 
transport (Fig. 5.6.A). On the other hand, the facilitatory action of 
CGS 21680 upon GABA transport was not additive with the 
facilitatory action of PKC blockade with GF109203X (Fig. 5.6.B). 
Taken together the above results suggest that to observe a 
facilitatory action of adenosine A2A receptors upon GAT-1- mediated 
GABA transport, PKC has to be submaximally activated. 
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Figure 5.5 – Influence of the PLC/PKC transduction pathway upon GABA 
transport. Panel (A) shows the consequences of manipulating PKC activity 
upon GAT-1 mediated GABA transport. Note that PKC activation with PDD 
(250 nM) decreased uptake, and that PKC inhibition with GF190203X (1 
µM) enhanced uptake. Panel (B) shows a saturation curve, depicting the 
amount of GABA taken up as a function of the concentration of GABA. 
Panels (C) and (D) show results from western blots with a GAT-1 antibody, 
performed in the membrane sediment after biotinylation (C), to assess 
GAT-1 surface density or in the supernatant (D), to assess the density in 
the intrasynaptosomal pool. Note that the surface GAT-1 density was 
decreased by the PKC activator, PDD whereas intrasynaptosomal GAT-1 
density was enhanced. The density of GAT-1 (ordinates) is expressed in 
immunofluorescence arbitrary units, after normalization against b-actin, 
which was used as a loading control; 100% corresponds to GAT-1 density in 
the absence of PDD. Representative western blots are showed in each 
panel below the corresponding column. Panel (E) shows the absence of 
modification of transport caused by blockade of PLC with U73122 (3 µM). 
All assays were performed after the removal of endogenous adenosine 
with ADA (1 U/ml).  In all panels the results are expressed as mean ± SEM 
from four to five experiments. The statistical significance was calculated 
through one way ANOVA followed by Bonferroni’s multiple comparison 
test (*p < 0.001). All tested drugs were incubated for 20 min before 
addition of [3H]GABA.  
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Figure 5.6 – Influence of PKC activity upon the A2AR mediated facilitation 
of GABA transport. Panel (A) illustrates how activation of PKC with PDD 
(250 nM) affects the action of the A2A receptors agonist, CGS 21680 (30 
nM) upon GAT-1 mediated GABA transport. Note that PKC activation with 
PDD fully prevented the effect of CGS 21680. Panel (B) shows how 
inhibition of PKC with GF109203X (1 µM) influenced the effect of the A2A 
receptors agonist CGS 21680 (30 nM). Note that both facilitatory effects 
were not additive. All assays were performed after the removal of 
endogenous adenosine with ADA (1 U/ ml). Results are as mean ± SEM 
from four experiments. The statistical significance was calculated through 
one way ANOVA followed by Bonferroni’s multiple comparison test, *p < 
0.05. The incubation period with test drugs was 20 min; whenever PDD or 
GF109203X were used together with CGS 21680, those PKC influencing 
drugs were added 10 min before CGS 21680.  
 
5.1.6 PKA and PKC interaction 
The results described above clearly indicate that both PKA and PKC 
are involved in the enhancement of GABA transport induced by 
adenosine A2A receptors activation. In an attempt to identify which 
mechanism would occur first, it was next investigated how both 
kinases cross-talked to modulate GAT-1-mediated GABA transport. 
So, experiments were designed in which activators or inhibitors of 
one transduction system were pre-incubated with the synaptosomes 
for 10 min before the addition of drugs towards the other 
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transduction system; the amount of GABA taken up only in the 
presence of the first (modifier) drug was taken as 100%. When PKC 
was previously inhibited by GF109203X (1 µM), the AC activator, 
forskolin (10 µM), was no longer able to enhance GABA uptake (Fig. 
5.7.A) whereas in the same synaptosomal batch but in the absence 
of GF109203X, forskolin caused its usual facilitation of GABA uptake 
(Fig. 5.7.B). On the other hand, previous blockade of PKA with H-89 
(1 µM) failed to influence the inhibition of GABA transport caused by 
PKC activation as PDD (250 nM) caused a similar inhibition of GABA 
uptake in the presence (Fig. 5.7.C) and in the absence (Fig. 5.7.D) of 
H-89, both effects being obtained from the same synaptosomal 
batch. Taken together these results suggest that modulation of 
GABA uptake by PKC can occur independently of PKA activity, and 
that PKC has to be active to see an action of PKA upon GAT-1 
mediated GABA uptake. Therefore, the direct modulator of GABA 
uptake appears to be PKC, PKA acting as a modifier of PKC-induced 
modulation. Reinforcing this conclusion was the observation that 
activation of AC with forskolin caused a pronounced change in the 
influence of the PKC blocker, GF109203X, upon GABA uptake 
(Fig.5.7.E and 5.7.F). Moreover, forskolin was able to counteract the 
inhibitory effect of PDD on GABA transport as GABA transport in the 
presence of Forskolin (10 µM) + PDD (250 nM) was similar (p > 0.05, 
n = 4) to that observed in the same synaptosomal batch in the 
control conditions (in the absence of any drug). 
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Figure 5.7 – PKC and PKA interaction. Panels (A) and (B) illustrate how the 
inhibition of PKC with GF109203X (1 µM) affects the facilitatory action of 
the AC activator, forskolin (10 µM), upon GAT-1-mediated GABA transport. 
Note that the facilitatory effect of forskolin was lost when PKC was 
previously blocked with GF109203X. Panels (C) and (D) show how 
inhibition of PKA with H-89 (1 µM) influences the action of the PKC 
activator PDD (250 nM). Note that the inhibitory effect of PDD was 
preserved when PKA was previously blocked with H-89. Panels (E) and (F) 
show how forskolin influenced the effect of GF109203X. Note that, when 
added alone the PKC inhibitor promoted GABA uptake into nerve endings 
(*p < 0.001, n = 4), while when AC was previously activated with forskolin, 
GF109203X decreased GABA uptake (*p < 0.01, n = 3). All assays were 
performed after the removal of endogenous adenosine with ADA (1 U/ml). 
The results are presented as mean ± SEM from three- four experiments (*p 
< 0.0005). The statistical significance was calculated through the Student’s 
t-test. The incubation period with test drugs was 20 min; when testing 
more than one drug, GF109203X (A), H-89 (C), or forskolin (E) were added 
10 min before the corresponding test drugs in those experiments [forskolin 
in (A), PDD in (C) or GF109203X in (E)]. 
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5.1.7 Discussion 
The main findings reported in this subchapter are that endogenous 
adenosine, through A2A receptor activation, promotes GAT-1-
mediated GABA transport into hippocampal nerve endings. This 
action might be mediated by the AC/PKA transduction system as the 
action of the A2A receptors agonist is mimicked by AC activation and 
is prevented by PKA inhibition. Furthermore, the results with drugs 
that manipulate the PLC/PKC pathway indicate that this transduction 
system is tonically restraining GAT-1-mediated GABA transport and 
that it has to be submaximally activated to allow the facilitatory 
actions of A2A receptors or AC. Altogether, these results indicate that 
adenosine, through A2A receptors activation and subsequent 
enhancement of AC activity, restrains the inhibition of GAT-1 by PKC 
(see Fig. 5.8). Results from biotinylation assays allowed the 
conclusion that the enhancement of GAT-1 activity promoted by A2A 
receptors activation is due to an increase in the surface membrane 
expression of GAT-1 transporters. This conclusion is corroborated by 
data from saturation curves, as the maximum velocity of transport 
(Vmax) was enhanced in the presence of A2A receptors agonists 
without appreciable changes in the affinity of the transporter for 
GABA (KM).  
In the hippocampus, A2A receptors activation promotes GABA 
release (Cunha and Ribeiro, 2000) and, as now showed, promotes 
GAT-1-mediated GABA uptake. Therefore A2A receptors influence 
GABAergic transmission in the hippocampus by fastening GABA 
signaling turnover. Indeed, through facilitation of GABA removal 
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from the synaptic cleft and enhancement of its uptake into nerve 
endings, A2A receptors may contribute to a reduction of tonic 
inhibition by GABA. On the other hand an enhancement of GABA 
transport will minimize GABA receptor desensitization and 
accelerate the replenishment of the GABA releasable pool at 
GABAergic nerve terminals. This will most probably lead to an 
enhancement in the efficiency of the phasic inhibitory signaling at 
the hippocampus, therefore contributing to a better control of 
hippocampal excitability. 
 The influence of adenosine A2A receptors on GABAergic transmission 
in the hippocampus may contrast with what occurs in the basal 
ganglia. Thus, in striatum, adenosine A2A receptors inhibit GABA 
release (Kirk and Richardson, 1995). It was also shown that A2A 
receptors agonist, CGS 21680, decreases GABA uptake, though this 
inhibition was observed at high and non-A2A receptor selective 
concentrations (100 nM–10 µM) of the agonist (Gonzalez et al., 
2006). Furthermore, full inhibition of transport was only attained by 
high (0.1–1 mM) concentrations of SKF 89976A (Gonzalez et al., 
2006), and so one cannot be sure if the transport was only occurring 
through GAT-1.  
The opposite effects mediated by A2A receptors into GAT-1 mediated 
GABA uptake in both hippocampus and basal ganglia can be related 
with the main transmission in each brain area. Then, hippocampal 
transmission is mainly glutamatergic while basal ganglia 
transmission is mainly GABAergic. So, at the hippocampus, A2A 
receptors facilitate the excitatory transmission as they promote 
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GABA uptake, reducing extracellular GABA levels while at basal 
ganglia, A2A receptors assist the inhibitory transmission by inhibiting 
GABA uptake, which will lead to an enhancement in ambient GABA 
levels. Then, adenosine, through A2A receptors activation, acts as an 
amplifier of the main transmission (excitatory at hippocampus and 
inhibitory at basal ganglia). 
Adenosine A2A receptors can couple to both PKA and PKC and this 
has been identified either at the hippocampus (Cunha and Ribeiro, 
2000) or at the striatum (Gubitz et al., 1996). These two 
transduction systems can cross-talk, as it has been shown in Aplysia 
sensory neurons where activation of PKC attenuates PKA-mediated 
actions of serotonin (Sugita et al., 1997). In the rat tail artery, 
adenosine A2A receptors mediated enhancement of noradrenaline 
release involves both PKA and PKC, PKA is operating downstream to 
PKC, as the consequences of manipulating PKC are blunted by PKA 
inhibition whereas the consequences of manipulating AC/PKA are 
not influenced by PKC inhibition (Fresco et al., 2004). The now 
reported influence of A2A receptors upon GAT-1 transporters also 
involves PKA and PKC, though PKC might operate downstream to 
PKA.  In fact, the effect of forskolin was prevented by PKC inhibition, 
but the blockade of PKA did not modify the consequences of PKC 
activation; thus, these results strongly suggest that PKC operate 
downstream to PKA.   
In cortical nerve terminals, PKA and PKC act synergistically to 
facilitate the release of glutamate (Millán et al., 2003). In what 
concerns modulation of GABA transport through GAT-1, it became 
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clear that PKA and PKC operate in opposed ways, with PKA 
facilitating GABA uptake and PKC inhibiting it. Moreover, the 
activation of PKC by PDD decreased the Vmax of GAT-1 but did not 
change the KM value of the transporter. These results indicate that 
the number of GAT-1 is reduced at the surface membrane level 
while the affinity of GAT-1 for GABA is not affected by PKC 
activation. Biotinylation assays corroborated these results as the 
membrane expression of GAT-1 is decreased while the GAT-1 levels 
are augmented in the intracellular fraction. PKC-induced 
internalization of GAT-1 has been shown by others using nerve 
terminals from the substantia nigra pars reticulata or cultured 
cortical neurons (Bahena-Trujillo and Arias-Montaño 1999; Wang 
and Quick, 2005). To my knowledge, the data herein reported were 
the first to show that GAT-1 mediated GABA uptake into nerve 
endings can be facilitated through a cAMP dependent process, and 
that this results from an increase in the surface expression of GAT-1 
transporters. It was also showed that the PKA-induced facilitation is 
due to decreased PKC-mediated inhibition. This counteracting 
activity does not necessarily result from a direct phosphorylation of 
PKC by PKA; instead, cAMP/AC/ PKA signaling may be affecting any 
PKC substrate involved in GAT-1 recruitment (see Fig. 5.8). 
 As mentioned above, the reported facilitation of GAT-1 mediated 
transport into nerve endings might contribute to fasten 
neurotransmitter recycling. Considering that A2A receptors activation 
also promote GABA release (Cunha and Ribeiro, 2000), both effects 
of adenosine A2A receptors lead to an enhancement of phasic 
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GABAergic signaling in the hippocampus. As disturbances in 
GABAergic transmission and, specifically, in GABA transport have 
been associated to several diseases, namely epilepsy and mood 
disorders (Conti et al., 2004; Gether et al., 2006), the data now 
reported expand the knowledge about the ways adenosine uses to 
influence neuronal functioning and reinforces the interest of using 
adenosine A2A receptors related drugs to correct brain dysfunctions.  
 
Figure 5.8 – Schematic representation of the influence of A2AR upon GAT-
1 mediated GABA transport into nerve endings. PKC is tonically 
restraining GABA uptake by hippocampal nerve endings through GAT-1 (A). 
The activation of A2A receptors leads to the activation of AC/PKA pathway, 
which reduces PKC-mediated tonic inhibition upon GAT-1 (B), resulting in 
an enhancement of GAT-1-mediated GABA uptake (C). 
Results 
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5.2 Modulation of astrocytic GABA Transport by Adenosine 
A1–A2A Receptor Heteromers  
5.2.1 Rationale  
Astrocytes modulate synaptic transmission because they can release 
and uptake neurotransmitters (Hamilton and Attwell, 2010) and, 
therefore, fine tune the balance between excitation and inhibition. 
GABA is the main inhibitory neurotransmitter in the CNS, playing a 
crucial role in the control of excitability (Krnjevic and Schartz, 1967), 
plasticity (Artola and Singer, 1987), and network synchronization 
(Blatow et al., 2003). These actions depend on changes in the 
extracellular concentrations of GABA, which are under control of 
GABA transporters (GATs) expressed in both neurons and astrocytes 
(Minelli et al., 1995, 1996). Cortical astrocytes express GAT-1 and 
GAT-3 subtypes, and it has been estimated that ≈ 20% of 
extracellular GABA may be taken up into astrocytes (Hertz and 
Schousboe, 1987). Astrocytes release large amounts of ATP, which is 
then hydrolyzed into adenosine by the action of ecto-nucleotidases 
(Hamilton and Attwell, 2010). Extracellular adenosine operates 
through G-protein-coupled receptors. In the case of neural cells, the 
adenosine A1 and A2A receptors are those that are most likely 
activated by basal levels of extracellular adenosine. The A1 receptors 
are often inhibitory and couple to Gi/o-proteins, whereas the A2A 
receptors are usually coupled to Gs-proteins, enhancing cAMP 
accumulation and PKA activity (Fredholm et al., 2001). A1 and A2A 
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receptors may closely interact in such a way that activation of A2A 
receptors can lead to inhibition of A1 receptors-mediated responses 
(Correia-de-Sá and Ribeiro, 1994; Cunha et al., 1994; Lopes et al., 
1999). Some interactions may occur at the functional and 
transduction system levels (Sebastião and Ribeiro, 2000), but energy 
transfer assays in the form of bioluminescence (BRET) and 
fluorescent (FRET) resonance energy transfer have identified the 
presence of adenosine A1–A2A receptor heteromers in immortalized 
transfected cells (Ciruela et al., 2006). In addition, 
coimmunoprecipitation experiments with presynaptic membranes 
showed that A1–A2A receptors heteromers modulate glutamate 
release from presynaptic nerve terminals (Ciruela et al., 2006). 
Together, these data suggest a putative role of adenosine A1–A2A 
receptors heteromers in neurons. However, direct evidence for 
adenosine A1–A2A receptor heteromerization in neural cells is still 
lacking, since direct BRET evidence was obtained in immortalized cell 
lines and coimmunoprecipitation indicates strong interaction but not 
necessarily heteromerization of proteins. The main aim of the 
present chapter was to clarify whether adenosine A1 and A2A 
receptors modulate GAT-1- and/or GAT-3-mediated GABA transport 
into astrocytes, due to the role of these cells in overall GABA 
transport. 
5.2.2 Endogenous adenosine tonically modulates GABA uptake 
To assess the role of adenosine during GABA uptake, the astrocytes 
were incubated with different concentrations of CADO, an 
adenosine analogue with similar affinity for adenosine A1 and A2A 
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receptors that is resistant to hydrolysis or uptake by the cells. As can 
be observed in panel A of figure 5.9, at a relatively low CADO 
concentration (0.3 µM), there was an inhibition of total [3H]GABA 
uptake by astrocytes (21 ± 3.8%, n=5, *p<0.05), whereas at higher 
concentrations (3–10 µM), CADO facilitated total [3H]GABA uptake 
(33 ± 9.5%, n=5, *p<0.05 and 24  ±  2.8%, n=4, *p< 0.05, for 3 and 10 
µM respectively). This biphasic influence on GABA transport could 
be either attributable to activation of different adenosine receptors, 
namely adenosine A1 and A2A receptors, or a differential influence 
over the two GATs present in astrocytes, GAT-1 and GAT-3 (Fig.  
5.9.F, 5.9.G). Hence, GAT-1 or GAT-3 activity was independently 
assayed. The removal of endogenous adenosine with ADA (1U/ml) 
led to a decrease in GABA transport, and this decrease was highly 
significant when transport was mediated by either GAT-1 (24 ± 5.0%, 
n=4, *p<0.01; Figure 5.9.B) or GAT-3 (18 ± 3.6%, n=4, *p<0.01; 
Figure 5.9.C), suggesting that extracellular adenosine is tonically 
facilitating GAT-1 and GAT-3 activity. To avoid occupation of 
adenosine receptors with the endogenous ligand, all subsequent 
transport assays were performed in cells preincubated with ADA (1 
U/ml). 
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Figure 5.9 – Adenosine receptor activation modulates [
3
H]GABA uptake 
in astrocytes. Panel A illustrate the effect mediated by CADO upon 
[3H]GABA uptake. Astrocytes were incubated with medium or with 
Increasing CADO concentrations and the total [3H]GABA uptake was 
determined. CADO had a biphasic effect, at 0.3µM, CADO decreased 
[3H]GABA uptake (21 ± 3.8%, n=5, *p<0.05) while at higher CADO 
concentration (3-10µM, [3H]GABA uptake was facilitated (33 ± 9.5%, n=5, * 
p<0.05 and 24  ±  2.8%, n=4, *  p< 0.05, for 3 and 10 µM respectively.  In 
panels B and C, it is shown the consequence of endogenous adenosine 
removal by ADA (1U/ml). Astrocytes that were incubated with (ADA 
1U/ml) showed a decreased GABA transport both by GAT-1(24 ± 5.0%, 
n=4, * p<0.01) and by GAT-3 ((18 ± 3.6%, n=4, * p<0.01). In D, for 
immunohistochemistry analysis of GAT-1 (green, top row) and GAT-3 
(green, bottom row) expression by astrocytes, GFAP (red) was used as 
astrocyte marker. In E, solubilized astrocytes were analyzed by SDS-PAGE 
and immunoblotted using rabbit anti-GAT-1 antibody (1:100) or rabbit 
anti-GAT-3 antibody (1:200) (M, molecular mass markers). Results in A–E 
are shown as mean ± SEM of four to five independent experiments. 
Statistical significance was calculated by one-way ANOVA, followed by 
Bonferroni’s multiple comparison test or by student T test *p<0.05 
compared with control (white bars). 
 
5.2.3 Adenosine A1 receptors activation decreased and adenosine 
A2A receptors activation enhanced GABA uptake 
Selective agonists of adenosine A1 and A2A receptors were used to 
assess the influence of the adenosine receptors on GABA 
transporters. The selective adenosine A1 receptor agonist CPA (30 
nM) decreased maximal velocity (Vmax) of GABA transport mediated 
by GAT-1 (Figure 5.10.A) or GAT-3 (Figure 5.10.B), whereas the 
selective agonist for adenosine A2A receptors, CGS 21680 (30 nM), 
enhanced Vmax for GAT-1 (Figure 5.10.A) and GAT-3 (Fig. 5.10.B), 
without affecting transport KM values (p < 0.05, n = 6). These data 
indicate that adenosine receptor activation modified maximum 
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transport capacity rather than in the affinity of the transporters for 
GABA and that inhibition of GAT-1 and GAT-3 is mediated by 
adenosine A1 receptors, whereas facilitation requires adenosine A2A 
receptors activation.  
 
Figure 5.10 – Adenosine A1 receptors activation decreased Vmax of GAT-1 
and GAT-3 while adenosine A2A receptors activation led to an 
enhancement of Vmax of both GAT-1 and GAT-3. The transport kinetics of 
GAT-1 (Panel A) and GAT-3 (Panel B) were determined using increasing 
[3H]GABA concentrations. The adenosine A2A receptors agonist CGS 21680 
(30 nM, squares) enhanced Vmax of both GAT-1 and GAT-3 without modify 
the KM. On the other hand,  the adenosine A1 receptors agonist CPA (30 
nM, triangles) decreased Vmax of GAT-1 and GAT-3, with no changes in the 
KM. statistical significance was calculated by one-way ANOVA followed by 
Bonferroni’s multiple comparison test (n=6).  Results are expressed in the 
tables 5.1 and 5.2 present in the next page. 
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Table 5.1 – GAT-1 transport kinetic constants (Vmax and KM) in control 
conditions and after the activation of adenosine A1 receptors (by CPA, 
30nM) and the adenosine A2A receptors (by CGS 21680 30nm). Results are 
present as Mean ± SEM. statistical significance was calculated by one-way 
ANOVA followed by Bonferroni’s multiple comparison test (* p < 0.05, 
n=6). 
 Control A1R Activation A2AR activation 
Vmax (pmol 
GABA/min) 
15 ± 0.9 8 ± 0.3 * 25 ± 1.7 * 
KM (µM) 5.0 ± 0.8 6 ± 0.9 4.9 ± 0.5 
 
Table 5.2 – GAT-3 transport kinetic constants (Vmax and KM) in control 
conditions and after the activation of adenosine A1 receptors (by CPA, 
30nM) and the adenosine A2A receptors (by CGS 21680 30nm). Results are 
present as Mean ± SEM of six independent experiments. Statistical 
significance was calculated by one-way ANOVA followed by Bonferroni’s 
multiple comparison test (* p < 0.05). 
 Control A1R Activation A2AR activation 
Vmax (pmol 
GABA/min) 
23 ± 1.6 14 ± 1.1 * 31 ± 1.6 * 
KM (µM) 18 ± 2.7 18 ± 1.9 18 ± 2.2 
 
To further confirm that adenosine A1 and A2A receptors affect GABA 
transport in opposite ways, combinations of selective agonists and 
antagonists for either receptor (Table 5.3) were used. For these 
experiments, the concentration of each compound was chosen to 
act in a selective way.  Results are summarized in Figures 5.11 and 
5.12. The effect of adenosine A1 receptor selective agonist (CPA, 
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30nM) and of the adenosine A2A receptor selective agonist (CGS 
21680, 30nM) effect were tested in the presence of the adenosine 
A1 receptor selective antagonist (DPCPX, 50 nM) or the adenosine 
A2A receptor selective antagonist (SCH 5826, 50 nM). Surprisingly, 
the effect of the adenosine A1 receptor agonist was fully prevented 
not only by previous blockade of the adenosine A1 receptors with 
DPCPX but also by the blockade of adenosine A2A receptors with SCH 
58261. Analogously, facilitation of GABA transport by the adenosine 
A2A receptors agonist CGS 21680 was completely abolished by the 
blockade of either adenosine A2A or A1 receptors. These results 
strongly indicate that adenosine A1 and A2A receptors are tightly 
interacting and represent a clear example of cross antagonism 
between the two receptors. Such antagonism may be attributable to 
heteromerization (Ferrada et al., 2009; Moreno et al., 2011); thus, it 
was decided to test whether adenosine A1 and A2A receptors may 
form heteromers in astrocytes. 
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Figure 5.11 – Inhibition of [
3
H]GABA uptake is promoted by adenosine A1 
receptors. Astrocytes were treated for 15 min with ADA (1 U/ml) before 
the addition of medium, the adenosine A1 receptor antagonist DPCPX (50 
nM), or the adenosine A2A receptor antagonist SCH 58261 (50 nM). After 
20 min, the adenosine A1 receptor agonist CPA (30 nM) was added, and 
the GAT-1 (A, B) or GAT-3 (C, D) mediated [3H]GABA uptake was measured 
as indicated in  Methods chapter.  Adenosine A1 receptors activation 
decreased [3H]GABA uptake by GAT-1 (16 ± 1.5%) and by GAT-3 (34 ± 
4.3%). The adenosine A1 receptors mediated effect was abolished by the 
previous blockade of adenosine A1 receptors and also A2A receptors. 
Results are mean ± SEM of six to eight independent experiments. 
Statistical significance was calculated by one-way ANOVA followed by 
Bonferroni’s multiple comparison test; * p < 0.001 compared with control 
(white bar); NS, p > 0.05. 
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Figure 5.12 – Adenosine A2A receptors activation facilitates [
3
H]GABA 
uptake. Astrocytes were treated for 15 min with 1 U/ml ADA before the 
addition of medium, the adenosine A1 receptor antagonist DPCPX (50 nM), 
or the adenosineA2A receptor antagonist SCH 58261 (50 nM). After 20 min, 
the adenosine A2A receptor agonist CGS 21680 (30 nM) was added, and the 
GAT-1 (A, B) or GAT-3 (C, D) mediated [3H]GABA uptake was measured as 
indicated in Methods. Adenosine A2A receptors activation increased 
[3H]GABA uptake by GAT-1 (24 ± 5.2%) and by GAT-3 (22 ± 4.6%). The 
blockade of adenosine A1 or A2A receptors totally prevented GABA uptake 
facilitation mediated by adenosine A2A receptors activation. Results are 
mean ± SEM of six independent experiments. Statistical significance was 
calculated by one-way ANOVA followed by Bonferroni’s multiple 
comparison test; * p < 0.001 compared with control (white bar); NS, p > 
0.05. 
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Table 5.3 – Binding affinity of agonists and antagonists of adenosine 
receptors (Ki values with 95% confidence intervals or ± S.E.M in 
parentheses) (adapted from Fredholm et al., 2001). 
Drug A1R A2AR A2BR A3R 
CPA 2.3 (1.5-
3.4) a 
790 (470-
1,360) a 
34,400 
(±11,100)b  
21,000 
(±4,300) d 
43 (30-61) a 
CGS 
21680 
290 (230-
360) a 
27 (12-59) a 
361,000  
(±21,100) b 
67 (50-90) a 
DPCPX 3.9 (3.5-
4.2) a 
129 (35-
260) a 
50 (±3.7) b 
51 (±6.1) d 
4,000 
(2,600-
6,000) a 
SCH 
58261 
290 (210-
410) c 
0.6 (0.5-0.7) 
c
 
 >10,000 c 
a-Klotz et al.,  1998; b- Linden et al., 1999; c -Ongini et al., 1999; d-Ji 
and Jacobson, 1999 
5.2.4 Adenosine A1 -A2A receptor heteromers in astrocytes 
The Bioluminescence Resonance Energy Transfer (BRET) approach 
was used to evaluate the ability of adenosine A1 receptors to 
heteromerize with adenosine A2A receptors in astrocytes. Adenosine 
A1 and A2A receptors expression is relatively low at 2 weeks of cell 
culture but increases later on. Thus, to avoid competition with 
endogenous receptors, BRET measurements were performed using 
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2-week cultured astrocytes transiently co-transfected with a 
constant amount of A2AR-RLuc (7.5 µg cDNA) and increasing 
amounts of A1R-YFP (4 to 15µg cDNA). Fusion of RLuc to A2A receptor 
or to YFP to A1 receptor did not modify receptor function as 
determined by cAMP assays (Canals et al., 2003). A positive and 
saturable BRET signal was found for the pair A2AR-RLuc and A1R-YFP 
(Figure 5.13.A). From the saturation curve, a BRETmax of 94 ± 15 mBU 
and a BRET50 of 16 ± 2 were calculated. As a negative control the 
A2AR-RLuc and serotonin 5HT2BR-YFP pair was used. As shown in 
Figure 5.13.A the negative control gave a linear non-specific BRET 
signal, thus confirming the specificity of the interaction between 
A2AR-RLuc and A1R-YFP in astrocyte primary cultures.  
Ligand binding assays to receptor heteromers in isolated 
membranes usually reveal a “biochemical fingerprint” which consists 
of changes in ligand binding characteristics of one receptor when the 
partner receptor is occupied by agonist (Ferré et al., 2009). No 
intracellular cross-talk can occur in disrupted membranes and 
therefore it can be assumed that the “fingerprint” results from 
intramembrane receptor-receptor interactions. Although an indirect 
approach, it is accepted as identifier of receptor heteromers in 
native tissues or in cells expressing the natural non-heterologous 
receptors (Ferré et al., 2009). Therefore, binding experiments were 
performed in collaboration with Prof. Rafael Franco’s group 
(University of Barcelona) to identify native adenosine A1-A2A 
receptors heteromers in 4-week cultured astrocytes. As shown in 
Figure 5.13.B, the displacement of adenosine A1 receptors agonist 
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[3H]R-PIA binding by the adenosine A2A receptor agonist, CGS 21680 
(but not by the adenosine A2A receptor antagonist, SCH 58261) was 
significantly (p<0.01) better represented by a biphasic than by a 
monophasic curve. It is not expected that the adenosine A2A 
receptors agonist, at concentrations lower than 500 nM, would 
significantly bind to adenosine A1 receptors (<1% binding to 
adenosine A1 receptors, according to known KD value). However, 500 
nM CGS 21680 significantly (p< 0.05) displaced the binding of the 
selective adenosine A1 receptor agonist, [
3H]R-PIA, with an IC50 value 
of 90 ± 30 nM. Obviously, higher concentrations of CGS 21680 
caused a further displacement of [3H]R-PIA binding that, according 
to its IC50 value (8 ± 4 µM), reflects the binding of CGS 21680 to the 
adenosine A1 receptors. As expected, the adenosine A2A receptors 
antagonist, SCH 58261, only displaced the adenosine A1 receptors 
agonist binding (IC50 of 500 ± 120 nM) at concentrations known to 
lose adenosine A2A receptors selectivity and to bind to adenosine A1 
receptors (Fig. 5.13.B). Taken together these data indicate that the 
biphasic [3H]R-PIA binding displacement curve observed in the 
presence of the A2A receptor agonist constitutes the fingerprint of 
the adenosine A1-A2A receptor heteromer in non-transfected 
primary cultured astrocytes.  
To evaluate whether adenosine A1-A2A receptors heteromerization 
could be influenced by agonist or antagonist binding, a series of 
experiments was performed in transiently co-transfected HEK-293T 
cells using a constant amount of A2AR-RLuc (1.5µg cDNA) and 
increasing amounts of A1R-YFP (1 to 8µg cDNA). In agreement with 
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previous results (Ciruela et al., 2006), a positive and saturable BRET 
signal was found. Stimulation (20min) with the adenosine A2A 
receptor agonist (CGS 21680, 30nM) (Figure 5.13.C), or with the 
adenosine A1 receptor agonist (CPA, 30nM) (Figure 5.13.D) did not 
promote any consistent (p>0.05) change in BRETmax or BRET50 values. 
Similar BRET values were also obtained in the presence or absence 
of adenosine A2A receptor (Figure 5.13.E) or adenosine A1 receptor 
(Figure 5.13.F) antagonists indicating that neither agonist nor 
antagonist binding affected the receptor oligomerization state. 
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Figure 5.13 – Adenosine A1-A2A receptor heteromers in astrocytes. In ( A, 
C, D, E, F)  BRET saturation experiments were performed using 2 weeks 
cultured astrocytes (A) or HEK-293 cells (C-F) co-transfected with 1.5 μg (A) 
or 1μg (C-F) cDNA corresponding to A2AR-Rluc and increasing amounts of 
cDNA corresponding to A1R-YFP (squares) or 5HT2B-YFP (triangles, as 
negative control) constructs. In (C to F) cells were treated for 10 min with 
medium (squares, solid line) or with 30nM CGS 21680 (C), 30nM CPA (D), 
50nM SCH 58261 (E) or 50nM DPCPX (F) (circles, dotted lines). The BRETmax 
and BRET50 values are shown in the inserts. Both fluorescence and 
luminescence of each sample were measured before every experiment to 
confirm similar donor expressions (about 100,000 luminescent units) while 
monitoring the increase acceptor expression (500 to 10,000 fluorescent 
units). Data are means ± S.D. of 3 different experiments grouped as a 
function of the amount of BRET acceptor. In (B) competition experiments 
of 0.8 nM [3H]R-PIA versus increasing concentrations of  the A2A receptor  
agonist, CGS 21680 (solid line), or the A2A receptor antagonist, SCH 58261  
(dotted line), were performed using astrocytic membranes (0.18 mg 
protein/ml). Experiments in B have been performed by a collaborator 
(Vicent Casadó) at University of Barcelona. Data are mean ± S.E.M. of a 
representative experiment (n = 3) performed in triplicates. 
 
5.2.5 Adenosine A1 or A2A receptors activation, but not its 
blockade, leads to internalization of the A1-A2A receptor 
heteromers 
Heteromerized receptors are expected to internalize together. To 
test this possibility, agonist-mediated internalization of adenosine A1 
receptors and A2A receptors was studied in astrocytes. Western blot 
data clearly showed that adenosine A1 receptors immunoreactivity 
at the cell surface did not only decrease after incubation of 
astrocytes with the adenosine A1 receptor agonist (21 ± 0.6%), but 
also after incubation with the adenosine A2A receptor agonist (20 ± 
1.5%), as can be seen in figure 5.14.A. This decrease was 
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accompanied by an increase in A1 receptors immunoreactivity in the 
intracellular fraction (36 ± 4.9%, after adenosine A1 receptors 
activation; 28± 4.2%, after adenosine A2A receptors activation), 
which is illustrated in the figure 5.14.B. No significant changes in 
surface (Figure 5.14.C) or intracellular (Figure 5.14.D) adenosine A1 
receptors immunoreactivity were detected upon incubation with 
either adenosine A1 or A2A receptors antagonists. Interestingly, when 
the adenosine A1 receptor agonist was added after previous 
blockade of either adenosine A1 or A2A receptors by the selective 
antagonists, it was no longer able to modify adenosine A1 receptors 
immunoreactivity at the cell surface (Figure 5.14.E) or in the 
intracellular fraction (Fig. 5.14.F). Similarly, adding the adenosine A2A 
receptor agonist after a previous blockade of adenosine A1 or A2A 
receptors did not promote any modification of adenosine A1 
receptors immunoreactivity at cell surface (Figure 5.14.E) or in the 
intracellular fraction (Fig. 5.14.F). It therefore becomes clear that 
blockade of either adenosine A1 or A2A receptors prevents adenosine 
A1 receptors internalization induced by exposure to adenosine A1 or 
A2A receptor agonists. 
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Figure 5.14 – Adenosine A1 or A2A receptors activation (but not their 
blockade) in astrocytes promotes internalization of adenosine A1-A2A 
receptors heteromers. Astrocytes were incubated for 30 min with the 
adenosine A1 receptor agonist CPA (30 nM) or with the adenosine A2A 
receptor agonist CGS 21680 (30 nM), alone (A and B) or in the presence of 
either the adenosine A1 receptor antagonist DPCPX (50 nM) or the 
adenosine A2A receptor antagonist SCH 58261 (50 nM) (E and F), or only 
with DPCPX (50 nM) or SCH 58261 (50 nM) (C and D), before starting the 
biotinylation protocol. When testing the action of agonists in the presence 
of antagonists, the antagonists were added 15 min before the agonists. 
Adenosine A1 receptors expression at surface membranes (left panels) and 
intracellular fraction (right panels) was determined as indicated in 
Methods. Results are mean ± S.E.M of 5 independent experiments. 
Statistical significance was calculated by one way ANOVA followed by 
Bonferroni’s multiple comparison test; *p<0.001 compared with control 
(100%, white bar). 
5.2.6 The adenosine A1-A2A receptor heteromer is coupled to Gi/0 
and Gs proteins   
To figure out which G protein(s) is (are) coupled to the adenosine A1-
AA receptors heteromer, assays of GTP-γ-[
35S] binding followed by 
immunoprecipitation using antibodies against different G proteins 
(Gs, Gi/0 and Gq/11) were performed. The approach is similar to that 
reported by Rashid and colleagues to identify Gq coupling to the 
dopamine D1-D2 receptor heteromer (Rashid et al., 2007). As 
illustrated in Figure 5.15.A, the adenosine A1 receptor selective 
agonist (CPA, 30nM) but not the adenosine A2A receptor selective 
agonist CGS 21680 (30nM) significantly increased the Gi/0 activity, an 
effect unpredictably prevented by the adenosine A2A receptor 
selective antagonist. In what concerns Gs activity (Figure 5.15.B), it 
was enhanced by the adenosine A2A receptor selective agonist CGS 
21680 (30nM), but not by the adenosine A1 receptor agonist, CPA 
(30nM); again, and unpredictably, the effect of the adenosine A2A 
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receptor agonist was fully abolished by the adenosine A1 receptor 
antagonist, DPCPX (50nM). None of the adenosine receptor agonists 
affected Gq/11 activity, which was enhanced by acetylcholine (10µM), 
used as a positive control in the same batch of astrocytic 
membranes (Figure 5.15.C). These data suggest that adenosine A1-
A2A receptor heteromers are coupled to both Gi/o and Gs proteins 
and not to a unique Gq/11 protein. 
G protein activity may be permanently modified by the binding of 
several toxins; thus these are useful tools to dissect out a differential 
receptor-G protein coupling in intact cells and to evaluate the 
functional consequences of G-protein-mediated-signaling blockade. 
GABA uptake assays were therefore performed using cholera toxin 
(ChTx), which uncouples Gs from the receptors due to ADP-
ribosylation and permanent activation of the αS-subunit (Gill and 
Meren, 1978), as well as using pertussis toxin (PTx), which catalyzes 
the ADP-ribosylation of the α Gi/0-subunit and locks it in the GDP-
bound inactive state thus preventing Gi/0 protein activation (Bokoch 
and Gilman, 1984). Inhibition of either GAT-1- or GAT-3-mediated 
GABA uptake induced by the adenosine A1 receptor agonist, CPA, 
was fully prevented by PTx, but, interestingly, this toxin also 
prevented adenosine A2A receptor-mediated facilitation of GAT-1- 
and GAT-3-mediated GABA uptake (Figure 5.16). Similar results were 
obtained in the reciprocal experiment using ChTx. In fact the toxin 
prevented not only the facilitation of GAT-1- and GAT-3-mediated 
transport caused by the adenosine A2A receptors agonist, CGS 
21680, but also the inhibition of GABA transport mediated by the 
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adenosine A1 receptors agonist, CPA (Figure 5.17). The ChTx and PTx 
data strongly suggest that the adenosine A1-A2A receptors heteromer 
is coupled to both Gs and Gi proteins. The results also indicate that if 
one G protein (Gs or Gi) is blocked or receptor-uncoupled, both 
adenosine A1 and A2A receptors agonists lose their effect upon GABA 
uptake. It seems therefore that the adenosine A1-A2A receptor 
heteromer coupled to both Gi/0 and Gs is the mediator of both the 
inhibitory and the excitatory effects triggered by, respectively, CPA 
and CGS 21680. 
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Figure 5.15 – [
35
S]GTP-γ-S assays suggest the involvement of both Gs and 
Gi/0 in the adenosine A1-A2A receptors heteromer. GTP-γ-[
35S] assays was 
performed as described in Methods to test Gi/0 activity (A), Gs activity (B) or 
Gq/11 activity (C) using membranes from astrocytes treated for 10 min with 
medium, the adenosine A2A receptor antagonist SCH 58261 (50 nM) or the 
adenosine A1 receptor antagonist DPCPX (50 nM) prior the activation with 
adenosine A2A receptor agonist CGS 21680 (30 nM) or adenosine A1 
receptor agonist CPA (30 nM) or Ach (10 µM) as positive control.  In Panel 
A, it is shown that only the activation of adenosine A1 receptors (CPA, 
30nM) led to an increase in Gi/0 activity (42 ±6.4%). This effect was totally 
abolished by the previous blockade of adenosine A2A receptors. The 
activation of adenosine A2A receptors was unable to modify Gi/0 activity. In 
panel B is illustrated the modulation of Gs activity.  The adenosine A1 
receptor agonist did not modify the Gs activity. The adenosine A2A receptor 
activation led to an enhancement of Gs activity (49 ± 14%). The previous 
blockade of adenosine A1 receptors prevented this increase mediated by 
adenosine A2A receptors activation. The panel C illustrates that only 
acetylcholine can increase Gq/11 activity (111 ±19%). Both adenosine A1 and 
A2A receptors activation were unable to modify Gq/11 activity. Results are as 
mean ± S.E.M from 5-8 independent experiments. Statistical significance 
was calculated by one way ANOVA followed by Bonferroni’s multiple 
comparison test; *p<0.001 compared with control (100%, white bar), ** 
p<0.001 compared with cells treated only with the agonist. 
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Figure 5.16 – Blockade of Gi/0 proteins by PTx prevents both effects 
mediated by adenosine A1 and A2A receptors. Astrocytes were treated 
with medium, PTx (5µg/ml) prior to stimulation with CPA (30 nM) or CGS 
21680 (30 nM) and GAT-1 and GAT-3 mediated [3H]GABA uptake was 
measured as indicated in Methods. PTx were pre-incubated with the 
astrocytes for 4h and then removed prior to uptake assays. The inhibitory 
effect mediated by adenosine A1 receptors (27 ± 5.8%, for GAT-1; 39 ± 
3.9% for GAT-3) was totally prevented by the previous incubation of 
astrocytes with the toxin. PTx was also able to prevent the facilitatory 
effect mediated by adenosine A2A receptors (30 ± 3.5%, for GAT-1; 33 ± 
6.4% for GAT-3). Results are as mean ± S.E.M from 4-6 independent 
experiments. Statistical significance was calculated by one way ANOVA 
followed by Bonferroni’s’s multiple comparison test; *p<0.01; NS: P>0.05. 
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Figure 5.17 – Blockade of Gs proteins by ChTx prevents both effects 
mediated by adenosine A1 and A2A receptors. Astrocytes were treated 
with medium, ChTx (5µg/ml) prior to stimulation with CPA (30 nM) or CGS 
21680 (30 nM) and GAT-1 and GAT-3 mediated [3H]GABA uptake was 
measured as indicated in Methods. ChTx was pre-incubated with the 
astrocytes for 4h and then removed prior to uptake assays. The excitatory 
effect mediated by A2AR (48 ± 8.0%, for GAT-1; 40 ± 5.8% for GAT-3) was 
totally prevented by the previous incubation of astrocytes with the toxin. 
ChTx was also able to prevent the inhibitory effect mediated by A1R (29 ± 
3.3%, for GAT-1; 35 ± 5.6% for GAT-3). Results are as mean ± S.E.M from 4-
6 independent experiments. Statistical significance was calculated by one 
way ANOVA followed by Bonferroni’s multiple comparison test; *p<0.01; 
NS: P>0.05. 
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5.2.7 The A1-A2A receptor heteromer signals through AC/PKA 
pathway 
The coupling of both Gs and Gi/0 to the adenosine A1-A2A receptors 
heteromer predicts that the transduction system operated by 
adenosine heteromer to modulate GABA transport into astrocytes is 
centered in the adenylate cyclase/cAMP/PKA cascade. To address 
the question of whether a single cAMP/PKA-centered transduction 
unit is able to both inhibit and facilitate GABA transport, it was 
tested the influence of drugs known to interfere with this 
transduction pathway upon the effect of adenosine A1 and A2A 
receptors agonists on GABA transport. In addition, phospholipase C 
(PLC) blocker was also tested, in order to evaluate a putative 
transduction pathway classically associated to Gq/11. The inhibitory 
action of adenosine A1 receptors agonist upon GAT-1 (Figure 5.18.A) 
and GAT-3 (Figure 5.18.C) still occurred in the presence of PLC 
blocker U73122 (3µM, Smith et al., 1990), but it was totally 
abolished by the blockade of PKA by Rp-cAMPs (100 µM, Wang et 
al., 1991). The activation of adenylate cyclase (AC) with a 
supramaximal concentration of forskolin (10µM, Awad et al., 1983), 
per se, increased GABA transport and occluded the inhibitory effect 
of the adenosine A1 receptors agonist (CPA) upon GABA transport 
(Fig. 5.18.A and 5.18.C). The facilitatory effect of the adenosine A2A 
receptors agonist, CGS21680, was not affected by the PLC inhibitor, 
U73122, but was totally impaired by the PKA blocker, Rp-cAMPs. The 
adenylate cyclase activator, forskolin, mimicked the action of the 
adenosine A2A receptor agonist and its facilitatory effect was not 
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additive with that of CGS 21680, indicating a common mechanism 
(Fig. 5.18.B and 5.18.D).  
It though appears that the adenosine A1-A2A receptor heteromer 
signals through the AC/cAMP/PKA cascade, which is in accordance 
with data obtained in the experiments designed to identify the G-
proteins involved in heteromer signaling. 
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Figure 5.18 – Adenosine A1-A2A receptor heteromer signaling. Astrocytes 
were treated for 15min with 1U/ml ADA before the addition of medium, 
the PLC inhibitor U73122 (3 µM), the PKA inhibitor Rp-cAMPs (100 µM) or 
the adenylate cyclase enhancer forskolin (10 µM). After 20 min, the 
adenosine A1 receptor agonist CPA (30 nM) (A and C) or the adenosine A2A 
receptor agonist CGS 21680 (30 nM) (B and D) were added and the GAT-1 
(A and B) or GAT-3 (C and D) mediated [3H]GABA uptake was measured as 
indicated in Methods. Panel A and C show that the inhibitory effect 
mediated by CPA (26 ± 2.7% for GAT-1; 20 ± 3.3% for GAT-3) persisted 
when PLC was previous blocked by U73122 (21 ± 0.4% for GAT-1; 23 ± 3.1% 
for GAT-3) but was totally abolished by the PKA inhibition.  The activation 
of AC by forskolin increased per se GABA uptake (21 ± 3.1% for GAT-1; 23 ± 
3.6% for GAT-3) and avoided the inhibitory effect mediated by CPA.  Panel 
B and D illustrate that the facilitatory effect mediated by CGS 21680 (24 ± 
2.3% for GAT-1; 24 ± 3.7% for GAT-3) persisted when PLC was previous 
blocked by U73122 (35 ± 7.2% for GAT-1; 32 ± 3.9% for GAT-3) but was 
totally abolished by the PKA inhibition.  The activation of AC by forskolin 
increased per se GABA uptake (26 ± 3.6% for GAT-1; 30 ± 5.6 for GAT-3). 
Both effects mediated by adenosine A2A receptor agonist and by AC 
activator are not additive, suggesting a shared mechanism. Results are 
mean ± S.E.M from 4-10 independent experiments. Statistical significance 
was calculated by one way ANOVA followed by Bonferroni’s multiple 
comparison test; *P<0.001 vs control (100%, white columns), φP<0.001 vs 
cells treated with the agonist alone.  
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5.2.8 Discussion  
This work clearly shows that GABA uptake by astrocytes is under 
modulation by extracellular adenosine, which, by interacting with a 
functional unit constituted by adenosine A1-A2A receptor heteromers 
coupled to two distinct G proteins, Gi/o and Gs, can either boost or 
depress the amount of inhibitory neurotransmitter available to 
neurons.  Using an adenosine analogue, CADO, with high structural 
similarity to adenosine but with the advantage of not being taken up 
by the cells nor metabolized by ecto-enzymes, it was observed that 
submicromolar concentrations of this agonist inhibit GABA uptake 
while at low micromolar concentrations there is an enhancement of 
GABA transport. Considering that the affinity of adenosine for the 
adenosine A1 receptors is slightly higher than for the adenosine A2A 
receptors (Fredholm et al., 2001), it is likely that the inhibition was 
mediated by adenosine A1 receptors and facilitated by adenosine A2A 
receptors. Accordingly, the adenosine A1 receptor selective agonist, 
CPA, inhibited GABA uptake into astrocytes, while the adenosine A2A 
receptor selective agonist, CGS 21680 facilitated it. Unexpectedly, 
the blockade of either receptor with selective antagonists prevented 
the effects mediated by either agonist, a strong indication that 
adenosine A1 and A2A receptors are interacting at the molecular level 
in primary cortical astrocytes. Abundant evidence of adenosine A1-
A2A receptors functional crosstalk has been described, namely, 
adenosine A2A receptors activation attenuates adenosine A1 
receptors-mediated responses in the hippocampus (Cunha et al., 
1994; Lopes et al., 1999), at the neuromuscular junction (Correia-de-
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Sá and Ribeiro, 1994), and in transfected cells (Ciruela et al., 2006); 
however, no attempt has been made to unequivocally and directly 
identify adenosine A1-A2A receptors heteromerization in neural cells. 
Therefore, to figure out the presence of adenosine A1-A2A receptor 
heteromers in neural cells, BRET (bioluminescence resonance energy 
transfer) assays were performed in primary cultures of astrocytes 
that were transfected with cDNAs for A2AR-RLuc and A1R-YFP. In 
these assays a positive, specific and saturable BRET signal for the 
energy transference between A2AR-RLuc and A1R-YFP was detected 
in living primary astrocytes. Moreover the heteromer in native 
astrocytes was detected by looking for a “fingerprint” which consists 
of changes in ligand binding characteristics of adenosine A1 receptor 
when the adenosine A2A receptor is activated. These results 
complemented and strengthened the evidence for adenosine A1-A2A 
receptor heteromerization in non-transfected astrocytes. 
Biotinylation assays showed that exposure to either adenosine A1 or 
A2A receptors agonists led to similar decreases in surface expression 
of adenosine A1 receptors, and to similar increases in the adenosine 
A1 receptors levels in intracellular fractions. It then appears that 
binding of a single ligand to the heteromer is sufficient to promote 
internalization of the two receptors. The previous blockade of 
adenosine A1 or A2A receptors prevents the heteromer 
internalization mediated by both adenosine A1 and A2A receptors 
agonists, suggesting that internalization of heteromer in response to 
agonists is a consequence of heteromer activity. Complementary 
immunohistochemistry assays in HEK cells coexpressing A1R-YFP and 
Setting GABA levels: GABA transporters modulation by adenosine receptors 
143 
A2AR-Rluc performed in collaboration with Prof. Rafael Franco group 
(University of Barcelona) corroborate this correlation (see Cristóvão-
Ferreira et al., 2011). 
Agonist exposure did not affect BRET, suggesting that agonist 
binding does not induce pronounced allosteric modifications in the 
receptors. It therefore appears that the adenosine A1-A2A receptor 
heteromer in astrocytes mostly works as an integral entity, leaving 
and probably also reaching the cell surface as a heteromeric 
structure. Furthermore, since antagonists did not modify the 
receptor levels at the membrane or the BRET signal, the loss of 
effect of one agonist upon previous blockade the other receptor 
cannot be attributed to heteromer disruption or formation. Cross-
antagonism, which is considered a heteromer fingerprint (Ferré et 
al., 2009), is likely due to conformational changes induced by the 
antagonist and leads to a non-functional state of the signaling 
receptor by uncoupling it from G-protein-mediated signaling.  
Heteromers may couple to G-proteins different from those to which 
each individual receptor partner usually couple. This is indeed the 
case of dopamine D1-D2 receptor heteromer, which couple to Gq 
(Rashid et al., 2007) in a clear shift from the canonical D1 coupling to 
Gs and D2 coupling to Gi/0. To identify the transduction system 
operated by the adenosine A1-A2A receptor heteromer in astrocytes. 
I first used an approach similar to that used by Rashid and colleagues 
(Rashid et al., 2007), i.e. GTP-γ-[35S] binding followed by differential 
immunoprecipitation. Data obtained allowed to conclude that the 
adenosine A1-A2A receptor heteromer in astrocytes seems to be 
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coupled to both Gi/0 and Gs proteins. Interestingly, the cross-
antagonism was also evident in these assays. Thus, the adenosine A1 
receptor agonist, but not the adenosine A2A receptor agonist, 
increased Gi/0 activity, but the enhancement was also prevented 
when the adenosine A2A receptor antagonist was present. 
Reciprocally, Gs activation, which was restricted to the adenosine A2A 
receptor agonist, was prevented when the adenosine A1 receptors 
were blocked with the antagonist. Similar conclusions could be 
drawn from GABA uptake assays since toxin-induced prevention of 
coupling of receptors to either Gs or Gi/0 led to reciprocal impaired 
function of adenosine A1 or A2A receptors agonists to modulate 
GABA transport. Altogether these data provide strong evidence for a 
heteromeric functional entity regulating GABA uptake by astrocytes. 
This functional unit consists of an adenosine A1-A2A-Gi/0-Gs complex, 
which signals through Gs when the adenosine A2A protomer is 
activated and through Gi when the adenosine A1 protomer is 
activated. Most importantly, the blockade of a single partner in the 
complex led to adjustments in the whole unit. Due to size 
constrictions (Han et al., 2009), the coupling of two different G 
proteins suggest that the minimal structure of adenosine A1-A2A 
receptor heteromer should be a tetramer, as two GPCR molecules 
cannot bind to more than a single G protein (Han et al., 2009). Work 
done in collaboration supports this hypothesis. In detail, co-workers 
of this study, using BRET assays with a double 
luminescence/fluorescence molecular complementation approach, 
have showed that adenosine A1-A2A receptor heteromers appear as 
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heteromers of homomers with a minimal structure consisting of an 
A1-A1-A2A-A2A complex (Cristóvão-Ferreira et al., 2011). The 
heterotetramer makes it possible to accommodate the two different 
G proteins. Data obtained also in collaboration using CellKey label-
free assays (Cristóvão-Ferreira et al., 2011) corroborate data 
acquired by me with GTP-γ-[35S] binding assays followed by 
differential immunoprecipitation of G proteins and also with 
functional data with cholera and pertussis toxin, as described in this 
chapter. Furthermore, the transduction system operated by the 
heteromer seems to involve the adenylate cyclase, consistent with 
the G protein data and the data obtained in the presence of 
forskolin or of the inhibitor of the PKA (Rp-cAMPs), both of which 
occluded the effects of the A1 or A2A receptors selective agonists 
upon GABA uptake. Altogether data obtained strongly suggest that 
functional unit is an A1-A1-A2A-A2A-Gs-Gi/0 complex (Cristóvão-Ferreira 
et al., 2011). 
At submicromolar concentrations, the adenosine analogue CADO 
activated the inhibitory component of the heteromer, inhibiting 
GABA uptake. A ten-fold rise in concentration of the non-selective 
ligand, CADO, was enough to gate adenosine A2A receptors 
activation and engages a completely opposite modulation of GABA 
uptake. Assuming a near 10 fold higher potency of CADO as 
compared to adenosine (Ribeiro and Sebastião, 1987), the shift from 
inhibition to enhancement of GABA uptake might occur at low 
micromolar concentrations of extracellular adenosine. These 
concentrations are easily attained at a tripartite synapse, where 
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astrocytes and neurons release considerable amounts of ATP, which 
are degraded into ADP, AMP and adenosine by ecto-5’-
nucleotidases. The higher the release of ATP, as at high neuronal 
firing rates in reciprocal neuron-to-astrocyte communication at the 
tripartite synapse (see Fields and Burnstock, 2006), the higher the 
expected concentration of extracellular adenosine. It is therefore 
likely that sustained neuronal firing promotes activation of the 
adenosine A2A protomer of the adenosine A1-A2A receptor heteromer 
leading to facilitation of GABA uptake. Activation of GABA uptake by 
astrocytes will lead to a decrease in ambient GABA and a 
subsequent depression of tonic GABAergic inhibition resulting in 
enhanced excitatory tonus. Conversely, at submicromolar adenosine 
concentrations, there is a preferential activation of the A1 protomer 
of the adenosine A1-A2A receptors heteromer and GABA uptake by 
astrocytes would be inhibited and tonic inhibition by GABA would be 
enhanced. Thus, through an adenosine action upon adenosine A1-
A2A receptor heteromers, astrocytes might behave as dual 
amplifiers, facilitating excitation at intense astrocytic to neuronal 
signaling and increasing inhibition at low neuronal firing rates. This 
switch in neural activity may require a highly efficient control to 
avoid sudden state transitions, and this seems to be the main 
advantage of heteromerization of adenosine A1 and A2A receptors in 
astrocytes. Indeed, overstimulation of just one of the receptor 
protomers leads to internalization of the whole functional unit, 
therefore allowing a double brake in the system and avoiding an 
abrupt inhibitory signaling and a sudden switch from excitation to 
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inhibition as a consequence of desensitization of only the excitatory 
protomer.  
To conclude, the present work provides strong and complementary 
evidence that, upon GABA uptake, adenosine has a biphasic effect, 
which is mediated by adenosine A1-A2A receptor heteromers coupled 
to both Gi/o and Gs proteins. Extracellular adenosine acting on these 
adenosine A1-A2A receptor functional units operates in a concerted 
way to balance a PKA-dependent action on GABA uptake as 
indicated in the scheme of Figure 5.19. The neural output would be 
inhibitory at low firing rates and facilitatory at high firing rates. This 
work therefore discloses a so far unknown way through which 
adenosine by acting on adenosine receptors in astrocytes may 
significantly contribute to neurotransmission in a dual manner, 
which depends on the concentration of the nucleoside that is in turn 
dependent on neuronal firing activity. This adds a novel conceptual 
way to understand the fundamental role of astrocytes at tripartite 
synapses. 
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Figure 5.19 – Schematic representation of adenosine A1-A2A receptor 
heteromer function. At low levels, adenosine binds preferentially to the A1 
protomer of the heteromer, which will activate Gi/0 protein, and through a 
mechanism that involves adenylate cyclase (AC), and PKA activity, leads to 
a decrease (-) in GABA uptake mediated by GAT-1 and GAT-3. At higher 
concentrations, adenosine activates the A2A protomer of the heteromer 
inhibiting A1 and, through Gs protein, couples to the AC/cAMP/PKA 
pathway, leading an enhancement (+) of GABA uptake.  
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6 General Conclusions 
The present work clearly demonstrates that adenosine, in a 
concentration dependent way, modulates GABA uptake into 
presynaptic terminals and astrocytes.  
According to the tripartite synapse model, the study of GABA 
transport should include both presynaptic terminals and astrocytes, 
since both components are active partners of the synapse, having 
the ability to influence each other. Although, GABA is mainly taken 
up into neurons, glial uptake can assume an important role, at least 
in some conditions. Here, it is postulate, that adenosine, depending 
on its concentration, drives the uptake of GABA into presynaptic 
terminals or into glial cells, which affects the intracellular releasable 
pool of GABA, and consequently the phasic inhibitory transmission.  
Results described in chapter 5.1 show that endogenous adenosine 
through activation of adenosine A2A receptors promotes GAT-1-
mediated GABA uptake into presynaptic terminals, an effect that 
occurs through activation of AC/PKA pathway. The increase of GABA 
uptake into presynaptic terminal accelerates the replenishment of 
GABA releasable pool at GABAergic nerve terminals, which is 
important, especially at periods of intense neuronal activity. On the 
other hand, the quick removal of GABA from the synapse minimizes 
GABA receptor desensitization at pos-synaptic neurons. Both effects 
contribute to the efficiency of the phasic inhibitory transmission. 
At the subchapter 5.2, I showed that, in astrocytes, low 
concentrations of adenosine inhibit both GABA uptake mediated by 
General Conclusions 
150 
GAT-1 and by GAT-3. In contrast, at higher concentrations adenosine 
promotes the GAT-1 and GAT-3 mediated-GABA transport. The 
adenosine effects in astrocytes are mediated by the activation of 
adenosine A1-A2A receptors heteromers, which are coupled to both 
Gi/0 and Gs proteins. The inhibitory effect is mediated by the 
activation of the A1 protomer, whose effects are due to the 
activation of Gi/0 proteins. The A2A protomer is activated by higher 
adenosine levels, and trough the activation of Gs proteins is the 
responsible for the excitatory effects. The entire heteromer works as 
a unique entity, being functional just when all the components 
(receptors and G proteins) are available. Furthermore, results herein 
reported indicate that the heteromer also reach and leave the 
membrane as an unique entity. This is probably a protective effect, 
which avoids sudden state transitions, as the two protomers 
mediate opposite effects. In detail, the activation of adenosine A1 
receptors by low levels of adenosine mediates inhibitory effects and 
leads to the internalization of both adenosine A1 and A2A receptors. 
When adenosine levels rise, the A2A protomer will be activated, 
mediating excitatory effects. But as the membrane expression of the 
A2A receptor is already decreased (in response to previous activation 
of A1 receptor), the amplitude of A2A receptor-mediated effect will 
be reduced. In case of an activation of the A2A protomer the whole 
unit will be further internalized, avoiding sudden state transition due 
to overactivation of inhibitory A1 receptor in the absence of the 
compensatory A2A receptor.  
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Putting all the results together, at low concentrations, adenosine 
decreases astrocytic uptake, driving GABA to presynaptic terminal, 
thus facilitating phasic inhibitory transmission, as the uptake to pre-
synaptic terminals will accelerate the recycling of intracellular 
releasable GABA pool. At higher adenosine concentrations, GABA is 
driven to astrocytes, which will shunt GABA from the presynaptic 
terminal, delaying the recycling of neuronal intracellular pools. 
Besides, the increase of astrocytic uptake reduces ambient GABA 
levels, decreasing tonic inhibition. Both actions contribute to 
facilitation of excitatory transmission. 
Due to adenosine modulation upon GABA transporters, adenosine 
can be seen as an amplifier of GABAergic tonus. For instance, in 
situations where the inhibitory tonus is predominant, adenosine 
drives GABA uptake into nerve terminals, facilitating phasic 
inhibition. In opposite, the adenosine excitatory mediated effect 
promotes GABA uptake into astrocytes, which reduces tonic 
inhibition, facilitating excitatory transmission. Thus, adenosine and 
GABA work synergistically in order to achieve brain homeostasis.  
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Low [adenosine]
+
-
High [adenosine]
+
+
GAT-1 GAT-3 A2A receptor
A1-A1-A2A- A2A heteromer
Figure 6.1 – Schematic representation of adenosine effect upon GABA 
transport at tripartite synapse. At low concentration, adenosine will 
decrease astrocytic uptake, driving GABA to presynaptic terminal. At 
higher adenosine concentrations, GABA will be driven to astrocytes.  
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7 Future perspectives 
After neurotransmitter receptors, transporters start to be seen as 
key components of transmission. It is nowadays accepted that 
transporters can release transmitters, even in physiological 
conditions, which modify the synapse scenario and justify the study 
of transporters modulation by different endogenous agents. On the 
other hand, transporters, by the clearance of transmitters from 
synapse, modify the expression of receptors, namely by reducing 
desensitization.  Then, the evaluation of transporters modulation 
assumes particular relevance for understanding brain function.  
In what concerns GABA transporters, their involvement (specifically 
GAT-1) in tonic and phasic transmission has been established during 
the last few years. In future work, it will be important to clarify the 
role of GAT-3 (and glial uptake) in the control of GABA levels, and 
consequently in tonic but also phasic inhibition.  
The work presented in this thesis clearly shows that adenosine 
modulates both GAT-1 and GAT-3 function. It therefore drives the 
interest of evaluating the consequences of this modulation on phasic 
and tonic transmission. 
Furthermore, GABA transporters, adenosine dysfunction and 
astrogliosis have been associated with epileptogenic status. In fact, 
the epileptogenic foci feature with low levels of adenosine.  Being 
adenosine a pleiotropic factor, it is not clear to figure out by which 
mechanism the lack of adenosine influences the epileptic status. 
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One possible hypothesis is the interference with GABA transporters 
system, since dysfunction of GAT-1 is closely connected with 
seizures occurrence. 
 In fact, GABA transporters have been associated with epilepsy, 
specially with seizures control, since a GAT-1 blocker (tiagabine) is 
used as adjunctive treatment for focal and secondarily generalized 
seizures in patients aged 12 or older (e.g. Genton et al., 2001). The 
therapeutic effect of tiagabine is related with an enhancement of 
extracellular GABA levels that occurs as consequence of GAT-1 
blockade; therefore the enhancement of extracellular GABA 
contributes to the control of overexcitation associated with seizure 
occurrence.  
On the other hand, a GAT-1 dysfunction was recently associated to 
the genesis of absence epilepsy (Cope et al., 2009).  Interestingly, 
systemic or intrathalamic administration of agents that promote 
GABAergic inhibition, including the anti-epileptic drugs vigabatrine 
and tiagabine, initiate or exacerbate seizures in patients and animals 
(Hosford and Wang, 1997; Hosford et al., 1997; Danober et al., 1998; 
Perucca et al., 1998 Ettinger et al., 1999). Thus, increased rather 
than impaired GABAAR inhibition may be a feature of absence 
seizures (Cope et al., 2009).  
Furthermore, it was shown in a model of absence epilepsy (GAERS – 
genetic absence epilepsy rats from Strasbourg) that the 
enhancement of GABAA receptors-mediated tonic currents was due 
to a impaired GABA uptake by GAT-1. This impaired GABA uptake 
could not be related with the protein levels, which is unchanged 
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and, interestingly, is restricted to thalamocortical neurons, which 
participate in absence seizure genesis (Cope et al., 2009). In 
addition, it was also shown that GAT-1 KO mice exhibited 
spontaneous absence seizures that were blocked by systemic 
administration of the anti-absence drug ethosuximide (Cope et al., 
2009).   
On the other hand, epilepsy can be considered as a disorder of 
astrocytes dysfunction (see Boison, 2010). In fact, astrogliosis has 
been associated to the epileptic brain as well as some modifications 
in distinct astrocytic membrane receptors and channels (Binder and 
Steinhauser, 2006). A direct involvement of astrocytes on epilepsy 
was firstly proposed in 2005, when a study showed that some anti-
epileptic drugs, namely valproate, gabapentine and phenytoin 
reduced the ability of astrocytes to propagate calcium signaling, 
suggesting that pathological activation of astrocytes may play a 
central role in the genesis of epilepsy (Tian et al., 2005). 
Furthermore, it was also shown that the paroxysmal depolarization 
shifts (abnormal prolonged depolarizations) were triggered by 
glutamate release from a non-synaptic source (Tian et al., 2005), 
proposing that glutamate release from astrocytes can trigger 
epileptic seizures. So, taken together, these results suggest that 
astrocytes may amplify, maintain and expanded neurogenic seizure 
activity as well as may be the source of epileptic activity (Tian et al., 
2005). 
In addition to being a source of glutamate, astrocytes are also an 
important source of ATP and consequently adenosine, which is an 
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endogenous anticonvulsant agent (see Boison, 2010). In fact, it was 
recently hypothesized that ATP released from astrocytes in response 
to neuronal activity inhibits adjacent neurons, a mechanism that 
could prevent seizures propagation (Kumaria et al., 2008). 
Then, taking together all the “puzzle pieces” and the knowledge 
about each one in the context of epilepsy, it is very pertinent to 
draw a project, whose main aim would be to evaluate how 
astrocytes-adenosine-GATs-GABA axis operates in physiological and 
also pathological conditions, namely epilepsy. The identification of 
possible astrocytes-adenosine-GATs-GABA axis dysfunctions may 
allow the development of new potential therapeutic avenues.  
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10 Annex   
 
 
 
 
 
The scientific content of the present thesis was published in the 
form of two original articles (see Annex).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
